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Summary 
 
 
The liver flukes Fasciola hepatica and F. gigantica cause infectious disease in 
ruminants and humans. The geographical range of these two parasite species 
(temperate and tropical respectively) ensures that infection can occur worldwide. 
Although anthelmintic treatment is effective against disease, emerging drug resistant 
strains leads to the development of a vaccine. However, despite several decades of 
research, there is no commercial vaccine available. Vaccine target antigens have 
been isolated and characterised from the fluke. The main challenge at present is to 
produce recombinant proteins in an immunologically active form using recombinant 
DNA technology. This is an essential step in Fasciola vaccine production.  
 
Cysteine proteases are probably the most important facilitators of virulence in flukes 
and are produced by all stages of the fluke life-cycle. Two classes of cysteine 
protease are found in the excretory and secretory material of liver flukes- these are 
cathepsin L and cathepsin B. As such, the major aims of this thesis were to 
investigate the expression and purification of Fasciola recombinant cysteine 
proteins, and characterisation by SDS-PAGE and immunoblotting using monoclonal 
and polyclonal antibodies. These studies demonstrate the production of functionally 
active cathepsin L5, cathepsin L1g and cathepsin B in S. cerevisiae BJ3505 cells 
which will lead to vaccine candidate analysis and to explore host-parasite 
relationships.  
 
The main goal of vaccine efficacy analysis and vaccine development is to observe 
immune responses in vaccinated animals. The second aim of this thesis was to 
determine the protective efficacy of stage specific target antigens against 
experimental infection. In addressing this issue, the protective efficacy of single and 
multivalent recombinant protein vaccinations of adult stage F. hepatica cathepsin 
L5, immature F. gigantica cathepsin L1g and juvenile F. hepatica cathepsin B were 
  2
analysed in Sprague Dawley rats against F. hepatica infection. In this study, the 
protective efficacy of anti-fluke vaccines was evaluated as parasitological 
parameters (recovered fluke burden, fluke body size and wet weight), pathological 
parameter (liver damage score), haematological parameter (leukocyte profile) and 
humoral responses (ELISA and western blotting) in vaccinated and control rats.  
 
This study demonstrates that juvenile fluke target antigen-cathepsin B induces 
better immune protection than adult fluke antigen-cathepsin L5.  The protective 
efficacy of cathepsin L1g was low compared to cathepsin B. The results of this study 
suggest that cathepsin B is a valuable target antigen for the development of an 
effective vaccine target against fluke infection. Cocktails of juvenile and adult stage 
fluke recombinant proteins (cathepsin B and L5) elicited the highest protective 
immunity against experimental infection and this combination showed not only 
reduction in fluke recovery and size of flukes, but also marked diminution in the 
intensity of liver lesions in vaccinated rats. The recombinant protein vaccines that 
hinder the transmission of infection via lowering the number of parasites in the host 
and block pathological symptoms in animals have been considered as potential 
components of disease control.  
 
In order to assess the immunogenic property of an early infective stage fluke 
secreting cysteine protease as a vaccine candidate, DNA vaccination vectors 
encoding cathepsin B were analysed in BALB/c mice. In this study, the ability of four 
DNA vaccination strategies such as secretory, chemokine-activating, lymph node 
targeting vectors encoding cathepsin B were assessed by antibody titre, antibody 
avidity, western blotting and ELIPSOT assay. The elucidation of the relative 
vaccination potential in each of these constructs was revealed as enhanced 
antibody responses (on lymph node targeting), high antibody avidity (of chemo-
attractant) or stronger cellular responses (of signal peptide carrying) in vaccinated 
animals. The results of this investigation demonstrate DNA vaccines have excellent 
  3
potential to induce both humoral and cellular immunity in vaccinated animals. The 
results have further validated the immunoprophylactic potential of a cathepsin B 
vaccine against F. hepatica.   
 
In this study, we have expressed and attained high yields of F. gigantica cathepsin 
L1g from E. coli BL21, and compared this to a yeast-expressed system. This 
protease was over-expressed and formed insoluble inclusion bodies that were 
subsequently solubilised with urea or guanidine hydrochloride. In order to purify the 
urea-solubilised protein, step-wise urea gradient chromatography was used. 
Guanidine hydrochloride solubilised protein was not subjected to chromatography. 
For refolding of solubilised protein, a dilution and dialysis procedure was utilised. 
The expression and refolding yielded 2.5 mg of protease from one litre of bacterial 
culture compared to 300 µg/litre from a corresponding yeast culture. Proteolytic 
activity was confirmed by gelatin SDS-PAGE analysis. 
 
Functionally active Fasciola proteins were purified from yeast. Protective immunity 
of the expressed proteins was observed in rats challenged with Fasciola infection. 
An enhanced immune response was observed when a juvenile fluke protein was 
used in targeting and non-targeting DNA vaccine forms. Fasciola protein was 
expressed in E. coli and was present in inclusion bodies in an inactive form. The 
active form of the protein was successfully obtained by refolding. In conclusion, the 
determination of the immune potential of recombinant stage specific antigens 
allows the development of effective vaccines against Fasciola infection. 
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Chapter 1 
Literature review 
1.1. Introduction 
 
1.1.1. Fasciolosis 
 
Fasciolosis is an infection mainly of ruminants and humans by digenetic trematodes, 
mainly Fasciola hepatica and F. gigantica. The former species has a world-wide 
distribution mainly in the temperate climates; but the latter species exists in tropical 
countries. Fasciolosis causes significant economic loss, as valued by animal 
productivity, estimated at approximately US$ 3.2 billion US dollars per annum to the 
global agricultural community with 600 million animals infected (Mas-Coma, 2005; 
McManus & Dalton, 2006; Spithill et al., 1997). Fasciola infects mainly sheep and 
cattle. Other animals that may be affected include goats, horses and pigs. Recently 
Mas coma (2005) reported that llmas in South America, camels in Africa and 
marsupials in Australia may be acting as reservoir hosts in these regions. 
 
1.1.2. Distribution and prevalence of Fasciola infection 
 
Fasciola infection occurs mainly in temperate regions and outbreaks have been 
reported throughout Europe. At present, fasciolosis is also highly prevalent in the 
US, Mexico, North Africa, New Zealand and Australia (Mas-Coma, 2005; Mas-
Coma, 2007; McManus & Dalton, 2006). F. hepatica has become a major threat to 
humans in South America especially in Brazil, Argentina, Uruguay and also Andean 
countries such as Bolivia, Peru and Equador (Espino et al., 1998; Mas-Coma, 
2005). F. gigantica infection has a more limited distribution because of the reduced 
survivability of snails (the intermediate host) in tropical regions. It is most prevalent 
in Africa (Egypt) and South East Asia (Mas-Coma, 2005; McManus & Dalton, 2006). 
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Both species have been reported in Japan, Korea, Taiwan and the Philippines 
(Agatsuma et al., 2000; Lim et al., 2007a).  
 
The distribution and prevalence of the Fasciola infected cattle population in 
Queensland, Australia is depicted in Figure 1.1. Among the two species, F. hepatica 
is present in Australia and the livestock production loss has been estimated to be 
approximately US$ 80 million/year (Molloy & Anderson, 2006; Mulcahy & Dalton, 
2001). In creeks within the Brisbane metropolitan area, a mixture of F. hepatica and 
F. gigantica were found about 25 years ago . As shown in Figure 1.1, the 
occurrence of F. hepatica infection is much more frequent in dairy herds than in beef 
herds. However, the dairy herds are usually in higher rainfall areas (southeast 
Queensland) with habitats suitable for the survival of aquatic snails . 
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Figure 1.1`. The distribution and prevalence of F. hepatica infection in dairy 
and beef herds in Queensland, Australia (adopted from Molloy and Anderson, 
2006).  The percentage of infection and postive cases of F. hepatica are noted 
as red dots.  
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1.1.3. Control of liver fluke infection 
 
Liver flukes are controlled by a combination of anthelmintic drugs and pasture 
management.  A series of chemotherapeutic agents are available for the treatment 
of animal fasciolosis, including closantal, clorsulan, rafoxanide, nitroxynil and 
triclabendazole (Dalton et al., 2003b; Fairweather & Boray, 1999). The major anti-
flukicide triclabendazole (FasinexR, Novartis Animal Health) is efficient against both 
juvenile flukes in the hepatic parenchyma and adult flukes in the bile ducts .  
However, triclabendazole resistant parasites have been reported in Europe and 
Australia . Most importantly, government and consumer concern about chemical and 
antibiotic residues in animal foods (milk and meat) and the environmental threat 
from chemical and pesticide (Molloscocide) use on pastures. Chemicals runoff into 
water supplies will make the chemical control of fasciolosis more difficult in the 
future (Dalton et al., 2003b). 
 
1.1.4. Life cycle of Fasciola spp. 
 
Two hosts (intermediate and definitive hosts) are involved in the liver fluke life cycle 
(Figure 1.2). The definitive host range is very broad which includes ruminants and 
humans (Boray et al., 1985; Mas-Coma et al., 1999). Intermediate hosts are fresh 
water snail species of the family Lymnacidae (Gastropoda: Basommatophora). 
Flukes attain maturity in the mammalian host bile duct and release eggs which are 
finally excreted with faeces. In damp and muddy areas the free swimming 
miracidium infect snails and this is followed by a series of developmental and 
multiplication stages such as sporocyst and redia.   
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After the development stages within the snail, the infective metacercariae emerges 
and get attached to the plant matter. The final host can be infected by eating 
contaminated aquatic plants such as water cress encysted with metacercariae. 
Following excystation in the gut of the host due to digestive juice activity, the newly 
excysted juvenile flukes penetrate the intestinal wall, enter the peritoneum and 
migrate into the hepatic parenchyma and the liver. Inside the liver, the immature 
flukes cause migratory tracts resulting in extensive haemorrhage and perforations 
(hepatic stage infection). This acute stage of infection can result in death in highly 
infected sheep, but rarely in cattle. At the final stage, flukes reach host bile duct. In 
chronic cases, infection causes oedema, bottle jaw, anaemia and thickening of bile 
duct (cirrhosis) (biliary stage infection) (Lim et al., 2007a). The life span of adult 
fluke in man is between 9 and 13.5 years (Mas-Coma et al., 1999; Mas-Coma, 
2005; Mas-Coma, 2007). 
The infection usually evolves as a chronic disease, subacute and acute fasciolosis 
with high rates of mortality are not rare in small ruminants. In sheep and cattle, the 
juvenile flukes induce a granulomatous lesion in the hepatic parenchyma, with 
numerous macrophages, lymphocytes and eosinophils (Boray et al., 1985; Mas-
Coma et al., 1999).  
1.1.5. Human fasciolosis 
 
 
Human liver fluke infections are classed as food borne zoonatic disease which is 
acquired by accidental ingestion of infective metacercariae. Human fasciolosis is an 
emerging health problem with an estimated 2.4-17 million people infected around 
the world with a further 180 million at risk of infection (Curtale et al., 2005; Mas-
Coma et al., 1999). The major clinical symptoms of human infection include fever, 
pain in the right hypochondrium, anorexia, persistent diarrhoea and vomiting .  
Human infections are always associated with local endemic animal infections. 
Vegetable contamination with infective metacercariae (fresh water aquatic plants –
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water cress) and free floating metacercariae in drinking water pipe lines play a major 
role in transmission of disease (Mas-Coma, 2007; Rokni et al., 2003). In addition, 
parasites in humans produce eggs that play a major role in overall transmission of 
disease in third-world countries . Immuno-suppression due to Fasciola spp. leads to 
multi-parasitism (e.g. Giardiasis) and such super infection has been reported in 
Egypt and South America (Brady et al., 1999; Mas-Coma, 2005). 
 
1.1.5.1. Epidemiological reports of human liver fluke infection 
 
Several epidemiological studies revealed that human infection is highly prevalent in 
the high altitude and rural poor regions of Bolivia, Peru and Equador (Curtale et al., 
2005; Esteban et al., 1999; Mas-Coma et al., 1999). Human infection is more 
prevalent among children of all ages in both sexes. This human pathogen can 
survive up to 13 years and lay up to 5000 eggs/gram faeces in infected Bolivian 
children who in turn act as disease carriers to humans and animals . The highest 
levels of human fasciolosis (due to F. hepatica) are noticed amongst the indigenous 
people of the Northern Bolivian Altiplano and prevalence is age-related with the 
highest infection rate in children aged 8-11 years . Human fasciolosis is also 
reported in the Guilan and Mazandaran provinces of Northern Iran with frequent 
outbreaks of up to 10,000 infections (Moghaddam et al., 2004; Rokni et al., 2002). 
Human infection in European countries occurs sporadically, but in Spain, France 
and Portugal there are approximately 50 to 100 cases per year (Mas-Coma et al, 
2005). 
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Figure 1.2. The life cycle of F. hepatica. Adopted from:  
http://www.dpd.cdc.gov/dpdx/HTML/Frames/A-F/Fascioliasis/body_Fascioliasis_page1.htm). 
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Human and animal infections with the tropical liver fluke F. gigantica have been 
reported in Russia, Africa, Asia and South East Asia including Thailand and Vietnam 
. In Vietnam, starting from 1997 to 2001, approximately 500 new cases were 
identified using eosinophilia and ELISA titres as markers of infection with upper 
abdominal pain. However, in the same study, only 14 of 285 (4% postive) cases had 
F.  hepatica eggs in stools .  
 
1.1.6. Diagnosis of liver fluke infection 
 
Traditional diagnosis of liver fluke infection has been made on the basis of detection 
of egg counts in faeces or flukes in the liver and bile ducts during post mortem. 
Faecal egg count detection is the conventional routine diagnostic method in 
livestock, but this procedure is cumbersome, labour intensive and shows low 
sensitivity (Molloy et al., 2005; Molloy & Anderson, 2006; Reichel et al., 2005). This 
method is unable to detect early infections as eggs appear at 10-11 weeks of post 
infection.  
 
Commercial ELISA kits utilise sensitive and specific serological tests for diagnosing 
infection . The diagnosis of F. hepatica antibodies  in milk and serum of infected 
cattle as well as serum from infected sheep was based on an indirect ELISA coated 
with the f2 antigen, and developed as a commercial kit by the Institut Pourier . 
Molloy et al. (2005) has evaluated this commercial kit (based on the ELISA) for 
detecting antibodies in milk and serum from sheep and cattle (F. hepatica) in 
Australia. The sensitivity and specificity of the ELISA was 98.2% and 98.3% using 
serum and 97.7% and 99.3% using milk in cattle. In sheep, the sensitivity and 
specificity of the ELISA was 96.9% and 99.4% using serum. The authors of this 
study conclude that this ELISA is considered as a potential routine diagnostic tool 
for F. hepatica infections in cattle and sheep.  
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1.1.6.1. Cathepsin protease based diagnosis 
 
Carnevale et al. (2001) have used crude extracts or excretory-secretory products 
(ES) as antigen for the diagnosis of serum antibodies. However, the complex nature 
of ES products and its low specificity due to cross reactivity with other parasites 
prevented wide use of this method as a diagnostic tool for Fasciola infection. 
Cathepsin L protease is a major protease of Fasciola ES material, extensively used 
for vaccine development, and humoral responses are raised against the protein 
during infection. This resulted in the development of a reliable diagnostic test for F. 
hepatica infection in rats , sheep (Wijffels et al., 1994a), ruminants (Fagbemi et al., 
1995; Fagbemi et al., 1997), and humans (Cordova et al., 1997; O'Neill et al., 1999).  
 
Native cathepsin L protease extracted from ES products of adult flukes were used  
in serological screening which showed cross reactivity with other parasites in 
herbivores (Cornelissen et al., 1999b; Cornelissen et al., 2001a) and humans 
(O'Neill et al., 1998; O'Neill et al., 1999).  
 
O'Neill et al. (1999)  have assessed yeast produced recombinant cathepsin L1 
enzyme for the diagnosis of human fasciolosis (Bolivian Altiplano regions) and its 
performance led to the  development of the first standardized assay for the sensitive 
and specific diagnosis of human Fasciola infection. The cathepsin L based 
diagnosis (ELISA and western blotting) is a promising tool for the diagnosis of 
tropical fasciolosis in domestic animals and humans (Intapan et al., 2005; Raina et 
al., 2006; Rokni et al., 2002; Wongkham et al., 2005; Yadav et al., 2005). Humoral 
responses to cathepsin L appear at 2 to 4 weeks post infection, and increase 
steadily throughout the 10 week period. This is mainly due to their continuous 
expression throughout the life cycle of the parasite in sheep and cattle (Dixit et al., 
2002; Dixit et al., 2004; Mulcahy et al., 1999). Recombinant pro-cathepsin B was 
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expressed in yeast and vaccine trials were performed in rats and sheep. After 
challenge infection with metacercariae, these recombinant proteins detected 
responses within 2 to 5 weeks of infection in sheep and within 5 weeks in rats. Thus 
Fasciola cathepsin B can play a pivotal role for diagnosis of the acute stage of 
fasciolosis (Law et al., 2003). 
1.1.7. Immune responses of infected animals against Fasciolosis 
 
Natural fluke infection has been characterised as classical cellular stimulation mainly 
of macrophages and eosinophils along with IgE effector immune responses . In the 
early infection stage, dominant suppression of lymphocyte proliferation helps the 
pathogen survive during the immature invasive stage and hepatic migratory activity 
of juvenile flukes. Secretions during the invasive stage of flukes play a major role in 
the reduction of nitrous oxide/ free radical production by peritoneal macrophages 
which permits the flukes to bypass the deleterious effects of cell mediated defence 
mechanisms .  
 
During the hepatic stage of infection with Fasciola, there appears to be a Th2 type 
immune response. Migratory juvenile and mature flukes ES material induce a Th2 
response along with the down- regulation of Th1 responses. Cathepsin L plays a 
pivotal role in the immuno-modulatory effects in ruminants and suppressive activities 
against T cell proliferation (O'Neill et al., 1999; O'Neill et al., 2000; Prowse et al., 
2002). Migratory flukes finally reach the bile ducts of their host where they attain 
maturity and start secreting proteolytic enzymes by regurgitation for the purpose of 
digesting host haemoglobin. This digestive and secretory molecule may be 
considered as an immunologically important antigen due to the induction of a Th2 
polarising activity during the chronic stage of infection (Dalton et al., 2003a; 
McManus & Dalton, 2006; Spithill et al., 1997).  
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Juvenile liver fluke is morphologically similar to adult stage and highly motile 
throughout its residence in the liver. After reaching the bile duct, the migratory 
activity reduces. Current vaccine candidates (Cathepsin L1, cathepsin L2, FABP, 
GST, aminopeptidase) mainly target the adult parasite in the bile ducts where a low 
concentration of antibodies and immune mediating effector cells are found. Thus, 
this site is considered to be an immunologically safe environment for adult flukes .  
 
1.2. Evaluation of Fasciola protein antigens 
 
The control of Fasciola infection is primarily by the use of anthelminthic drugs and 
pasture management. The appearance of drug resistance in the parasite and the 
aversion to the presence of chemical residues in food and the environment has 
increased the need for a vaccine as an alternative to chemotherapeutic drugs 
(Dalton, 2003 a). Spithill et al. (1997) observed in sheep and cattle that ruminants 
acquired resistance to both F. hepatica and F. gigantica infection after vaccination 
using irradiated metacercariae and crude parasite extracts.  
 
The emergence of bioinformatics and biotechnology presents the possibility of 
discovering and synthesising potentially protective Fasciola antigen molecules 
capable of inducing immunological protection (Knox & Redmond, 2006; Smith & 
Zarlenga, 2006). Recent developments in molecular biology contribute to study the 
host-parasite interaction and vaccine development (Knox et al., 2001; Knox & 
Redmond, 2006). Genetic information related to the Fasciola organism such as EST 
databases, the mitochondrial genome sequence as well as phylogenetic analyses of 
the proteins of the ES has been generated, analysed and many of the biologically 
important molecules from Fasciola have been cloned (fatty acid binding proteins, 
glutathione S transferase, aminopeptidase, cathepsin L and cathepsin B) and 
expressed as recombinant proteins.  
 
  15
The production of vaccines by recombinant DNA technology or by naked DNA may 
eventually lead to commercialisation of Fasciola vaccines (Dalton & Mulcahy, 2001; 
Hillyer, 2005). Despite many attempts, no commercially viable vaccine against 
Fasciolosis has been developed. However, a number of Fasciola proteins have 
been evaluated as immunogens or vaccine candidates. A series of native and 
recombinant proteins from Fasciola spp. have shown to promise as vaccines. These 
include fatty acid binding proteins, glutathione S transferase, haemoglobin, leucine 
amino peptidases and cysteine proteases such as cathepsin L and cathepsin B 
(Dalton et al., 2003a; Hillyer, 2005; McManus & Dalton, 2006; Spithill et al., 1997). 
 
1.2.1. Fatty acid binding protein (FABP) 
 
 
This adult F. hepatica antigen is a major component of E/S material, and is involved 
in binding and transportation of hydrophobic ligands, especially long chain fatty 
acids and bile acids. The parasite is unable to synthesize their own fatty acids de 
novo and liver flukes may use the FABP to acquire fatty acids from the host serum . 
The FABP protein was termed Fh12 (12 kDa mass) (Hillyer et al., 1987; Hillyer & 
Soler de Galanes, 1988). Subsequent vaccination trials in Castillian sheep using 
Fh12 and rFh15 failed to induce high levels of protection, although anti-fecundity 
effects were observed .  F. gigantica FABPs were used as vaccines in cattle, but 
only a 31% reduction in worm burden was observed (Estuningsih et al., 1997; 
Smooker et al., 1997). F. hepatica rFh15 in an adjuvant/immunomodulator (ADAD) 
system was tested in mice and sheep challenged with metacercariae. The ADAD 
system consist of an extract of Polypodium leucotomos (PAL) and/or a Quil A in a 
water/oil emulsion (30/70) with non-mineral oil (Montanide). The mice vaccinated 
with ADAD and Fh15 showed a survival rate of 40–50% and the sheep immunised 
with ADAD and Fh15 showed lower fluke recovery (43%) and less hepatic lesions 
than control animals . E. coli expressed F. gigantica FABP was used as a vaccine in 
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Freund’s adjuvant to evaluate the protection in Indian buffalo (Bubalus bubalis) 
calves  and vaccination showed a moderate level of protection in terms of reduced 
fluke burden (35.8%)(Nambi et al., 2005).  
 
1.2.2. Glutathione S-transferase (GST) 
 
GSTs constitute a large family of isoenzymes involved in cellular detoxification of 
xenobiotics and toxic compounds. F. hepatica GST was proposed as a vaccine 
candidate because Schistoma GSTs showed protection in laboratory animals 
against F. hepatica infection . The Spithill laboratory (1999b) has identified eight 
native and four recombinant isoenzymes of GST. Vaccination with GST showed 49 
to 69% protection in Hereford and Swiss Red Holstein/Simmental cattle (McManus 
& Dalton, 2006; Spithill et al., 1997). Significant reductions in the faecal egg count 
were observed in all vaccine trials (up to 65%). Vaccination of cattle with 
Schistosoma bovis GSTs supplemented with different adjuvants such as with Quil A, 
aluminium hydroxide or Freunds adjuvant did not induce effective protection against 
challenge infection with F. hepatica metacercariae . These inconsistent protective 
efficacies elicited by this protein in both sheep and cattle vaccine trials lead largely 
to a discontinuation of its development as a vaccine candidate. 
 
1.2.3. Leucine amino peptidase 
 
Leucine amino peptidase is secreted from the gut of F. hepatica and may facilitate 
food digestion . A high level of protection (71%) was observed with a cocktail 
vaccine containing cathepsin L1 and amino peptidase. The recombinant version, 
expressed in E. coli, induced 81% protection in rabbits along with the least amount 
of damage to the liver of vaccinated animals. Using two dimensional gel 
electrophoresis and immunoblotting techniques, Marcilla et al. (2008) have found 
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that recombinant leucine aminopeptidase is recognised by sera from Fasciola 
infected humans in Peruvian Altiplano. 
 
1.2.4. Haemoglobin 
 
 Haemoglobin is also proposed as an antigen in the ES material of adult F. hepatica. 
It was suggested that this protein may be essential for oxygen transport and/or 
storage in migrating flukes. A cocktail vaccine using F. hepatica cathepsin L2 
/haemoglobin yielded up to 72% protection, but  haemoprotein alone gave 43.8% 
protection and combination of the two cathepsin L1/haemoglobin induced 51.9% 
protection . 
 
1.2.5. Cysteine proteases 
 
Cysteine proteases play major roles in cellular, developmental and digestive 
processes, blood coagulation, inflammation and hormone processing of the parasite 
(Turk et al., 2000; Williamson et al., 2003). Mammalian lysosomal cysteine 
proteases (cathepsins B and cathepsin L) have been implicated in a variety of 
pathological processes such as cancer, tumour angiogenesis, and neuro-
degeneration (Stahl et al., 2007; Tort et al., 1999; Turk et al., 2000). Fasciola 
cysteine proteases present in ES material may facilitate biological functions such as 
parasite immune evasion, excystment/encystment, moulting and tissue invasion  .  
Fasciola cysteine proteases are considered to be a potential target for the 
development of new immunotherapeutic and sero-diagnostic agents for the next 
generation of anti-parasite intervention. 
 
 
1.2.5.1. Cathepsin L protease 
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The most abundant proteins in Fasciola ES materials are cathepsin L proteases 
which are encoded by an estimated seven genes . The majority of cathepsin L is 
secreted by epithelial cells lining the gut lumen (Collins et al., 2004) and facilitates 
parasite penetration of host tissues. Most of the cathepsin L cDNA’s have been 
isolated from adult flukes (Wijffels et al., 1994a; Yamasaki & Aoki, 1993). Each 
stage in the fluke life-cycle contains the same genes, but only those genes needed 
for that stage are expressed (McManus & Dalton, 2006; Mulcahy & Dalton, 2001). A 
most striking feature is that cathepsin L and cathepsin B expression are 
developmentally regulated during maturation in the host, as juvenile parasites 
secrete cathepsin B (Grams et al., 2001; Meemon et al., 2004; Tkalcevic et al., 
1995; Wilson et al., 1998), immature flukes secrete both cathepsin L and  cathepsin 
B (Harmsen et al., 2004; Meemon et al., 2004), whereas a series of cathepsin L 
proteases are secreted by adult Fasciola (Dowd et al., 1995; Smith et al., 1993a; 
Smith et al., 1993b; Wilson et al., 1998). Jefferies et al. (2001) and Wijffels et al. 
(1994a) observed multiple cathepsin L’s in adult fluke ES material using two 
dimensional gel electrophoresis and western blotting. Adult fluke cathepsin L and 
NEJ cathepsin B are the prominent proteolytic enzymes of their respective ES 
materials, although cocktails vaccines with these proteins have yet to be reported. 
 
These proteolytic enzymes from the gastro-epidermal cells of Fasciola are secreted 
at approximately 0.5-1 µg/adult parasite/hour in an acidic environment (Collins et al., 
2004). Most studies revealed that cathepsin L like proteases are the major enzymes 
which are homologues of the mammalian lysosomal cathepsin L (Dowd et al., 1994; 
Hawthorne et al., 2000; Heussler & Dobbelaere, 1994; Wijffels et al., 1994a; 
Yamasaki & Aoki, 1993). The involvement in biological roles that are essential for 
fluke survivability in the mammalian host makes this adult fluke protein (cathepsin L) 
an important vaccine target against infection.  
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Cathepsin L1 and cathepsin L2 have been studied extensively with different 
substrates (Dowd et al., 1994; Dowd et al., 1995; Dowd et al., 1997). The cathepsin 
L’s inhibit antibody-mediated eosinophil attachment to juvenile flukes  and cleavage 
sites of cathepsin L1 and cathepsin L2 in the heavy chain of human IgG have been 
clearly demonstrated . F. hepatica cathepsin L suppress sheep T cell proliferation 
and down regulate surface CD4 expression on both human and ovine T cells 
(Prowse et al. 2002). In a comparative study, F. hepatica cathepsin L2 was able to 
cleave fibrinogen to produce a clot  whereas Fasciola cathepsin L1 could not induce 
a clot. Both proteins comprise 326 amino acids, with 17 amino acids for the signal 
peptide, 90 amino acids for the pro region and 219 amino acids for the mature 
region (Dalton et al., 2003b). Smooker et al. (2000) described a cDNA encoding a 
seventh (at that time) cathepsin L, denoted as F. hepatica cathepsin L5 which 
encodes a proteinase showing 86% identity to cathepsin L1 and 80% identity to 
cathepsin L2. Both the cathepsin L1 and L2 cysteine proteases have shown 
proteolytic activity against a number of natural substrates such as gelatin (Dalton & 
Heffernan, 1989; Kesik et al., 2007), haemoglobin , collagen , immunoglobin  , 
globin and albumin .  
 
Cathepsin L is involved in protecting the parasite from the host immune system as it 
can effectively cleave immunoglobin in the hinge region, isolating Fab from the Fc 
region, preventing antibody mediated attachment of eosinophils to the parasite 
surface (Berasain et al., 1997; Carmona et al., 1993; Smith et al., 1993a). Cathepsin 
L may aid in suppression and/or immune modulation of Th1 responses and 
induction of nonprotective host Th2 responses (Dalton et al., 1996; O'Neill et al., 
2000). Th1- specific responses to a bacterial pathogen, Bordetella pertussis, (IFN-γ 
indicative marker) were suppressed . Conversely, this enhanced non-protective Th2 
response may favour the longevity of the parasite in the host . Cathepsin L is not 
highly immunogenic in the early stages of infection, and may be considered at that 
stage as a hidden antigen .  
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1.2.5.2. Cathepsin B protease 
 
1.2.5.2.1. Cathepsin B as a potential vaccine candidate 
 
 
Juvenile and immature stages of F. hepatica secrete cathepsin B-like proteases 
which are the major component of the ES material of newly excysted juvenile flukes 
(NEJ) (Creaney et al., 1996; Tkalcevic et al., 1995; Wilson et al., 1998). It is 
released by early migratory flukes up to 5 weeks post infection, and may help in 
excystment and migration of young flukes into host tissues (Law et al., 2003; Wilson 
et al., 1998). A similar biological function (tissue invasion) has been reported for 
mammalian cathepsin B secreted by macrophages, osteoclasts and malignant 
tumour cells (Turk et al., 2000; Williamson et al., 2003). The high level of cathepsin 
B in the mammalian tissue invasion stage of F. hepatica is indicating that it may be 
required for successful parasitism. NEJ secreting cathepsin B show fluorogenic and 
gelatin substrate activity, and digest the heavy chain of immunoglobulin and bovine 
serum albumin . Therefore, F. hepatica cathepsin B of the NEJ and immature stages 
is regarded as a potential vaccine candidate and drug target against Fasciola 
infection (Creaney et al., 1996; Law et al., 2003; Wilson et al., 1998) 
 
 
 
1.2.5.3. Genomics of Fasciola cathepsin L and cathepsin B proteases 
 
 
Many Fasciola gene and cDNA sequences are available in the GenBank database, 
although the entire genome sequence has yet to be solved. Many genes are only 
expressed at a specific stage in the life cycle. The gene sequence analysis of F. 
hepatica was initiated by Heussler and Dobbelaere. (1994) and Fasciola cathepsin L 
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database entries have been gradually increased since this time. At present 29 and 
11 known cathepsin L and cathepsin B nucleotide sequences respectively are 
available (http://www.ncbi.nlm.nih.gov/sites/entrez). The three cDNAs encoding 
cathepsin B proteases from adult, NEJ, and metacercaria of F. gigantica were 
analysed for their stage- and tissue-specific expression by Northern hybridization, 
PCR techniques and RNA in situ hybridization .  
 
1.2.5.4. RNAi studies with F. hepatica cathepsin L and cathepsin B 
 
 
RNA interference (RNAi) is a recent genomic tool for exploiting the transcriptomic 
data (RNA-mediated interference) from parasites. Double stranded (ds) RNA 
stimulates an intracellular cascade which results in degradation or suppression of 
the expression of homologous mRNA transcripts . Double-stranded RNA is prepared 
from cDNA sequences and is then administered by microinjection into the germline 
syncytium .  The ds RNA can spread across cell boundaries from the intestine and 
can be mediated by feeding worms on E. coli that are expressing parasite ds RNA 
or simply soaking worms in a diluted ds RNA solution. Currently, successful 
application of RNAi for the suppression of gynecophoral canal protein , cathepsin B , 
a facilitated diffusion glucose transporter (SGTP1) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH)  gene expression has been studied in Schistosoma 
species.  
 
McGonigle et al. (2008) showed inhibition of cathepsin B and cathepsin L in F. 
hepatica NEJ. RNAi silencing of cathepsin B and cathepsin L induced a marked 
reduction in transcript level as well as encoded proteins in the fluke gut . The F. 
hepatica cathepsin B and cathepsin L-RNAi on NEJs were shown to have specific 
effect on three factors: (a) mRNA transcript levels, (b) target protein expression, and 
(c) functionally, by altered NEJ gut penetration. Abrogation of expression of either 
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cathepsin L or cathepsin B induced abnormal locomotory phenotypic changes and 
subsequently reduced invasion of the rat intestinal wall. The results of this study 
concludes that both cathepsin B and cathepsin L proteases are essential to NEJ 
penetration of the gut, and that interference with the function of either cathepsin L or 
cathepsin B has a severe impact on worm virulence. The specific sensitivity of NEJs 
to RNAi yields broad ranging opportunities to further probe the biology of cysteine 
proteases genes in F. hepatica.  
 
1.2.5.5. Structural analysis of Fasciola cathepsin L and B 
 
Structural analysis is useful to identify regions of a target molecule which are likely 
to be immunogenic and therefore available for interaction with immune effectors. 
Molecular homology modelling of Fasciola cathepsin B using the MODELLER 
program was based on the human cathepsin B structure. Stereochemistry analysis 
of this protease paved the way to the discovery that the active site of this enzyme 
was partially buried by a unique structure called the occluding loop (Law et al., 
2003) (Figure 1.3). Molecular modeling studies were performed for cathpsin L5 
where a single amino acid substitution in the mature protein may be responsible for 
the difference in specificity at the S2 subsite.  Human cathepsin L was used as 
template for building these models . Using homology modelling, Irving et al. (2003) 
predicted the S2 subsite specificity of cathepsin L5 and cathepsin L8, which have a 
leucine and a tryptophan at the crucial amino acid (#69), respectively. The structure 
of F. hepatica  cathepsin L1 has been recently released . 
 
1.2.5.6. Enzymatic activity of Fasciola proteases 
 
Fasciola cysteine protease cathepsin L enzyme activity may be important in  
parasitic activities such as invasion of host tissues, digestion of host proteins, 
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helping the parasite to evade the host immune responses and mediation of molting 
of immature stages of flukes .   Cathepsin B shows a unique feature in the active site 
of the enzyme known as the occluding loop (Figure 1.3). This structure partially 
occludes the active site of the enzyme, restricting access of extended substrates 
and inhibitors such as the cystatins. These proteases possess an essential cysteine 
residue that forms a covalent intermediate complex with substrate. Cathepsin B 
proteases are expressed in greater amounts in parasitic and non-parasitic 
nematodes such as Haemonchus contortus, Ancyclostoma duodenale, Toxacara 
canis, Onchocerca volvulus than in trematodes such as Fasciola hepatica, Fasciola 
gigantica, Schistosoma mansoni, Schistosoma japanicum (Brady et al., 1999; Law 
et al., 2003; Smith et al., 1993a; Tort et al., 1999). The functions of these various 
cathepsin B enzymes remain to be determined (Law et al., 2003). 
 
F. hepatica cathepsin proteases consist of a pre-region or signal peptide (12-20 
amino acids), a prosegment (100 amino acids) and a mature enzyme (200 amino 
acids) .  Adult cathepsins L’s are expressed as an inactive protease and require 
proteolytic removal of their pro region in order to access active site residues. The 
substrate specificity of this proteolytic enzyme was assessed using synthetic 
fluorogenic peptides which were also used for characterisation of mammalian 
cathepsin L’s, S’s, K’s (Z-Phe-Arg-NHmec) and  cathepsin B (Z-Arg-Arg-NHmec) 
(Kirschke et al., 1982; Smooker et al., 2000). The two main forms of cathepsin L (L1 
and L2) do not possess glycosylation sites in their mature form. Cathepsin L5, like 
L1 does not exhibit proteolytic activity against substrates containing proline, 
however the authors of this study have highlighted a single amino acid substitution 
that does affect the specificity of this protease.  
 
Recombinant cathepsin B yeast expression was initiated by Law et al. (2003), but 
they failed to demonstrate auto-processing. Cathepsin B was subsequently 
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expressed in the methylotrophic yeast Pichia pastoris. In order to obtain the 
active form of this enzyme, the expressed protease was processed by an 
asparaginyl endopeptidase via cleavage at an unusual position N-terminal to 
the normal cleavage site (Beckham et al., 2006).  
 
1.3. From Fasciola genes to protein vaccine candidate 
 
Functional expression of cloned cathepsin genes has been used to determine the 
immunogenic potential of these proteases. Vaccine development processes are 
presented in Figure 1.4. The protective efficacy and success of these vaccine trails 
have demonstrated that each of these antigens delivered as proteins, can effectively 
elicit protection in terms of reduction in worm burdens, anti-fecundity, smaller fluke 
size, anti-pathology (less liver damage) and reduction in parasite egg output 
compared to non-vaccinated controls.  
 
The native cathepsin L was isolated from Fasciola flukes and detailed biochemical 
and immunological assessment was performed independently by two research 
groups, Spithill (Australia) (Estuningsih et al., 1997; Smooker et al., 2000; Spithill et 
al., 1997; Wijffels et al., 1994a; Wijffels et al., 1994b) and Dalton (previously in 
Ireland) (Dalton et al., 1996; Dalton et al., 2003b; Dowd et al., 1994; Dowd et al., 
1997; Piacenza et al., 1999; Roche et al., 1997).  
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A 
 
 
B 
Figure 1.3. Molecular structure of F. hepatica (A) mature cathepsin L1  and (B) 
model of cathepsin B (Law et al., 2003).  
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Figure 1.4. Involvement of four inter-related aspects in parasite vaccine 
development processes (adopted from ). 
 Vaccine development processes 
1. Parasite Biology 
 
 Epidemiology 
 Disease transmission 
 Host resistance/susceptibility 
 Farm management 
 Resistance to drugs 
2. Molecular Biology 
 
 Gene cloning and isolation 
 Gene sequencing 
 Genomics/proteomics 
 Bioinformatics 
 Recombinant protein production 
by prokaryotic and eukaryotic 
expression 
 DNA vaccines 
 Transcriptional analysis-RNAi 
 DNA microarray 
3. Immunology 
 
 Native/acquired immunity  
 Th1/Th2 dichotomy 
 Protective immunity 
 Target antigen 
 Mucosal/systemic immunity 
 
 
4. Vaccine trials 
 
 Laboratory animal models 
 In vitro parasite killing 
 Field trails 
 Regulatory issues 
 Consumer issues 
 Safety issues 
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1.3.1. Bacterial expression of cathepsin L and cathepsin B 
 
Yamasaki et al. (2002) have expressed Fasciola gigantica cathepsin L1 proprotein 
and mature cathepsin L1 in E. coli, and inferred that the pro region of the protease is 
essential for correct folding of the protease. Kesik et al. (2007) expressed cathepsin 
W as inclusion bodies in E. coli, and this protein was used for enteral vaccination of 
rats against Fasciola infection. Though E. coli remains the preferred host for 
recombinant protein production, due to its ease of handling, cost effectiveness and 
high success rates, it often has shortcomimgs undesired effects such as the inability 
to perform post-translational modification and ends in inclusion body formation . The 
E. coli cytoplasm is a reducing environment that is unfavourable for correct 
disulphide bond formation . Proteins expressed in the E. coli system may lack 
biological function and antigenicity due to the lack of post translational modification, 
or misfolding. To obtain biologically active proteins, many renaturation methods 
have been implemented. These include dialysis, dilution and column 
chromatography .  
 
1.3.2. Yeast expression of cathepsin  
 
Saccharomyces cerevisiae has been developed as an alternative eukaryotic 
expression system and has been extensively studied as an expression system for 
Fasciola cathepsin L genes. Intracellularly expressed cathepsin L underwent 
proteolytic degradation during isolation. The recombinant protein can be secreted 
into the medium by co-expression with yeast expressed signal sequences such as 
α- secretion signal (Lipps et al., 1996). Recombinant cathepsin L1 and cathepsin L2 
were expressed and secreted by S.cerevisiae transformed with plasmids containg 
cDNA’s (Dowd et al., 1997). These were correctly processed, secreted as mature 
enzymes and showed similar biochemical and substrate specificity to native 
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cathepsins (Brady et al., 1999; Roche et al., 1997). Then, these proteases were 
rapidly purified by gel and ultra filteration chromatography (Dalton et al., 2003b). The 
cathepsin L1 and cathepsin L2 expression yields were low (100 µg/ L) (Dowd et al., 
1997; Roche et al., 1997), but  expression of F. hepatica cathepsin L5 in pFLAG has 
attained 2 mg/L of culture and can be purified by His6 tag nickel chelate affinity 
chromatography and cation exchange chromatography .   
 
Wild-type procathepsin L1 expressed in Pichia pastoris showed an intermolecular 
processing event resulting in an intermediate form. A high level of expression was 
observed, with no hyperglycosylation (Collins et al., 2004; Dowd et al., 2000). 
Excellent expression has been achieved (800 mg/L) and purification by His6 tag 
affinity chromatography (Collins et al., 2004). Fasciola cathepsin B was expressed in 
P. pastoris, yielded 40µg/ L and showed enzymatic activity (Beckham et al., 2006). 
 
1.3.3. Insect cells  
 
Insect cell expression has been studied extensively in parasite recombinant protein 
production and has yielded recombinant proteins capable of inducing protective 
immunity against challenge infection . Baculovirus contains a gene encoding an 
abundant protein, polyhedron, which has a very strong promoter (polh). Polyhedrin 
is not important for viral replication and the gene can be replaced with heterologous 
genes which are then expressed in the system. Baculovirus expression allows 
correct folding with disulfide bond formation and post-translational modifications . 
Fasciola procathepsin L3 (Fhe CL3) was expressed in the baculovirus system and 
also S.cerevisiae, but only baculovirus expressed Fhe CL3 induced significant 
protection against liver flukes in challenged rats . 
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1.4. Vaccine trials with cathepsin L and cathepsin B 
 
1.4.1. Vaccination with native cathepsin L  
 
1.4.1.1. Ovine vaccine trials 
 
Cathepsin L1 and cathepsin L2 vaccine potential have been extensively evaluated in 
sheep and cattle. Wijffels et al. (1994b) performed immunisation of native cathepsin 
L1 and L2 in sheep. This Freunds adjuvant vaccine formulation induced 70% 
reduction with faecal egg count and 67% reduction in worm fecundity, but did not 
show a signicant reduction in worm burden against challenge infection. In contrast, 
F. hepatica cathepsin L1 and cathepsin L2 vaccine trials were performed in 
Uruguayan sheep breeds which induced 34% and 33% fluke burden reduction and 
elicited 71% and 81% anti-fecundity respectively. A cocktail of the two enzymes 
showed 60% reduction in worm burden. Vaccination of Australian Merino sheep with 
two cathepsins induced 69% egg output reduction .  
 
1.4.1.2. Bovine vaccine trials 
 
Cattle vaccination against Fasciola infection is experimentally feasible, but more 
extensive vaccine research is needed before an effective vaccine is developed.  The 
vaccine efficacy of both secreted cathepsin L1 and cathepsin L2 proteinases were 
tested alone or in combination with F. hepatica haemoglobin in cattle (Dalton et al., 
1996; Mulcahy et al., 1999). These immunogens have given consistent levels of 
protection against infection in cattle which ranges from 38.2-68.5%. The 
combination of both antigens (L1 and L2) has never been tested in cattle, but when 
combined with haemoglobin, showed 51.9 % and 72.4% protection against infection. 
In bovine vaccine trials, reductions in egg production and egg viability ranging from 
40 to 65% were observed, whereas cocktail vaccine with haemoglobin ranged from 
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80 to 98% reduction (Dalton et al., 1996; Dalton & Mulcahy, 2001; Dalton et al., 
2003b).  Cathepsin L’s from adult F. gigantica have been tested in Brahman cross-
bred cattle using DEAE dextran/sm as adjuvant. These vaccinations induced high 
antibody titres, but no reductions in faecal egg count . The above mentioned vaccine 
efficacy trials in sheep and cattle have been evaluated using native cathepsin L 
peptidases. 
 
1.4.2. Vaccine trials with recombinant cathepsin L and B 
 
Production and purification of recombinant cathepsin protease that mimic the levels 
of immunogenicity induced by native protease is needed. Expression of cathepsin B 
and L in yeast revealed that production of biologically active, native-like recombinant 
cathepsin protein is possible (Beckham et al., 2006; Dowd et al., 1997; Law et al., 
2003; Lipps et al., 1996; Roche et al., 1997). Recombinant cathepsin L expressed in 
P. pastoris was used as a vaccine in sheep and induced protection ranging from 35-
45% and had an anti-fecundity effect of 50%. Recombinant procathepsin L3 was 
expressed by baculovirus and S. cerevisiae. Baculovirus expressed protease 
evoked 52% protection in rats, but yeast expressed protease did not induce a 
significant protective effect (Reszka et al., 2005). Recombinant cathepsin W 
cysteine protease was expressed in the form of inclusion bodies, and used for 
intranasal immunisation in Holstein-Friesian calves and elicited 54% protection 
against infection, whereas 56.5% protection was achieved in Corriedale lambs  . 
Native cathepsin B from NEJ or immature liver flukes is secreted in only small 
quantities, so performing vaccine trials with the native protein is difficult. Therefore 
recombinant FhCatB immunization was performed in rats. The yeast expressed 
protein was formulated in Quil A or Freunds adjuvant and induced IgG antibody 
titres of 106 and 105 respectively in vaccinated animals (Law et al., 2003). There is 
no data on vaccine trials with recombinant cathepsin B protein and protection 
against challenge infection in animals. 
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1.4.4. Factors hindering Fasciola vaccine development  
 
 Although cellular infiltration and high anti-fluke antibody titres were observed in 
many immunisation studies, commercial success has not yet been attained. There 
are three factors responsible for slowing down the development of an effective 
vaccine: 
 
1. The infective stage juvenile flukes after excysting from metacercariae invade 
three different locations of the host,  
A. the wall of the small intestine  
B. the peritoneal cavity 
C. the hepatic parenchyma and liver surface, finally reaching the bile duct .  
 
There are very few reports describing the influence of the site in the host (gut, 
peritoneum and liver) or stages of fluke life-cyle on the induction of innate and 
acquired immunity  (McGonigle et al., 2008; Meeusen & Piedrafita, 2003; van 
Milligen et al., 1998).  
 
2. Rapid migratory activity of immature flukes throughout hepatic tissues causes 
extensive haemorrhage, fibrosis and calcification which has been confirmed in goats  
and sheep . This activity makes it difficult for effective cellular defence mechanisms 
against flukes to operate. 
 
3. Cathepsin L and cathepsin B cysteine proteases liberally secreted by all stages of 
Fasciola inhibit the lympho-proliferative responses by inducing (non-protective and 
immuno-pathological) Th2 responses via IL-4 and IgG1 (Brady et al., 1999; O'Neill 
et al., 2001). 
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Most vaccine candidates are extracted from adult parasites . No cocktail vaccine 
study has been conducted using various stage-specific Fasciola antigens for 
inducing protective immunity. However, our laboratory is interested in investigating 
the immune potency of three stage-specific cathepsins in providing a protective 
effect against experimental rat fasciolosis. 
 
1.4.4.1. Immuno reactivity of rodent model against fluke infection  
 
The immune response to F. hepatica infection has been evaluated in different 
mammalian hosts from rats to ruminants (Mulcahy et al., 1998; Mulcahy et al., 1999; 
Mulcahy & Dalton, 2001). Many mammalian hosts recognize potentially protective 
fluke antigens, but only rats exhibited the cellular effector mechanism for killing 
newly excysted juvenile flukes (Piedrafita et al., 2001; Piedrafita et al., 2007). 
Production of free radicals is 30 fold higher in the rat model than the mouse animal 
model when they were challenged with crude antigens.  
 
Oxidative stress is a general mechanism whereby free radicals induce oxidative 
damages and reduce the antioxidant defences of the biological systems. Oxidative 
stress is a significant feature of chronic F. hepatica infection in grazing sheep 
(Saleh, 2008).  
1.5. DNA vaccines 
 
The use of plasmid DNA to induce the immune system to develop immunity against 
infectious disease provides a variety of practical benefits for large scale vaccine 
production which are not attainable with other forms of vaccines including 
recombinant protein or neoplastic cells . DNA immunisation against intracellular 
parasites has been demonstrated in Leishmania (Gurunathan et al., 2000b), 
Toxaplasma  and Malaria (Rainczuk et al., 2004; Smooker et al., 2004). Smooker et 
al. (2004) have reviewed the application of DNA vaccines against parasites. 
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1.5.1. Advantages of DNA vaccines 
 
DNA vaccines offer a number of advantages than protein based vaccines. Plasmid 
DNA vaccines can encode multiple immunogenic epitopes and elicit both humoral 
and cell mediated immune responses . DNA vaccines are considered to be safe with 
no risk of reversion to a virulent form (Ulmer et al., 1993). Plasmid vectors can be 
rapidly constructed, easily tested, produced and are cheaper to manufacture than 
protein vaccines .  
 
DNA is thermostable and there is no need for a cold chain cycle (Ramsay et al., 
1997; Ramshaw & Ramsay, 2000), and therefore can be ideal for application in 
developing countries where the cost per dose of veterinary vaccines is the main 
concern (Watts & Kennedy, 1999; Watts et al., 2000). The encoded protein can be 
presented to the immune system in the same manner as it occurs during native 
infection. Another major advantage is the capability of expressing immunogenic 
epitopes for a longer duration. DNA vaccines can be administered repeatedly 
without inducing anti-vector immunity. Hundreds of publications have now reported 
the efficacy of DNA vaccines in the lab animals than livestock models of infectious 
diseases, cancer and autoimmune diseases . 
 
1.5.2. Properties of DNA vaccine vectors 
 
The basic requirements for the backbone of a DNA plasmid vector are a eukaryotic 
promoter, a multiple cloning site, a polyadenylation sequence, a selectable marker 
and a bacterial origin of replication (Gurunathan et al., 2000a; Smooker et al., 2004), 
as depicted in Figure 1.5. A strong promoter is required for optimal expression in 
mammalian cells, and typically the strong promoter from cytomegalovirus (CMV) is 
used. A cloning site should be provided for insertion of the heterologous gene 
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Figure 1.5. The back bone of DNA vaccine vector (adopted from ) 
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 and inclusion of a transcription termination sequence such as bovine growth (BGH) 
provides stabilisation of mRNA transcripts. The E. coli Col E1 origin of replication is 
used in DNA vaccines, due to its high copy number in bacteria enabling high yields 
of plasmid DNA on purification. 
 
1.5.3. Immune responses after vaccination with DNA vaccines 
 
1.5.3.1. Humoral immune responses 
 
Plasmid DNA vaccination induces humoral immune responses against bacterial, 
parasitic and neoplastic proteins (Donnelly et al., 2005; Gurunathan et al., 2000a; 
Smooker et al., 2004). After plasmid DNA encoded antigens are expressed in vivo, 
they can form a native structure with intact epitopes, therefore conformational 
epitopes can elicit neutralizing antibodies (Kumar & Sercarz, 1996; Ulmer et al., 
1993). Therefore DNA vaccination presents antigenically relevant epitopes to the 
immune system which may not be readily attainable by vaccination with other types 
of vaccines containing inactivated or irradiated organisms, or recombinant or purified 
native antigens which are delivered with adjuvant.  
 
Longevity of humoral responses along with induction of antibody isotypes IgG, IgM 
and IgA has been seen in humans (Justewicz et al., 1995; Justewicz & Webster, 
1996). The induction of subclass serum antibodies IgG1, IgG2a and IgG2b were 
reported by number of authors (Kennedy et al., 2006; Mitchell, 2002; Smooker et al., 
1999; Smooker et al., 2001; Tachedjian et al., 2003). Furthermore, IgE antibody 
production was stimulated by DNA vaccines encoding allergen, suggesting that this 
approach may be effective for attenuating allergic responses (Hsu et al., 1999; Hsu 
et al., 2001; Raz & Spiegelberg, 1999). Enhancement of immune responses against 
DNA encoded protein differs with dose and boosting, site and method of vaccination 
and co-injection with stimulatory molecules or cytokines (Boyle et al., 1999; Donnelly 
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et al., 2005). Antibody titre is generally dependent on the nature of the antigen, dose 
and number of vaccinations (Boyle et al., 1998; Deck et al., 1997). After DNA 
vaccination, the antibody peak response occurs between 4-12 weeks post 
vaccination (Gurunathan et al., 2000c). 
 
1.5.3.2. Helper T cell responses 
 
1.5.3.2.1. CD4+ helper T cell responses 
 
In many animal models, it has been demonstrated that after vaccination with a DNA 
vaccine the encoded protein can induce CD4+ T cells and CTLs (Kumar et al., 2001; 
Ulmer et al., 1993; Ulmer et al., 1994). Th1 type T-helper cells typically produce IFN-
γ whereas Th2 cells typically secrete IL-4 and IL-5. IL-12 facilitates Th1 
differentiation, whereas IL-4 facilitates Th2 differentiation . Bacterial DNA contains 
CpG motifs which can trigger the immune system to induce the IL-12 cytokine, 
which would generate Th1 responses, while protein, killed/inactivated vaccine 
typically induces Th 2 responses (Klinman et al., 1997; Krieg et al., 1998; Raz, 
1997). Intramuscular DNA injection usually induces the IgG2a isotype and IFN-γ 
secretion which is consistent with a Th1 response (Boyle et al., 1998; Donnelly et 
al., 1995; Donnelly et al., 1997; Gurunathan et al., 2000b).  
 
1.5.3.2.2. CD8+ helper T cells responses 
 
Plasmid DNA encoded protein can be easily modified and the method of 
immunisation permits for optimisation of both quantitative and qualitative aspects of 
CTL responses . An effective method of inducing CD8+ T cells against dominant 
and sub-dominant epitopes is to generate the same breadth of responses as that 
induced by natural infection. Subdominant epitopes may be important in mediating 
an effector role in the absence of CTL responses to dominant epitopes.  DNA 
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vaccines can elicit broad memory response to multiple epitopes (Fu et al., 2004; Fu 
et al., 1997).  
 
1.5.3.3. Methods of vaccine delivery 
 
Two main vaccine delivery methods for DNA vaccination include intra-muscular 
injection with saline and intra-dermal with saline or gold particles via a gene gun.  
 
1.5.3.3.1. Intradermal delivery 
 
Transfection of keratinocytes along with transfection of MHC class II expressing 
professional antigen presenting cells (APCs) is caused by biolistic intra-dermal DNA 
vaccination. The main advantage of gene gun immunisation is the amount of DNA 
required to achieve immune responses are only nanograms of DNA required, which 
is 100-1000 fold less than for intramuscular saline injection . Sixteen ng of plasmid 
has been found to induce an immune response using the gene gun, whereas 5000 
times more DNA (both ID and IM route) was required to attain comparable results in 
mice via ID route (Pertmer et al., 1995; Pertmer et al., 2001). Gene gun delivery or 
subcutaneous (SC) injection of the DNA vaccine induced Th1-like response and 
presence of IgG2 antibodies in vaccinated animals gave rise to protective immunity 
against experimental challenge infection. Thus, DNA vaccine efficacy in sheep is 
strongly influenced by the route of vaccination (De Rose et al., 2002).   
1.5.3.3.2. Intramuscular immunisation 
 
Intramuscular DNA injection elicits strong CD8+ responses, however muscle cells, 
which express MHC class I molecules, do not express B7.1 and B7.2 (CD 80 and 
CD 86), which are utilized for ligation of CD 28 on the T cell surface and provide the 
co-stimulatory signal (Gurunathan et al., 2000a; Smooker et al., 2004).  After DNA 
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vaccination APCs have been shown to present the encoded antigen to T cells, 
rather than muscle cells (Doe et al., 1996). There are several theories regarding 
antigen presentation after intramuscular DNA vaccination. It has been shown that 
the muscle cells cannot directly prime T cells, as they do not express appropriate 
co-stuimulatory molecules. Hence, the muscle cells act as a “factory” for protein 
production. In order for antigen to be presented to T cells, APC must take up the 
antigen. This can be resident APC’s in the muscle bed, which either take up the 
plasmid, or protein secreted by muscle cells, or access protein via cross-
presentation of antigen from muscle cells. 
 
1.5.3.4. The importance of the dendritic cells (DC) in antigen presentation 
 
Dendritic cells (DCs) play a major role in inducing immune responses after DNA 
immunisation. After vaccination, only a limited fraction of injected DNA molecules 
are available for DCs. The major DNA fractions are taken up by other cells 
(Keratinocytes or myocytes) which in turn produce encoded proteins, which can be 
recognised by B cells. These proteins can be efficiently captured and processed by 
DCs through receptor-mediated endocytosis and then presented via MHC class I 
and class II (Cross-priming) (Donnelly et al., 2005; Smooker et al., 2004; Steinman 
et al., 1997; You et al., 2001).  
 
1.6. Improving the immunogenicity of encoded antigens of plasmid DNA 
 
A rational approach to improve the efficacy of DNA vaccination would optimise 1. 
The vector backbone DNA sequence, 2. The co-expression of stimulatory 
sequences, 3. The delivery system used for the vector and targeting of vector for 
appropriate immune stimulation (Donnelly et al., 1997; Gurunathan et al., 2000a; 
Smooker et al., 2004).  The backbone of DNA could be further modified to enhance 
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immunogenicity via manipulation of DNA to include certain sequences. The CpG 
motifs in plasmid DNA induce a Th1 like pattern of cytokine production . It is 
possible to increase responses to DNA vaccine vectors by incorporating further CpG 
motifs into the DNA backbone of the plasmid . 
 
There are various strategies designed to improve immune responses after DNA 
vaccination. Some of these are as follows: 
1. Entrapment of DNA in liposomes  or micro-particle encapsulation such as 
attenuated intracellular bacteria . 
2. Cytokines and co-stimulatory DNA adjuvants enhance immune responses (IL-2; 
IL-4; GM-CSF) (Gurunathan et al., 2000c). 
3. Protein boosting: After priming DNA vaccination antibody responses are 
increased after a protein boost (Kennedy et al., 2006; Rainczuk et al., 2003). 
4. Use of secretory signals encoded in vectors such as the VR1020 plasmid (Boyle 
et al., 1999; Smooker et al., 1999). 
5. Targeting of APCs and lymph nodes (Boyle et al., 1998; Drew et al., 2001; 
Rainczuk et al., 2003; Tachedjian et al., 2003). 
6. Electroporation of injected DNA vaccines . 
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Figure 1.6. Immune mechanism of DNA vaccination ( adopted from ). 
The gene of interest is inserted in a plasmid. Secreted proteins elicit cytokines, Th 
cells, and antibodies to act against infection via prophylactic and therapeutic 
vaccination.  
  41
1.6.1. Secretory and cytoplasmic sequences in plasmid DNA  
 
Boyle et al. (1997) has demonstrated higher CTL responses and antibody titres after 
DNA immunisation with ovalbumin in a secreted form (Boyle et al., 1997). Rainczuk 
et al. (2003b) used pVR1020 to secrete encoded Plasmodium falciparum MSP4/5 
protein against lethal malarial challenge. After three vaccinations, the IgG antibody 
titre attained a high level as well as significant protection upon protein boosting. F. 
hepatica glutathione S transferase targeting the encoded protein to the cytoplasm 
(VR1012) and extracellular compartment (VR1020) were evaluated in vitro (COS 7 
cells) and in vivo (BALB/c mice). The secretory form of the DNA vaccine induced a 
mixed Th1/Th2 response after intramuscular vaccination . The active secretion of 
DNA encoded protein would allow optimal release of antigen from the transfected 
myocyte into the extracellular space where it could then either migrate to lymph 
nodes or be captured by migrating APCs. The expression of cytoplasmic antigen, 
would release either small doses of antigen trafficking to lymph node or make 
protein accessible after the death of transfected muscle cells (Boyle et al., 1997; 
Drew et al., 2000).  
 
1.6.2. Chemo-attractant Monocyte chemotactic proteins (MCP3) 
 
Chemokines are 8 to 12 k Da size peptides and two chemokine families are 
recognised based on the cysteine residues in their N-termini . Immature DCs 
express chemoreceptors from CCR1 to CCR6 . MCP3 has been shown to bind to 
chemokine receptor CCR1, CCR2 and CCR3 which are expressed on immune cells 
such as monocytes, T lymphocytes, eosinophils, basophils and dendritic cells (Gong 
et al., 1996; Xu LL et al., 1995). Poorly immunogenic encoded antigen can be 
efficiently rendered immunogenic by targeting them to APCs via differentially 
expressed chemokine receptors. In this way, many neoplastic and HIV antigens 
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fused with a pro-inflammatory chemo-attractant, induced potent and protective 
immunity in mice (Biragyn et al., 2001).  The chemokine fusion protein once 
internalised is degraded and can be presented using both the MHC class I and class 
II pathways . It has also been suggested that MCP3 fused antigens do not require 
adjuvants and are able to stimulate immune response in vivo and in vitro using 
relatively low doses (Biragyn et al., 1999).  
 
MCP3 is able to interact with at least three types of receptors,  
1. MCP1 receptors on monocytes and basophils,  
2. Selective Rantes receptor on basophils and eosinophils,  
3. Selective M1P1α on basophils, eosinophils and neutrophils (Ben-Baruch et al., 
1995; Gong et al., 1996).  
 
1.6.3. Lymph node targeting cytotoxic lymphocyte antigen- 4 
 
 
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is expressed on activated T cells and 
shows strong binding affinity to both B7-1 (CD 80) and B7-2 (CD 86) molecules 
expressed on APCs (Huang et al., 2000). It is a homologue of the T cell 
costimulatory molecule CD28 (Chambers et al., 2001). Direct targeting of antigens 
to APCs via fusion to CTLA4, which in turn interacts with B7 enables antigens to be 
processed and presented to T cells with much higher efficiency, leading to a 
stronger and faster immune response (Boyle et al., 1998; Huang et al., 2000). 
Fusion with CTLA4 allows an encoded protein to be efficiently captured by APCs, 
processed in endosomes and presented to MHC class II by DCs to induce CD4+ Th 
cells and to cross- present internalised antigen to MHC class I to elicit CTL 
responses. This vaccination strategy can induce strong immunity and may provide a 
novel, generic DNA vaccine design for development of therapeutic and preventive 
DNA vaccination (Drew et al., 2000; Drew et al., 2001). Drew et al. (2001) used 
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CTLA4 and L-selectin targeted DNA vaccines in mice and sheep, and demonstrated 
that CTLA4-targeted immunogen generated antigen-specific antibody responses 30 
fold higher than the non-targeted type. Kinetics of the antibody response after 
CTLA4 targeted DNA vaccinations were significantly faster than the non-targeted 
one. Rainczuk et al. (2003) found an enhanced antibody response at 20 weeks after 
CTLA4/MSP4/5 vaccination, irrespective of the route (intramuscular or intradermal). 
A study in sheep with CTLA4 fused to the F. hepatica cathepsin B showed 
enhanced speed and magnitude of the primary immune response . 
 
 1.7. Fasciola DNA vaccines 
 
A DNA vaccine encoding a Fasciola antigen was first reported several years ago 
(Smooker et al., 1999; Smooker et al., 2001). The induction of humoral responses to 
the GST antigen was in a mode-specific manner.  Fasciola GST cDNA subcloned 
into the cytoplasmic vector pVR1012 and secretory vector pVR1020 was injected 
intramuscularly into BALB/c mice. The cytoplasmic construct resulted in a Th1 type 
response, whereas the secretory construct yielded a mixed Th1/Th2 isotype 
response, as inferred by the titres of antibody isotypes. The humoral response and 
antibody isotype profile against Fasciola GST was influenced by the mode of 
vaccine delivery and targeting of the encoded antigen (Smooker et al., 2001). 
 
Kofta et al. (2000) designed a pCDNA plasmid vaccine encoding a cysteine 
protease which was injected intramuscularly to male and female rats. All rats were 
challenged against fluke metacercariae, and male rats showed 100% protection, 
whereas female rats revealed 74% reduction in fluke burden.  
 
The isotype profile induced after secretory construct VR1020/FABP vaccination 
showed an IgG1 dominant response with significant a IgE, IgG2a and 2b response 
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remarking a mixed Th1/Th2 response in mice (Smooker et al., 2001). However 
VR1012/cathepsin L5 showed moderate IgG2a and no IgG2b response, but 
predominant IgG1, IgE responses indicating a predominantly Th2-like response 
(Smooker et al., 2001). It should be noted that the VR1012/cathepsin L5 construct 
retained the native signal sequence for the protease, and hence it was secreted 
from host cells. The humoral and cellular response to DNA vaccination encoding the 
saposin like protein (Fh SAP-2) in secretory (FLAG-CMC/SAP) and cytoplasmic 
(FLAG/SAP-2) forms has been investigated both in vivo and in vitro (Espino et al., 
2005). They observed that vaccination with cytoplasmic construct induced a mixed 
Th1/Th2 response. 
 
1.8. Scope and aims of the project 
 
 
Fascioliasis is an economically important veterinary parasite disease. Although anti-
helminthic drugs are effective against this organism, drug resistant strains have 
emerged . In addition, anti-flukicides have their own demerits against the 
environment and residues in animal food products. Vaccination offers an effective 
alternative to drug treatment. The complex lifecycle and immunomodulatory property 
of the parasite makes Fasciola vaccine development challenging. At each stage of 
fluke development, the parasite secretes different antigens. In addition, at different 
development stages the fluke resides at a different location in the definitive hosts.  
 
The Faciola vaccine development process involves identification of stage specific 
antigens (juvenile, immature and mature stage), their subsequent isolation, 
recombinant protein expression, biochemical and immunological characterisation . 
The secreted cysteine protease family has been extensively studied, with the most 
promising antigens appearing to be cathepsin L (Dalton et al., 2003b; Kesik et al., 
2007; Spithill et al., 1997; Wijffels et al., 1994b) and cathepsin B (Beckham et al., 
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2006; Kennedy et al., 2006; Law et al., 2003; Meemon et al., 2004). Functional  
expression in yeast has proved to be more effective for cathepsin L (Dowd et al., 
1994; Roche et al., 1997), cathepsin L5  and cathepsin B (Law et al., 2003) than 
other system.  
 
Most Fasciola vaccine experiments have correlated protection against challenge 
infection with immunological parameters (IgG1, IgG2 and IgE or Th1/Th2) (Kesik et 
al., 2007; Mulcahy et al., 1998; Mulcahy & Dalton, 2001; Wedrychowicz et al., 2003; 
Wedrychowicz et al., 2007). Pathological (liver damage) and parasitological 
parameters (fluke recovery, size and wet weight of the flukes) are naked eye 
observations of the vaccine efficacy.  Rats were challenged with natural infection of 
Fasciola hepatica showed a much higher immunoreactivity to cathepsin L 
proenzyme (Harmsen et al., 2004). Medium resistance group showed considerable 
macroscopic liver damage with calcification and dilatation of bile duct. Bovine, 
rodent and human beings belonged to this group.  Rats are often used as a model to 
study immunity in cattle (Van Milligen et al., 1998). Thus, rats are often used as a 
model to study immunity in cattle. Experimental oral challenge, liver score analysis, 
pathogenocity and immunity assessment in rodent model are evaluated easily for 
laboratory based vaccine analysis. However, our vaccine research team are 
interested in investigating the immune potency of cathepsin proteins using this 
classical infection rodent model of Fasciola. 
 
 
Escherichia coli expression leads to production of inactive cathepsin L inclusion 
bodies which subsequently refold to active form of cathepsin L by using 
cumbersome renaturation methods (Kesik et al., 2007; Yamasaki et al., 2002). 
Cathepsin L contains cysteine residues and requires disulfide bond formation for 
proper folding of the protease, but expressed insoluble proteases consist of 
misformed disulfide bridges due to over expression. These misfolded proteases are 
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not active. In order to utilize these proteins fully, refolding into an active form was 
pursued. 
 
In addition to identifying new antigens, it is advantageous to evaluate vaccine 
potential of novel vaccination strategies. DNA vaccines are a new proliferating 
vaccine research and have the capability of eliciting CD4+ and CD8+ T cell 
responses against infection. DNA vaccines are easily manufactured and transported 
to an endemic area without cold storage. In vitro and in vivo analysis of DNA 
vaccines F. hepatica cathepsin L5 was initiated by Smooker et al. (2001), ovine 
CTLA4 fused to cathepsin B was analysed by Kennedy et al. (2006) and the 
protective efficacy of cathepsin L was reported by Kofta et al. (2001). Each of these 
trials induced humoral responses against target antigen. The stunning sucessess in 
murine models demonstrate that DNA could be used to identify candidate antigens 
for more conventional vaccines and provide useful tools to understanding the 
immunology relavant to these models (Boyle et al., 1999). More over, these models 
may eventually unravel the mechanism of DNA uptake and immune induction. Low 
resistance group showed prolonged Fasciola infection with no calcification which 
includes sheep, mice and rabbit (Spithill et al., 1997). However, further immune 
induction studies are planned using the BALB/c mice to elucidate the relative 
vaccine effect of four different vaccine constructs encoding cathepsin B and before 
this approach can be applied to target species includes sheep, a more complete 
understanding of mechanism underlying antigen targeting and DNA vaccine delivery 
will be required. These mechanisms may then be manipulated for higher efficiency 
and thus efficacy in ruminants be augmented. 
 
In summary, the aims of the work described in this thesis are: 
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1. To evaluate yeast expression, purification and immunological properties of adult 
F. hepatica cathepsin L5, immature stage F. gigantica cathepsin L1g and juvenile F. 
hepatica cathepsin B. 
 
2.  To determine the protective efficacy of these stage specific Faciola recombinant 
cathepsin proteins using the rat model of fasciolosis. 
 
3. To characterise the immunological potency of various DNA vaccine constructs 
encoding cathepsin B using a mouse vaccination model. 
 
4.  To analyse E. coli expression and refolding of the of Faciola gigantica cathepsin 
L1g.  
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Chapter 2 
Materials and Methods 
 
2.1 General Procedures 
 
Routine methods are presented in this section. Methods specific for studies 
described in individual chapters are presented there.All buffers, culture media 
solutions were prepared in Milli Q, using the Millipore water system unless otherwise 
specified. Liquid, agar media and glassware were sterilised by autoclaving at 121°C 
for 20 mins. Glassware was washed in Pyroneg detergent by using a dishwasher 
(Galaxy scientific, Australia). 
 
2. 2. Materials 
2.2.1. Materials for specific application 
 
Cell culture reagents 
Concanavalin A     Sigma-Aldrich Pty. Ltd, USA 
L- glutamine      Sigma-Aldrich Pty. Ltd, USA 
HEPES Buffer      Cytosystem Pty Ltd 
Incubator, for tissue culture    Forma Scientific 
Newborn calf serum     Sigma-Aldrich Pty. Ltd, USA 
LipofectamineTm LTX reagent    Invitrogen 
RPMI medium                Thermo Trace, USA 
Tissue Culture Flask (25 cm2, 50 cm2, 75 cm2) Nunc, Denmark 
Trypsin        Sigma-Aldrich Pty. Ltd, USA 
ELISAs                                                          
Anti-rat IgG-Horse Radish peroxidise conjugate Sigma-Aldrich Pty. Ltd, USA 
Anti-mouse IgG-Horse Radish peroxidise conjugate Sigma-Aldrich Pty. Ltd, USA 
ELISA 96wellplate     Nunc, Denmark 
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Phosphate Buffered Saline (PBS)   Oxoid Australia Pty. Ltd 
Skim milk powder     local supermarket 
Sulphuric acid      BDH Chemicals, Australia 
3, 3’, 5, 5’-tetramethylbenzidine dihydrochloride BD Pharmingen, USA 
TweenR 20      Sigma-Aldrich Pty. Ltd, USA 
ELISPOT assay 
IFN-γ capture antibody    BD Pharmingen, USA 
IFN-γ biotin conjugated antibody   BD Pharmingen, USA 
IL-4 biotin conjugated antibody   BD Pharmingen, USA 
IL-4 capture antibody     BD Pharmingen, USA 
Multi screen plates     Millipore, USA 
Strepavidin Alkaline phosphatase   Sigma-Aldrich Pty.Ltd, USA 
Enzymes 
 
Restriction endonucleases such as, BamH I, EcoR I, Kpn I, Pst I, Not I, Mlu I were 
used in this study from Promega. 
Calf intestinal alkaline phosphatise   Roche Diagnostics 
DNase       Sigma-Aldrich Pty.Ltd, USA  
RNase       Roche Diagnostics  
T4 DNA ligase and buffer    Invitrogen, Australia 
Molecular biology kits 
ABI Prism BigDye Terminator Cycle  
Endo free plasmid Giga Kit    QIAGEN, Germany 
EXPAND PCR System    Roche Diagnostics 
QIA quickR PCR purification kit   QIAGEN, Germany 
QIAEXRII Gel Extraction Kit    QIAGEN, Germany 
Qiaprep Mini Spinkit      QIAGEN, Germany 
Sequencing Ready Reaction Kit    Perkin-Elmer Corp, USA 
TA cloning Kit      Invitrogen, Australia 
PCR reagents 
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Gene specific primers were synthesised at Gene works, Melbourne, Australia. 
dNTPS      Bioline, Australiai 
Lambda DNA      Pharmacia LKB, Sweden 
200µLPCRtubes     Axygen, USA 
Plasmids, E. coli and yeast strain 
pMCP3 was constructed by Dr. Peter Smooker 
pCTLA-4 was a kind gift from Dr. Andrew Lew. 
E. coli DH 5α      Stratagene, USA 
E. coli BL21 DE3 pLysS    Novagen, USA 
pVR1012 and VR1020    Vical Inc, USA 
pCR2.1      Invitrogen, Australia 
pRSET-A      Invitrogen, Australia 
S. cerevisiae BJ3505     Kodak, USA 
Protein purification 
Membra-CelTm15-kDa/cut-offDialysismembrane Viskase, USA 
Ni-nitrilotriacetic acid     Amersham-Biosciences,  
       Australia 
Chromatography column (5 mL and 2 mL)  QIAGEN, Germany 
SDS-PAGE, SDS-gealtin-PAGE and western blotting 
Anti-cathepsin B antibody was kindly supplied by Dr. David Piedrafita (Monash 
University, Melbourne), anti-cathepsin L monoclonal antibody was a kind from Dr. 
Rudi Grams (Thamasaat University, Thailand). 
Anti-rat Alkaline phosphatase   Invitrogen 
Anti-mouse Alkaline phosphatase   Invitrogen 
Anti-His monoclonal antibody raised in mouse Sigma-Aldrich Pty. Ltd, USA 
Anti-rabbit Horse Radish Peroxidase conjugate Sigma-Aldrich Pty. Ltd, USA 
Ammonium persulphate (APS)   Sigma-Aldrich Pty. Ltd, USA 
Gelatin from cold water fish skin   Sigma-Aldrich Pty. Ltd, USA 
Mark12unstained protein marker   Invitrogen, Australia 
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4-Chloro-1-naphthol     Sigma-Aldrich Pty. Ltd, USA 
L-Cysteine      BDH Chemicals, Australia  
Dithiothreitol (DTT)     Bio-Rad Laboratories, USA  
NBT/BCIP substrate solution    Roche Diagnostics, Australia 
Nitrocellulose membrane    Bio-Rad Laboratories, USA 
Sodium citrate      BDH Chemicals, Australia  
Sodium dodecyl sulphate (SDS)   BDH Chemicals, Australia  
SeeBlueRPlus2 prestained standard   Invitrogen, Australia 
TEMED (N, N, N’, N’-tetramethylethylenediamine) Bio-Rad Laboratories, USA 
Triton-X 100      Sigma-Aldrich Pty. Ltd, USA 
Trans-blot electrophoretic transfer cell  Bio-Rad Laboratories, USA 
Whatmann blotting paper    Whatmann, USA 
Two Dimensional gel analyses 
IPTG strips (pH 3-11), rehydration buffer, equilibration buffer I and II, 4-20%,11 cm 
criterion precast gel, Protean IEF cell system, Electrophoretic unit were purchased 
from Bio-Rad Laboratories, USA.  
Vaccine trials 
Female BALB/c mice    Monash Animal Services, Australia 
Male Sprague Dawley rats   Monash Animal Services, Australia 
F. hepatica metacercariae   Macarthur Agricultural Institute,  
      Australia 
Syringe (1 mL, 5 mL, 10 mL, 20 mL, 50 mL) Terumo pty Ltd, Australia 
Quil A (Quillaja saponaria A extract)  Sigma-Aldrich pty. Ltd, USA 
 
2.2.2. General chemicals and equipment 
 
Acetic Acid, Glacial  BDH Chemicals, Australia 
Acrylamide-bis-Acrylamide (40%)   BDH Chemicals, Australia 
Acetone      BDH Chemicals, Australia 
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Agarose (DNA Grade)    Progen Industries, Australia 
Albumin, Bovine serum    Sigma-Aldrich Pty. Ltd., USA 
Ammonium acetate     Ajax Chemicals Ltd, Australia 
Ammonium chloride     BDH Chemicals, Australia 
Ammonium hydroxide      BDH Chemicals, Australia 
Ammonium persulphate    Bio-Rad Laboratories, USA 
Ampicillin      CSL, Melbourne 
L- Arginine      Sigma-Aldrich Pty. Ltd., USA 
Bacteriological agar     Oxoid Australia Pty. Ltd 
Balance Analytical Balance    Sartorius GMBH, Germany  
(ii) Balance (0.1-500g)     U-Lab, Australia 
Bicine       Sigma-Aldrich pty Ltd, USA 
Bromophenol blue     BDH Chemicals, Australia  
Capillary tubes     Becton Dickenson & Co, USA  
Cell strainer      BD Pharmingen, USA  
Centrifuge 
(i) Microcentrifuge     Zentrifugen, Germany 
(ii) Bench Top Centrifuge    Beckman, USA 
(iii) High Speed Centrifuge    Beckman, USA 
Centrifuge Tubes  
(i) 1.5 mL Eppendorf Tubes     Sarstedt, Germany  
(ii) 10 mL Centrifuge Tubes    Greiner Labortechnik, Germany  
(ii) 15 mL Centrifuge Tubes    Greiner Labortechnik, Germany  
(iii) 50 mL Centrifuge Tubes    Greiner Labortechnik, Germany  
4-Chloro-1-napthanol     Sigma-Aldritch Pty. Ltd., USA  
Coomassie Brilliant Blue R-250   Bio-Rad Laboratories, USA  
Coomassie Brilliant Blue G-250   Bio-Rad Laboratories, USA  
Coverslips      Mediglass, Australia  
Cryovials (1.8 mL)      Nalgene Company, USA  
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Electrophoresis Units  
(i) DNA  
a) Mini-gel      Pharmacia LKB, Sweden  
b) Midi-gel      Bio-Rad Laboratories, USA  
c) Maxi-gel      Pharmacia LKB, Sweden  
(ii) Protein  
a) Mini Protean II gel system    Bio-Rad Laboratories, USA  
b) Maxi Protean gel system    Bio-Rad Laboratories, USA  
c) Protean IEF Cell     Bio-Rad Laboratories, USA  
Ethylene glycol     Sigma-Aldrich Pty. Ltd, USA  
Ethylenediamine tetra acetic acid (EDTA)   BDH Chemicals, Australia  
Ethanol      BDH Chemicals, Australia  
Ethidium Bromide     Roche Diagnostics, Germany  
0.2µm, 0.45µm Filter (Acrodisc)    Gelman Sciences, USA  
D-Glucose       BDH Chemicals, Australia  
Glycerol      BDH Chemicals, Australia  
Glycine       BDH Chemicals, Australia  
Hydrochloric Acid (32%) v/v     Eqicell products Pty Ltd  
Hydrogen peroxide (30%)    BDH Chemicals, Australia  
Imidazole       Sigma-Aldrich Pty. Ltd., USA  
Iodoacetamide     Bio-Rad Laboratories, USA  
IPTG       Sigma-Aldrich Pty. Ltd., USA  
Isoamyl alcohol     BDH Chemicals, Australia  
Isopropanol      BDH Chemicals, Australia  
Kanamycin      Sigma-Aldrich Pty. Ltd., USA  
Lambda DNA      Pharmacia LKB, Australia  
Lithium chloride     BDH Chemicals, Australia  
Lysozyme      Roche Diagnostics, Germany  
Magnesium chloride     Perkin Elmer, USA  
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Β-mercaptoethanol      Bio-Rad Laboratories, USA  
Methanol      BDH Chemicals, Australia  
Microscopes  
(i) Light Microscope     Olympus Optical  
(ii) Phase Contrast Microscope   Nikon Kogaku KK, Japan  
PEG1000      Sigma-Aldrich Pty Ltd, USA 
Penicillin/Streptomycin    Thermo Trace, USA  
Petri Dish      Nunc, Denmark  
pH meter      Radiometer, Denmark  
Phenol       BDH Chemicals, Australia  
Phenol/Chloroform/Isoamyl Alcohol   BDH Chemicals, Australia  
Phosphate Buffered Saline (PBS)    Oxoid Australia Pty. Ltd  
Polyethylene glycol 8000    Sigma-Aldrich Pty. Ltd., USA  
Potassium acetate      BDH Chemicals, Australia  
Potassium chloride     BDH Chemicals, Australia  
Potassium hydrogen carbonate    BDH Chemicals, Australia  
 Silver nitrate      Sigma-Aldrich Pty. Ltd., USA  
Sodium chloride      BDH Chemicals, Australia  
Sodium hydroxide     BDH Chemicals, Australia  
Sorbitol      Sigma-Aldrich Pty. Ltd, USA 
Sulphuric Acid      BDH Chemicals, Australia  
Transilluminator (UV)      Bio-Rad laboratories, USA  
Tris-Base       Roche Diagnostics, Germany  
Tris-HCl      Roche Diagnostics, Germany  
Tryptone      Oxoid Australia Pty. Ltd  
Yeast extract       Oxoid Australia Pty. Ltd  
X-Gal       Sigma-Aldrich Pty. Ltd., USA  
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2.3. Bacterial and yeast culture methods 
2.3.1. Solution and buffers 
 
 
Ampicillin 
Ampicillin was dissolved in 5 mL sterile Milli Q water, making a stock solution of 100 
mg/mL and stored in 1 mL aliquots at –20°C. The ampicillin was added to media or 
broth at the final concentration of 100 µg/mL. 
Isopropyl-β-D-thiogalactopyranoside (IPTG) 1 M stock 
200 mg/mL IPTG filter sterilised through 0.2µm filter. Aliquots stored at -20°C.  
TE buffer (10X) 
Buffer contained 100 mM Tris and 10 mM EDTA, pH 8.0. 
Kanamycin 
Kanamycin was made up as a stock solution of 50 mg/mL in sterile Milli Q water and 
stored in 1 mL aliquots at -20°C. The working concentration of Kanamycin was 50 
µg/mL. 
 
2.3.2. Growth media 
 
Luria-Bertani (LB) media 
LB broth-0.5% yeast extract, 1% tryptone, 1% sodium chloride. When required, 
ampicillin was added to a final concentration of 100 µg/mL or 50 µg/mL of 
kanamycin. 2% bacteriological agar was added for preparing plates. 
Minimal media +uracil+Lysine 
0.67% (w/v) yeast nitrogen base, 2% (w/v) dextrose, 0.002% (w/v) uracil, 0.003% 
(w/v) lysine. Media was prepared as a 10X stock solution and filtered sterilised. For 
broth, stock was added to autoclaved Milli Q water and for preparing plate, 2% 
bacteriological agar was autoclaved and mixed with the stock solution. 
 
  56
YPD media 
The components were 2% (w/v) D-glucose, 2% (w/v) peptone, 1% (w/v) yeast 
extract, 1.5% (w/v) agar. 
YPHSM media 
The components were 1% (w/v) yeast extract, 8% (w/v) peptone, 1% (w/v) D-
glucose, 3% (w/v) glycerol, 20 mM calcium chloride. The components were 
dissolved with Milli Q water (1: 20 dilution), and then autoclaved prior to use. 
 
2.3.3 Storage of bacterial and yeast strains 
 
Bacterial and yeast liquid cultures were pelleted by centrifugation, resuspended 
gently in growth medium and glycerol to a final concentration of 50% glycerol and 
stored at -70°C. 
2.3.4. Bacterial and yeast culture Conditions  
 
Both E. coli strains  (DH5α and BL21)were grown on LB broth at 37°C shaking (120 
rpm) for overnight.BJ 3505 strain was grown on minimal medium at 28°C shaking 
(120 rpm) for 72 hours. 
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2.3.5 Bacterial and yeast strains  
 
Table  2.1.  Bacterial and yeast strains used in this study 
 
Strain Genotype Source  
E. coli DH5α  supE ∆lacU169 (ф80 lacZ∆M15) hsdR17 recA1 
endA1 gyrA96 thi-1 relA1 
Stratagene 
E. coli BL 21(DE3) 
pLysS  
F- ompT hsdSB(rB-mB-) gal dcm (DE3) pLysS 
(CamR) 
Novagen 
S.cerevisiae 
BJ3505 
MATa ura3-52 trp1-∆101lys2-208 gal2 
can1Pep4::HIS3prb∆1.6R 
Kodak 
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2.4. DNA manipulation methods 
2.4.1. Buffers and reagents 
 
Alkaline lysis solution I 
The components were 50mMGlucose, 10mM EDTA, and 25mM Tris-Cl pH 8. The 
prepared solution stored at 4°C. 
Alkaline lysis solution II 
0.2 M NaOH, 1% SDS. The components were prepared using sterile MilliQ prior to 
use. 
Alkaline lysis solution III 
5 M potassium acetate. The solution prepared using MilliQ water and stored at 4°C.  
X-Gal solution 
X-Gal (100 mg) was dissolved in 5 mL of N, N’-dimethylformamide and stored at –
20°C.  
Isoproply-β-D thiogalactopyranoside (IPTG) (100 mM)  
IPTG (1.2 g) was dissolved in 50 mL of sterile Milli Q water, filter sterilised and 
stored at 4°C. 
NB buffer 
0.15 M NaCl, 10 Mm bicine were prepared using 10 mL of Milli Q water 
PEG-Bicine buffer 
40% PEG 1000, 200 mM bicine were dissolved in 5 mL of Milli Q  prior to use. 
SBEG buffer 
1M sorbitol, 10 M bicine, pH 8.4, 3% ethylene glycol dissolved in 5 mL of Milli Q 
water. 
6x Loading buffer 
40% sucrose, 0.25% (w/v) bromophenol blue and 0.25% xylene cyanol dissolved in 
sterile Milli Q water and stored at 4°C. 
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TAE buffer 50X 
The buffer components were 24.2% (w/v) Tris-base, 5.17% glacial acetic acid and 
1.86% EDTA (w/v) was dissolved in deionised water.  
2.4.2. DNA purification methods 
 
2.4.2.1. DNA vaccine preparation using Endotoxin free plasmid Giga kit 
(QIAGEN) 
 
Plasmid DNA for vaccination was prepared from one litre of E. coli DH 5α using the 
Endotoxin free plasmid Giga kit according to the manufacturer’s protocol. A single 
colony containing each DNA vaccine of interest was chosen after two rounds of 
selection on LB plates (supplemented with 100 µg/mL ampicillin or 50 µg/mL 
kanamycin). This was used to inoculate a starter culture of 10 mL kanamycin-LB 
broth (section 2.3.2). After overnight incubation, the grown culture was inoculated 
into 1 litre kanamycin-LB broth and this was incubated at 37°C for 16 hours with 
shaking (200 rpm). The grown culture was pelleted by centrifugation, resuspended 
in Tris-EDTA buffer supplemented with RNase A, lysed with NaOH/SDS and then 
neutralised with potassium acetate. The flocculent material was separated from 
DNA containing solution by vacuum-driven filtration through QIA filter. The filtered 
solution was then treated with “Endotoxin removal buffer” by incubation with on ice. 
The endotoxin free plasmid solution was then subjected to pre-equilibrated anion-
exchange column purification, followed by a wash with Isopropanol and then eluted 
with elution buffer. The purified plasmid was precipitated using 0.7 volumes of 
isopropanaol and subjected to high speed centrifugation. The DNA pellet was 
washed with 70% ice cold ethanol, air dried and then resuspended in endotoxin free 
MilliQ water. 
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2.4.2.2. Miniprep alkaline lysis purification method 
 
Ten millilitres of LB broth was inoculated with a single colony of bacteria and grown 
overnight with shaking at 37°C. The grown culture was pelleted by centrifugation at 
4,000 x g for 3 minutes. The pellet was resuspended in 100 µL of ice-cold alkaline 
lysis solution I and incubated at room temperature for 5 min, followed by lysis with 
200 µL of alkaline lysis solution II and then neutralised with 150 µL of ice-cold 
alkaline lysis solution III. The mixture was centrifuged for 10 min at 12,400 g and the 
resulted supernatant was then treated with an equal volume of phenol/chloroform 
(24 chloroform: 1 isoamyl alcohol) by inverting five times. The supernatant was 
collected after the centrifugation at 12,400 g for 5 min. The DNA was mixed with an 
equal volume of isopropanol and followed by centrifugation for 10 min at 12, 400 g. 
The DNA pellet was washed with 1 mL of ice-cold 70% ethanol and then air-dried for 
15 min. The DNA pellet was finally resuspended in 40 µL of sterile Milli Q water. 
 
2.4.2.3. Determination of DNA concentration  
 
DNA concentration and purification were determined by measuring the absorbance 
of the DNA sample, diluted 1/200, in matching quartz cuvettes at 260 nm using a 
Schimadzu UV-160 spectrophotometer. An OD
260 
of one is equal to a DNA 
concentration of 50 µg/mL. An OD
260
/OD
280 
ratio was used to measure the quality of 
the DNA. Ratios of 1.8-2.0 indicated good quality DNA. 
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2.4.3. Recombinant DNA techniques 
 
2.4.3.1. Restriction endonuclease screening and phosphatase treatment of 
plasmid DNA 
 
Restriction digestion of plasmid DNA (for example, pRSET-A vector) was scaled 
according to the quantity of plasmid to be prepared. The reaction mixture contains 
the following components and was incubated at 37°C for 1 hour. 
 
Plasmid DNA   50 to 100 ng 
10X buffer   4 µL 
Enzyme   1 Unit 
Sterile MilliQ water  makes up to 40 µL 
Phosphatase treatment of plasmids was performed by incubating 10 µg restriction 
digested plasmid DNA with 0.5 µL calf intestinal Alkaline phosphatase (CIP) in 10 µL 
10X buffer for 45 minutes. After incubating for 45 minutes, the reaction was stopped 
by heat inactivation of the enzyme at 65°C for 15 minutes. 
 
2.4.3.2. DNA ligation 
 
The sizes and concentrations of gel purified products (inserts) were estimated. 
Ligation was performed at ratio of 1 plasmid DNA molecule to 3 molecules of insert 
DNA with 1 unit of T4 DNA ligase in 1 µL T4 DNA ligase buffer. The reaction volume 
made up to a total of 10 µL with sterile Milli Q water and incubated in 16°C for 16 
hours. The mixture was then used for transformation in competent E. coli BL21 or 
DH 5 α cell through electroporation. The total amount of insert DNA was calculated 
using the following formula. 
ng of insert = ng of vector X size of insert (kb) X 3/ size of vector (kb)  
  62
 
2.4.3.3. Transformation of competent E. coli with plasmid DNA 
2.4.3.3.1. Preparation of competent cells 
 
E. coli BL21 (DE3) pLysS or DH5α were grown in 10 mL of LB broth on a shaker at 
37°C for overnight. Two millilitres of this culture was used to inoculate 200 mL of 
pre-warmed LB broth in a flask and shaken vigorously at 37°C until approximately 
mid-log phase, an absorbance at 600 nm of 0.4-0.5, was reached. The cells were 
chilled on ice for 30 min and collected by centrifugation at 4000 g for 10 min at 4°C. 
The supernatant was completely drained off before the cells were washed in 200 mL 
of ice-cold sterile Milli Q water and collected by centrifugation at 4000 g for 10 min. 
This step was repeated with 100 mL of ice-cold sterile Milli Q. The cell pellet was 
resuspended in 10 mL of ice-cold 10 % sterile glycerol and centrifuged as before. 
The cells were resuspended in a final volume of 0.7 mL of ice-cold 10 % sterile 
glycerol and divided into aliquots of 40µL each and stored at -70°C. 
 
 2.4.3.3.2. Electroporation of competent cells and blue - white colony 
screening 
 
An aliquot of frozen electro-competent cells was thawed on ice for 15 min and mixed 
with DNA (approximately 40 ng) and transferred to an ice-cold electrocuvette with a 
0.2 cm gap. The pulse settings used to deliver DNA into the cells were 2.5kV, 25mF 
and 200Ω. After the pulse, 1 mL of SOC medium was immediately added to the cells 
and they were incubated at 37°C for 1 hour. One hundred microliters of transformed 
culture was plated out onto LB agar containing the appropriate antibiotic and/ or a 
final concentration of 100 µg/Ml, 40 µL each of 100 mM IPTG and 2% X-Gal plates. 
IPTG induced the promoter of the plasmid’s lac Z gene. If lac Z had been disrupted 
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by the insertion of a foreign insert into multiple cloning sites, then no β-
galactosidase was produced and colonies remained white. If however the plasmid 
was non-recombinant, active β-galactosidase acted on X- Gal to form a product that 
coloured colonies blue. Thus, cells transformed with recombinant and non-
recombinant plasmids were discriminated based on colony color. 
 
2.4.3.3.3. DNA sequence analysis and purification of PCR products for 
sequence analysis 
 
All DNA sequencing was carried out using the ABI PRISM Big Dye Terminator Cycle 
Sequencing Ready Reaction Kit according to the manufacturer’s instructions: 
Terminator ready reaction mix  2.0 µL 
Buffer      3.0µL  
Template DNA 
Double stranded DNA   X µL (200-500 ng) 
or PCR product    X µL (30-90 ng) 
Primer (100 ng/mL)    0.5 µL     
 
Milli-Q water      x µL 
 
Total volume     25.0 µL 
 
The PCR programme used for the sequencing of a DNA segment was as follows:  
 
Number of cycles Temperature   Duration 
 
25    94°C   10 seconds 
 
25    50°C   5 seconds 
 
25    60°C    4 minutes 
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Two µL of sodium acetate (pH 4.6) and 50 µL of 95% ethanol were added to 25 µL 
of sequence reaction, mixed and placed on ice-bath for 10 minutes and then 
centrifuged for 30 minutes at 5000 g. The supernatant was discarded and the pellet 
was rinsed in 250 µL of 70% ethanol, vortexed briefly and then centrifuged again for 
10 minutes at 5000 g. The pellet was air-dried and then analysed on ABI prism 377 
DNA sequencer at Monash University, Clayton, Victoria, Australia. 
 
2.4.4. Recombinant protein analysis 
 
2.4.4.1. Buffer and stock solution 
 
Bradford Coomassie reagent 
0.05% Coomassie blue R-250 was dissolved in 25 mL 95% ethanol and 50 mL 88% 
phosphoric acid  then made up to 500 mL using sterile Milli Q. To ensure thorough 
mixing of the components, the components were incubated at room temperature 
with shaking for 1 hour and then filtered through 0.45 µM filter and stored at 4°C. 
Coomassie Brilliant Blue staining solution 
0.05% Coomassie Brilliant Blue R-250 was dissolved in 250 mL methanol and 50 
mL acetic acid. After the Coomassie Brilliant Blue had dissolved, the solution was 
diluted to 500 mL with sterile Milli Q. 
Coomassie destaining solution 
The solution components were 10% Ethanol and 10% acetic acid. 
10x SDS-PAGE buffer 
3% Tris Base, 14.4% Glycine and 1% SDS was dissolved in Milli Q pH 8.3. 1X 
dilution of the buffer was used for running SDS-PAGE. 
SDS-PAGE sample buffer  
The components were 20 mM Tris- HCl, pH 8, 50 % glycerol, 2.5% SDS, 5% 
mercaptoethonol, 0.02% bromophenol blue. For preparing non-reducing SDS-PAGE 
sample buffer, 5% mercaptoethonol was excluded from SDS-PAGE sample buffer. 
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Silver staining fixative solution 
50% methanol, 10% acetic acid mixed in 100 mL of Milli Q  
Silver staining solution 
0.36% sodium hydroxide, 14.8 M ammonium hydroxide and 0.15% silver nitrate 
were used to prepare 100 mL of staining solution 
Silver staining development solution 
1% citric acid and 0.05% of formaldehyde were dissolved in 100 mL of Milli Q. 
Triss buffered saline (TBS)  
10 mM Tris base and 500 mM NaCl was dissolved in sterile Milli Q pH 7.4. 
Western blot transfer buffer 
25 mM Tris, 192 mM glycine, 20% methanol was dissolved in sterile Milli Q water. 
Western blot blocking solution  
5% skim milk powder was dissolved in TBS.  
Western blot developing solution 
The substrate, 30 mg 4-chloro-1-naphthol, was dissolved in 10 mL of Methanol. This 
solution was added to 50 mL of 1X TBS buffer, and 30 µL of hydrogen peroxide
 
pH 
7.4. The substrate NBT/BCIP, 200 µL of stock solution was added to 10 mL of 
1XTBS, pH 7.4. 
 
2.4.4.2. Bradford assay 
 
A standard curve was set up from a 1 mg/mL BSA stock at 30, 60, 90, 120, 150, 180 
and 210 µg/mL in 0.15 M NaCl. The purified protein samples were diluted 1/10 with 
0.15 M NaCl in a total volume of 100 µL. Bradford reagent (1mL) was added to each 
standard and test solution and incubated at room temperature for 2 min. 200 µL of 
mixtures were loaded in duplicate into 96 well plates, and absorbance’s read at 
600nm.  
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2.4.4.3. Protein purification by dialysis method 
 
Dialysis tubing of dialysis membrane 
 
Dialysis tubing buffer I 
2% sodium hydrogen carbonate and 1 M EDTA were dissolved into 800 mL of Milli 
Q and pH was adjusted to 8.0. 
Dialysis tubing buffer II  
1 M EDTA was dissolved into 800 mL of Milli Q and pH was adjusted to 8.0. 
 
Dialysis of yeast supernatants 
Prior to column purification, yeast supernatants were subjected to dialysis. After 
each use, the membrane was washed with Milli Q water several times and then 
immersed in boiling dialysis buffer I (by using gas burner) for 30 minutes. This was 
followed by washing the boiled membrane twice with Milli Q water and then 
immersion in boiling dialysis buffer II for 30 minutes. The membrane was stored in 
buffer II and or sterile Milli Q at 4°C until use. After pouring the yeast supernatant, 
the ends of dialysis membrane were tied by plastic clips. The assembly was placed 
into 5 litres of Milli Q water containing 250 mM sodium chloride (dialysis buffer) and 
the dialysis was performed for 1 litre of yeast culture for 4 buffer changes and at 
least 4 hours per change. 
2.4.4.4. Refolding of E. coli expressed proteins 
 
Buffers and solutions 
 
Inclusion body phosphate buffer 
The buffer contained 50 mM Na2HPO4 and 300 mM NaCl  
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Bacterial cell lysis buffer 
50 mM Na2HPO4, 0.5 M NaCl, 20 mM lysozyme, pH 8.0. The components were 
dissolved in Milli Q water prior to use. 
Solubilisation buffer  
50 mM Na2HPO4 pH 8.0, 10 mM EDTA and either 10 M urea and 10 mM β-
mercaptoethonol or 6 M guanidine hydrochloride and 10 mM DTT (Gdn HCl). The 
components were dissolved in 10 mL of Milli Q water. 
Urea gradient buffer 
Urea from 10 M to 0 M in 50 mM Na2HPO4, 0.5 M NaCl, 10 mM β- mercaptoethonol 
and 20% glycerol, pH 8.0. The buffer was prepared using sterilised Milli Q. 
Renatuation buffer 
 
50 mM Na2HPO4, 50 mM NaCl, 5 mM  EDTA, 4 mM  GSH,0.4 mM GSSG, 0.7 M L-
arginine mono hydrochloride, pH 10.5. 
 
2.4.4.5. Ni-NTA affinity chromatography purification 
 
Starter buffer or mixing buffer 
Buffer components were 250 mM sodium dihydrogen phosphate and 2.5 M sodium 
chloride and the pH was adjusted to 7.6. 
Running buffer 
The buffer components were 350 mM sodium chloride, 25 mM sodium dihydrogen 
phosphate and 1 mM imidazole (50 mL in sterile Milli Q) and the pH was adjusted to 
7.6. 
Washing buffer 
350 mM sodium chloride, 25 mM sodium dihydrogen phosphate and 10 mM 
imidazole was made up to 50 mL in sterile Milli Q and the pH was adjusted to 7.6. 
Mono-S-buffer 
25 mM sodium acetate, 1 mM ethylenediaminetetraacetic acid (EDTA), pH 5.0. 
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Chromatography column purification of proteins 
The NTA resin containing polypropylene column (5 mL) was charged with 1 mL of 
0.2 M Nickel sulphate and then 50 mL of sterile Milli Q passed through the Ni-NTA. 
This was followed by washing with 50 mL of the running buffer and dialysed yeast 
supernatants were loaded into the column. After washing with wash buffer, the 
protein was eluted using 100 to 400 mM imidazole (appropriate imidazole 
concentration optimised according to the protein visualisation in Coomassie stained 
SDS-PAGE). The eluted fractions were collected in eppendorf tubes and further 
analyses (by Bradford assay and SDS-PAGE) were performed. 
2.4.4.6. SDS-PAGE, gelatin substrate PAGE, Coomassie and silver staining  
 
2.5 mL of 1.5 M Tris pH 8.8, 100 µL of 10 % SDS, and 3.1 mL of 40% 
bis/acrylamide were added to 4.3 mL of Milli Q water. 50 µL 10% ammonium 
persulphate and 10 µL TEMED was added and mixture was mixed thoroughly prior 
to use. For preparing a SDS-gelatin separating gel, 0.5% gelatin was added in 
addition to above mentioned mixture. 
SDS-gelatin PAGE buffer I 
0.1M sodium citrate, pH 4.5 and 2.5% Triton X-100 was made up to 100 mL in Milli 
Q prior to use. 
SDS-gelatin PAGE buffer II 
0.1 M sodium citrate, pH 4.5 and 2 mM DTT or L- cysteine was made up to 100 mL 
in Milli Q prior to use. 
Stacking gel (4%) for both SDS-PAGE and SDS-gelatin PAGE 
1 mL of Tris pH 6.8, 40 µL of 10% SDS, 2.6 mL of Milli Q water, 20 µL 10% of 
ammonium per sulphate and 5 µL of TEMED was added and mixed thoroughly 
before use.  
SDS-PAGE, SDS-gelatin PAGE, Coomassie and silver staining 
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The purified proteins from the Ni-NTA column was mixed with SDS-PAGE sample 
buffer (5:1) followed by vortexing for 2 minutes and then heated at 100°C for 10 
minutes in heating column. SDS-PAGE stacking gel wells were loaded with 10 to 20 
µL of heated sample and electrophoresis was performed at 80 volts for 30 minutes 
and then 180 volts for 50 minutes. After electrophoresis, gels were stained with 
Coommassie Brilliant blue R 250, and destained with Coommassie destaining 
solution. If previously stained with Coomassie Blue, gels were rinsed with 50% 
methanol overnight with at least two changes. Gels were then fixed in silver staining 
fixative solution (2.4.4.1) for one hour with at least 3 changes. Following rinsing with 
Milli Q water the gels were immersed in silver staining solution (2.4.4.1) for 30 
minutes with at least 3 changes. After rinsing with Milli Q water, the gels were 
incubated in developer (2.4.4.1) and development was stopped by adding 1% acetic 
acid.  
 
For SDS-gelatin PAGE, protein samples were incubated with non-reducing SDS-
PAGE sample buffer for 30 minutes at 370C. This was followed by electrophoresis at 
200 volts for 1 hour at 40C, and the gels were incubated twice in buffer I for 30 
minutes. The gels were then immersed in buffer II for 4 to 12 hours at 370C. After 
incubating with gentle shaking, gels were stained with Coommassie Brilliant blue R 
250, destained and visualised under a light box.  
 
2.4.4.7. Western blot  
 
2.4.4.7.1. Electro-transfer of proteins to blotting membrane 
 
Following electrophoresis, the gel, a piece of nitrocellulose membrane, scotch-brite 
pads and 4 pieces of Whatmann paper were immersed in western blot transfer 
buffer. To assemble the western blot, a pad was placed on the apparatus, followed 
by the gel, the membrane, the Whatmann paper, and another pad. The air bubbles 
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were removed by using a glass rod. The apparatus was assembled according to the 
manufacturer’s instructions, and the western blot was performed at 75 volts for 1 
hour. 
 
2.4.4.7.2. Western blotting 
 
The blotting membrane or strip was blocked for 1 hour in TBS/Skim milk (5% v/v) at 
room temperature and then the membrane was rinsed 3 times in 1X TBS. The 
primary antibody or vaccinated animal sera was diluted in 1X TBS/skim milk (1 % 
v/v), added to the membrane and incubated overnight at 4°C. After incubation, the 
membrane was washed thrice for 10 min in 1 X TBS (1% v/v). The secondary 
antibody, either HRP or Alkaline phosphatase conjugate (dilution according to 
manufacturer’s instructions) was diluted in 1X TBS/skim Milk (1% v/v), added to the 
membrane and incubated for 1 hour shaking at room temperature. The membrane 
was then washed twice in 1X TBS (1% v/v). The membrane was developed by the 
addition of western blot substrate solution (2.4.4.1) (either 4-chloro-1-naphthol or 
NBT/BCIP) and incubated until the colour developed. 
 
2.5. Vaccination 
 
The DNA vaccination in BALB/c and recombinant protein immunisation in Sprague 
Dawley rats were performed with the approval of the RMIT and Monash University 
Animal Ethics committees respectively. 
2.5.1 Buffers and reagents  
 
ACK lysing buffer 
 NH
4
Cl (0.15 M), KHCO
3 
(10 mM) and Na
2
EDTA (0.1 mM) dissolved in sterile Milli Q 
and  pH adjusted to 7.4 with 1 M HCl and filter sterilised through a 0.2 µM filter.  
ELISA coating buffer I 
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NaHCO
3 
(8.4 g) was added to 100 mL of sterile Milli Q. 
ELISA coating buffer II 
Na
2
CO
3 
(10.6 g) was added to 100 mL of sterile Milli Q. 
ELISA Substrate Solution 
Equal volumes of reagent A and reagent B of TMB substrate were mixed prior to 
use. 
ELISPOT blocking buffer 
Newborn Calf Serum (5% v/v) was filter sterilised into sterile PBS. 
ELISPOT coating buffer 
Carbonate buffer 1 (4.53 mL) was added to Carbonate buffer 2 (1.82 mL) and 
diluted to 100 mL with sterile Milli Q. The pH was adjusted to 9.6 with either 
Carbonate buffer 1 or 2.  
SDS-gelatin PAGE buffer I 
0.1M sodium citrate, pH 4.5 and 2.5% Triton X-100 were diluted to 100 mL of Milli Q 
and prepared prior to use. 
SDS-gelatin PAGE buffer II 
0.1 M sodium citrate, pH 4.5 and 2 mM DTT or L- cysteine were diluted to 100 mL of 
Milli Q and prepared prior to use. 
 
2.5.2. ELISA  
 
 
The column purified protein was diluted to 5 µg/mL in carbonate coating buffer and 
100 µL was added to 96 well plates and allowed to incubate overnight at 4°C. Plates 
were washed in PBS/Tween 20 three times and then blocked for 1 hour in PBS/skim 
milk (5% v/v). Vaccinated mice or rat serum was diluted in PBS/Tween 20 and skim 
milk (1% v/v) at the appropriate concentration and 100 µL was added to each well in 
duplicate. Serum was incubated for 2 hours at 37°C. Plates were washed 3 times in 
PBS/T, and any remaining liquid was removed by tapping the plates on paper 
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towels. Secondary antibody (either anti-mouse or anti-rat HRP conjugate) was then 
diluted in optimal concentration in PBS/Tween 20 and 100 µL was added to each 
well and incubated for 1 hour at 37°C. After washing plates 4 times in PBS/T and 
twice in PBS, 100 µL of substrate was added to each well and allowed to develop 
for 30 min. The reaction was then stopped by the addition 100 µL of 0.2 M sulphuric 
acid. Absorbances were then measured on ELISA plate reader at an absorbance of 
450 nm. 
 
2.6. Bioinformatics and statistics analysis 
 
All the bioinformatics programs used in this thesis were found at the Australian 
National Genomic Information Service (ANGIS) (www.angis.org.au) or clone 
manager by Scientific and Educational Software. Statistical analyses were 
performed using SPSS (window version of 1.5) and Graphpad Prism (3.02 
software). 
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Chapter 3  
Recombinant yeast expression of secreted Fasciola cathepsin 
proteases 
3.1. Introduction  
 
Protein-based therapeutics are emerging as the fastest growing class of chemical 
compounds within the drug industry. Vaccine target antigens have been isolated and 
characterised from many endoparasites of veterinary and human importance. The 
main challenge at present is to produce these antigens in an immunologically active 
form using recombinant DNA technology. Recombinant DNA technology allows a 
vaccine candidate to be synthesised cheaply, safely and in bulk. The expressed 
antigens can then be evaluated as vaccines under laboratory and field conditions. 
 
At present, there are two commercialised anti-parasite vaccines -TickGard and 
Gavac, that  have been produced in E. coli and Pichia pastoris respectively. Many E. 
coli expressed nematode antigens have proven to be ineffective as vaccine 
molecules because they lacked the necessary post-translational modifications 
(Emery et al., 1993). The yeast expression system has been successfully used for 
nearly two decades in the biotechnology industry for the production of heterologous 
proteins of human, animal, plant or viral origin. S. cerevisiae is the most popular 
yeast for the expression of proteins as it is genetically well characterised and it has 
ability to perform many post-translational modifications such as O- or N- linked 
glycosylation, phosphorylation, disulphide bridge formation, proteolytic processing 
and folding (Dowd et al., 1997). 
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The liver fluke has a blind end gut and median pore at the posterior of the body. The 
contents of the parasite gut are regurgitated via the mouth and excreted through a 
median pore. F. hepatica ES products are proposed to have roles in crucial 
biological functions such as immune evasion, tissue penetration and nutrition. Two 
dimensional gel electrophoresis (2 DE) has been very useful in identifying target 
antigen analysis of ES material using polyclonal antisera raised against fluke 
proteins. Dalton and Heffernan (1989) analysed cysteine proteases that are 
secreted into the culture medium when flukes are incubated. N-terminal sequencing 
of the enzymes and biochemical analysis of these proteases showed that they 
consisted of two cathepsins, L1 and L2, which are proteins with distinct 
physiochemical properties and substrate specificities. Cathepsin L1 was purified 
from the ES products of F. hepatica, but the production of sufficient quantities of 
pure cathepsin L1 is a time consuming, complicated and expensive process. To 
solve this, recombinant cathepsin L1 and cathepsin L2 was expressed in yeast 
(Dowd et al., 1997; Roche et al., 1997). They observed that yeast expressed F. 
hepatica cathepsin L1 and cathepsin L2 exhibited biochemical properties in common 
with the F. hepatica native enzymes. 
 
The cDNA sequences encoding juvenile F. hepatica cathepsin B as well as cDNAs 
from metacercariae, NEJ and adult F. gigantica were isolated (Heffernan et al., 
1991; Meemon et al., 2004; Tkalcevic et al., 1995; Wilson et al., 1998). Yeast 
expressed cathepsin B was antigenic in rats, however the purified protein was 
unable to undergo autoprocessing (Law et al., 2003). To improve autoprocessing a 
recombinant cathepsin B was expressed in P. pastoris and the purified enzyme was 
activated by low pH and the presence of dextran sulphate (Beckham et al., 2006). 
 
Cathepsin L and cathepsin B enzyme expression and purification from yeast was 
observed for clones isolated from other parasites such as Schistosoma (Brady CP et 
al., 1999; Lipps et al., 1996) and Clonorchis sinensis (Park et al., 2001). 
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In the present investigation, Fasciola recombinant protein was expressed and 
purified from yeast, and characterised by SDS-PAGE and immunoblotting using 
monoclonal and polyclonal antibodies. 
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3.2. Materials and methods 
 
3.2.1. Plasmid clones encoding cathepsins B, cathepsin L1 and cathepsin L5 
 
Clones expressing recombinant cathepsin B cDNA (mutagenesis of pFLAG/CatB 
was performed to remove potential N-linked glycosylation sites, Asn-X-Ser/Thr, from 
the predicted protein prior to expression in S. cerevisiae to avoid hyper-
glycosylation) and cathepsin L5 were previously constructed in the pFLAG 
expression vector by Dr. Peter Smooker (Law et al., 2003). Proteins expressed in 
this system contain a poly-His tag to facilitate affinity chromatography. A similarly 
cloned cathepsin L1g construct was provided by Luke Norbury. Plasmid DNA was 
propagated in E. coli DH5α cells and extracted by the alkaline lysis miniprep method 
(see section 2.4.2.2).  
 
3.2.2. PEG-Bicine transformation of S. cerevisiae  
 
 
BJ3505 cells were cultured for 24 hours in 10 mL of yeast peptone dextrose (YPD) 
broth (see section 2.4.1) at 280C and then inoculated into 100 mL of YPD. The 
mixture was grown for four hours until the OD600 reach 0.6. 10 mL of aliquots were 
removed and centrifuged for 5 minutes at 4000 g and the cell pellet was 
resuspended in 5 mL of SBEG buffer (section 2.4.1). Following centrifugation for 3 
minutes at 4000 g, the pellet was resuspended in 200 µL SBEG buffer and 
incubated at 280C for 5 minutes with shaking (120 rpm). Plasmid DNA (1 µg) was 
added, mixed and incubated at 280C for 10 minutes without shaking. The mixture 
was placed at -800C for 30 minutes. The suspension was thawed in a 370C water 
bath, 1.5 mL of PEG-Bicine buffer (section 2.4.1) added and incubated at 280C for 1 
hour without shaking.   This was followed by the addition of 2 mL NB buffer (section 
2.4.1), and the mixture was then centrifuged for 3 minutes at 4000 g. The pellet was 
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then resuspended in 500 µL NB buffer and dispensed in 100 µL aliquots onto 
minimal media plates. 
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3.2.3. Cathepsin B, cathepsin L5 and cathepsin L1 protein expression 
 
 
Expression and purification of cathepsin B and cathepsin L5 from S. cerevisiae BJ 
3505 cells proceeded according to Law et al. (2003) and Smooker et al. (2000). 
pFLAG cathepsin B, pFLAG cathepsin L5 and pFLAG cathepsin L1g transformants 
were grown at 280C using shaking (120 rpm) in 10 mL minimal medium (section 
2.3.1). After 72 hours growth, the cells were centrifuged and the cell pellet was put 
into YPHSM medium (one litre) and incubated with shaking at 120 rpm for 72 hours 
(see section 2.3.1). 
 
3.2.4. Dialysis and Ni-NTA chromatography purification of recombinant 
proteins 
 
After incubation and centrifugation to remove yeast cells, the culture supernatant 
was dialysed as described in section 2.4.4.3. The dialysed supernatant was mixed 
with mixing buffer (section 2.4.4.5) and the mixture inverted several times to ensure 
uniform mixing of solution. The whole mixture was centrifuged for 10 minutes at 
9000 g (Beckman high speed centrifuge). 
 
For purification of proteins from the yeast supernatant, Ni-nitrilotriacetic acid (NTA) 
resin was used to capture the hexahistidine tagged protein in a chromatography 
column. Five mL polypropylene columns were packed with 2 mL of NTA resin and 
charged with 0.2 M nickel sulphate. Purification proceeded as described in section 
2.4.4.5. The protein was finally eluted with 250-400 mM imidazole (optimal imidazole 
concentration for cathepsin L5 and cathepsin L1g elution is 250 mM and cathepsin 
B is 400 mM). The eluted fractions were collected in 1.5 mL eppendorf tubes. 
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3.2.5. Protein concentration assay 
 
Cathepsin protein concentrations were estimated using the Bradford method (refer 
to 2.4.4.2), with Coommassie Blue G 250 used as the dye reagent to measure the 
absorbance at 600 nm. Bovine serum albumin (BSA) was used to create a standard 
curve. 
 
3.2.6. SDS-PAGE analysis 
 
An aliquot (20 µL) of each eluted fraction from the column was boiled with SDS 
sample buffer (section 2.4.4.1) and separated by 12.5% SDS-PAGE. Protein was 
visualised by Coomassie Brilliant Blue staining (see section 2.4.4.6). 
 
3.2.7. Autoactivation of F. hepatica cathepsin L5  
 
Eluted fractions containing protease were pooled and dialysed in a mono-S-buffer 
(section 2.4.4.5). The dialysed procathepsin L5 proteins were mixed with 10 mM 
cysteine hydrochloride and incubated for 2 hours in a water bath (370C). After 
incubation, the mixture was applied to a Mono-S column and eluted using a buffer 
containing 250 mM NaCl.  The eluted fractions were dispensed in eppendorf tubes. 
Aliquots of 20 µL of each fraction were run in SDS-PAGE and stained with silver 
nitrate. 
 
3.2.8. Western blot analysis 
 
F. hepatica ES material, F. gigantica ES material, F. hepatica native cathepsin L 
proteins and rat anti-cathepsin B sera were previously purified by Dr. David 
Piedrafita (Monash University, Melbourne), and yeast expressed F. hepatica 
cathepsin L2 was previously purified by Luke Norbury (RMIT University, Melbourne). 
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Native cathepsin L, ES material and recombinant cathepsin protease was separated 
on a 12.5% SDS-PAGE gel and transferred to a nitrocellulose membrane (see 
section 2.4.4.7.2). The membrane was incubated with either anti-cathepsin L 
specific monoclonal antibody (from Dr David Piedrafita, 1:3000 dilution) or anti 
cathepsin B rat sera (see Chapter 4, 1:2000 dilution) overnight at 40C, followed by 
incubation with anti-mouse alkaline phosphatase (1:5000 dilution) or anti-rat HRP 
(1:3000 dilution) conjugate. The membrane was developed by the addition of 
western blot substrate solution (either 4-chloro-1-naphthol or NBT/BCIP) (see 
section 2.4.4.1) and incubated until colour development. 
 
3.2.9. Proteomic analysis of F. hepatica excretory and secretary products 
  
3.2.9.1. First dimensional gel analysis of ES material  
 
3.2.9.1.1. Passive rehydration of ES material 
 
Two dimensional gel electrophoresis of ES material was performed essentially 
according to the manufacturer’s instructions (BioRad). F. hepatica ES material (30 
µg) with rehydration buffer (185 µL) was loaded into a rehydration tray. After 
removing the cover sheet from an IPG strip (pH 3-11) this was placed gently on the 
protein, and 2 to 3 mL of mineral oil was added to prevent evaporation, followed by 
covering the tray with a plastic lid and incubation at room temperature. 
3.2.9.1.2. Isoelectric focusing of ES material 
 
Isoelectric focusing (IEF) was performed on a Bio-Rad Protean IEF cell at 20°C 
using the following program: 
a. 300 V for 1 h (step and hold); 
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b. 4,000 V for 2 h (linear voltage ramping until reaching 4,000 V); and  
c. 4,000 V for 6.5 h (step and hold). 
 
In the isoelectric focussing (IEF) tray, the two paper wicks were placed on each end 
of electrodes. After draining the mineral oil from the IPG strips, they were transferred 
to the IEF tray. The IPG strip was covered with 2 mL of mineral oil and placed in an 
IEF cell. 
3.2.9.1.3. IPG strip equilibration and two dimensional gel electrophoresis 
 
 
The mineral oil from the strip was decanted and 4 mL of equilibration buffer I was 
added and incubated for 10 minutes. After decanting, 4 mL equilibration buffer II 
was added onto the strips. Following 10 minutes of incubation at room temperature, 
this buffer was decanted. The equilibrated IPG strips were inserted into a 4-20 %, 11 
cm criterion precast gel (Bio-Rad) assembly using a plastic comb. Agrose (Bio-Rad) 
was used to seal the gap between the IPG strip and the precast gel and placed in 
the electrophoresis cell. Electrophoresis was performed for 65 minutes at 200 volts.  
The gel was removed from the casting and stained with silver nitrate. 
 
3.2.10. Silver staining of SDS-PAGE and two dimensional gels 
 
The gels were carefully removed from the gel assembly and placed into a clean 
glass container (see section 2.4.4.6). The gel was fixed in a fixative (section 
2.4.4.1). The gels were immersed in a silver staining solution (section 2.4.4.1). 
Finally the gel was developer (section 2.4.4.1). Once spots were visually obvious, 
the reaction was stopped by the addition of 1% acetic acid. 
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3.3. Results 
 
3.3.1. Expression and purification of recombinant Fasciola cathepsin proteins 
 
Yeast expression of cathepsin B was performed using pFLAG cathepsin B 
transformed into BJ3505. Cathepsin L5 and cathepsin L1g expression used a pre-
existing glycerol stock of S. cerevisiae containing the plasmids. After column 
chromatography, the cathepsin L’s were eluted using a buffer supplemented with 
250 mM imidazole, cathepsin B 400 mM imidazole (data not shown). 
 
Analysis of 20 µL of each SDS-PAGE eluted fraction stained by Coomassie staining 
demonstrates the expression of each enzyme (Figures 3.1). The three purified 
cathepsins were observed at the predicted molecular masses, between 36.5 and 50 
kDa in SDS-PAGE. From the gel (Figure 3.1), the fractions from 3 to 6 revealed 
procathepsin B. The mature cathepsin L5 was observed to autoprocess during 
purification, as shown by SDS-PAGE analysis (Figure 3.2). The purity of cathepsin 
L5 revealed a doublet form (Figure 3.1.C) where as cathepsin L1g (Figure 3.1.B) 
and cathepsin B (Figure 3.1.A) showed a single band in the stained gels. 
 
3.3.2. Protein concentration of purified proteins 
 
Ni-NTA column purified protein fractions were pooled and the concentration was 
assessed by the Bradford assay. The yield from one litre of yeast culture is 
presented in a Table 3.1. 
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                                     1       2     3     4    5    6                   7 
 
A. Cathepsin B 
 
                                    1     2    3     4    5    6                    7 
 
B. Cathepsin L1g   
 
       1    2     3     4      5      6     7    8     9   10 
  
C. Cathepsin L5 
 
 
    50 kDa 
    36 kDa 
 
 
   36 kDa 
   31 kDa 
 
 
 50 kDa 
 36 kDa 
  
Mature    
cathepsin L5 
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Figure 3.1. Eluted fractions of Ni-NTA column purified proteins resolved by 
12.5% SDS-PAGE.   
  
Eluted fractions of (A). Cathepsin B. Lanes 1-6, fractions after addition of elution 
buffer; lane 7, pre-stained protein marker. (B). Cathepsin L1.  Lanes 1-6, fractions 
after addition of elution buffer; lane 7, Mark 12 unstained protein marker. 
(C).Cathepsin L5. Lanes 1-8, fractions after addition of elution buffer; lane 9, pre-
stained protein marker; lane 10, ninth fraction.  
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                                                   1           2              3         
 
 
Figure 3.2. The autocatalytic processing of F. hepatica pro-cathepsin L5 
observed by SDS-PAGE analysis.   
 Lane 1, activated fraction from the mono-S-column purification; lane 2, an eluted 
fraction from Ni-NTA column purification.  
 
  
      50 kDa 
  
      36 kDa 
 
 
 
      22 kDa    
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Table 3.1. The yield of recombinant proteins from one litre of yeast culture 
 
 
Yeast expressed protein 
Average yield of protein / litre of 
culture (µg / L) 
Cathepsin B 500 
Cathepsin  L5 1300 
Cathepsin L1g 300 
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3.3.3. SDS-PAGE analysis and Two dimensional gel electrophoresis (2 DE) of 
F. hepatica ES material 
 
The ES material showed a major band at a molecular mass of 28 kDa in Coomassie 
stained gel, but was negatively stained using silver nitrate (Figure 3.3). The ES 
material showed a major band at a molecular mass of 28 kDa in Coomassie stained 
gel, but was negatively stained using silver nitrate (Figure 3.3).” Negative staining in 
silver gels is a well known phenomenon (although it is not really negative- it just 
means that there is an overabundance of protein at that point). This overloading was 
not evident in the 2D. With the aim of characterising proteins secreted by F. 
hepatica that could be involved in host-parasite interactions, the ability of these 
proteins to bind anti-cathepsin L and anti-ES antibodies was investigated. F. 
hepatica ES material was subjected to 2 DE and stained with silver nitrate.  The 
isoelectric focussing pattern of adult F. hepatica ES material revealed up to 15 
bands in pH range from 3 to 11. Several bands were located between pH 3-7 in the 
focussed and silver stained IPG strips as shown (Figure 3.4). In Figure 3.4, the 
double brackets indicate the presence of protein spots of similar molecular mass but 
differing isoelectiric points (Figure 3.4). The spots may be cathepsin L or possibly 
glutathione S transferase, which have approximately the same molecular mass. 
Some of the constituents of ES have been previously identified in several reports 
(Jefferies et al., 2001; Robinson et al., 2008; Wijffels et al., 1994a) using peptide 
mass fingerprinting (PMF). A similar pattern was observed in 2 DE of F. hepatica ES 
material by Robinson et al. (2008).  To attempt to confirm the identity of cathepsin 
L’s within the ES material, western blotting of two dimensional gels was performed. 
However, this was unsuccessful, therefore dot blot and western blot analysis of ES 
material probed with cathepsin L (monoclonal) and ES antibodies (monoclonal and 
polyclonal) were performed.  
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                                               1      2             3    4     5     6 
 
                                                       A                        B 
                                                          
Figure 3.3. SDS-PAGE analysis of F. hepatica ES material (Composite image) 
 (A), F. hepatica ES material (0.5 µg) was run on SDS-PAGE and stained with silver 
nitrate; lane 1, ES material, lane 2, Mark 12 unstained protein marker; (B) lanes 3 to 
5, ES material stained with Coomassie blue; lane 6, protein marker. In 2 DE of this 
same protein, ES material was fractionated into various spots according to their iso-
electric points and molecular weights. So the region or spots in that gel stained by 
the silver staining did not make negative staining due to their small amount.  
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Figure 3.4. Isoelectric focussing and two dimensional gel electrophoresis of F. 
hepatica ES products 
Adult ES products were run on a 11 cm ready IPG strip in the first dimension and 
then a criterion precast gel (Bio-Rad) in the second dimension and visualised with 
silver staining. The double brackets were indicated here for the identification of 
protein spots which may be cathepsin L, glutathione S transferase and FABP that 
have been previously identified in several reports (Jefferies et al., 2001; Wijffels et 
al., 1994) using peptide mass fingerprinting. 
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3.3.4. Immune reactivity of Fasciola proteins against a cathepsin L specific 
antibody and anti-cathepsin B sera 
The reactivity of F. hepatica ES proteins and yeast-derived recombinant proteins 
with various antibodies was tested. The following antisera were used: 
 
1. Monoclonal antibody raised against F. gigantica cathepsin L (from Dr Rudi 
Grams) 
2. Rat anti-cathepsin B sera 
 
A 29k Da protein in the ES material of both Fasciola species was recognised by the 
monoclonal antibody (Figure 3.5).  Native cathepsin L and cathepsin L5 showed a 
strong reactivity to this antibody, whereas cathepsin L1g showed moderate reactivity 
and cathepsin L2 was only faintly recognised. The antibody recognised the mature 
cathepsin L5 (lower band after autoprocessing). As expected, the cathepsin L 
monoclonal antibody did not recognise cathepsin B. Cathepsin B specific rat sera 
reacts strongly with the yeast-expressed cathepsin B (Figure 3.6).  
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Figure 3.5. Coomassie-stained SDS–PAGE (A) and Western blot analysis 
using anti-cathepsin L antibody (B) of Fasciola proteins.  
Lane 1, yeast expressed cathepsin L1g; lane 2, recombinant cathepsin L5; lane 3, 
yeast expressed cathepsin L2; lane 4, yeast expressed cathepsin B; lane 5, F. 
hepatica native cathepsin L; lane 6, purified F. hepatica ES material; lane 7, purified 
F. gigantica ES material; lane 8, pre-stained protein marker. 
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                                                          1      2 
 
 
Figure 3.6. F. hepatica cathepsin B specific antibody raised in rats reacts with 
cathepsin B in a western blot. 
Lane 1, pre stained protein marker; lane 2, recombinant cathepsin B. The cathepsin 
B specific rat sera showed strong reactivity to cathepsin B.  
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3.4. Discussion 
 
3.4.1. Cathepsin B, cathepsin L5 and cathepsin L1g expression and 
purification 
 
In order to progress to the vaccine trials discussed later in this thesis, it was 
necessary to optimise the expression and purification of the three cathepsin 
proteases, L5, L1g and B. These three recombinant proteins were expressed from 
cDNA generated from flukes at different life stages. Cathepsin L5 cDNA was 
isolated from adult fluke, while cathepsin B and L1g were isolated from NEJ and 
metacercariae, respectively. It is known that cathepsin B is expressed up to the age 
of 5 weeks, however it is not known if L5 and L1g are restricted to adult and juvenile 
expression, respectively. 
 
The yeast expressed cathepsin B, cathepsin L5 and cathepsin L1g protein yield per 
litre of culture was higher than previous yeast expressed F. hepatica cathepsin L1 
and cathepsin L2 by Dowd et al (1997) and Roche et al (1997) (100 µg/ L of yeast 
culture). In other studies, a high level of cathepsin L1 was expressed in P. pastoris, 
which carried a hexahistidine tag allowing purification by one step affinity 
chromatography procedure using Ni-NTA (800 mg/litre). The protease was 
expressed as a pro-mature enzyme which could be activated at low pH to fully 
active mature enzyme (Collins et al., 2004). The recombinant cathepsin L5 that was 
used in these experiments was previously expressed in yeast and yielded 2 mg per 
litre of yeast culture .  
 
Both F. hepatica cathepsin L1 and cathepsin L2 were previously purified using ultra- 
filtration and gel filtration chromatography on sephacryl S 200 HR columns (Dalton 
et al., 2003b; Dowd et al., 1997; Roche et al., 1997). In the current experiments, 
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simple affinity chromatography has been used. Ni-NTA affinity column 
chromatography is an attractive tool for large scale purification of yeast expressed 
proteins. NTA resin is reusable and cost effective compared to gel filtration 
chromatography .  
 
3.4.2. Biochemical analysis of Fasciola proteins 
 
3.4.2.1. SDS-PAGE analysis 
 
 
Using SDS-PAGE, the expressed proteins were separated on gels and the 
molecular weight was estimated between 36 and 50 kDa. Cathepsin L was found to 
be major component of ES. The mature, active cathepsin L5 migration pattern 
(approximate molecular weight is 28 kDa) behaved in the same way as F. hepatica 
ES (approximate molecular weight of the major band 29 kDa) in SDS-PAGE. The 
pattern of negative staining in the SDS-PAGE is mainly happened especially in the 
bands containing large amount of the proteins. 
3.4.2.2. Two dimensional analysis of F hepatica ES material 
 
There are growing numbers of reports involving F. hepatica secreted proteins, with a  
proteomic approach used to identify specific proteins (Allam AF et al., 2002; 
Jefferies et al., 2001) to target secreted proteins for analysis in humans  and 
ruminants (Wijffels et al., 1994a). The isoelectric focussing of ES products 
demonstrates 17 bands from F. hepatica and 22 bands from F. gigantica between 
pH 3.5 to 10 . The results of this study suggest that isoelectric focussing of adult 
fluke ES material showed 15 bands in IPG strips. It was not possible to identify 
individual proteins due to the lack of resolution of these gels.  
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3.4.3. Immune reactivity of Fasciola proteins with monoclonal and polyclonal 
antigen specific antibodies  
 
The expressed recombinant proteins and native proteins of Fasciola species 
showed immunoreactivity towards a cat L-specific monoclonal antibody and anti-
cathepsin B rat sera in western blotting. The monoclonal F. gigantica cathepsin L 
detects recombinant cathepsin L5, recombinant cathepsin L1g and native cathepsin 
L, F. hepatica ES and F. gigantica ES. This result suggests that a common 
immunoreactive epitope exists in all these protein antigens. The results also suggest 
that there is common epitope expressed between F. hepatica and F. gigantica. The 
cathepsin L monoclonal antibody identifies both immature and adult stage 
cathepsins (cathepsin L1g and cathepsin L5). Cathepsin L5 showed strong reactivity 
to the monoclonal antibody. 
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3.5. Conclusion 
 
The production of functionally active cathepsin L5, cathepsin L1 and cathepsin B in 
S. cerevisiae BJ3505 cells will allow for the evaluation of these proteins in a vaccine 
trial. Further experiments are required to analyse the protective immune responses 
of these recombinant proteins against experimental rat fasciolosis (chapter 4).  
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Chapter 4  
Protective efficacy of Fasciola developmental stage specific 
recombinant antigens 
 
4.1. Introduction 
 
Liver flukes cause infectious disease in humans and ruminants world-wide. The 
causative pathogens are F. hepatica and F. gigantica. This emerging human 
pathogen is highly prevalent in South American countries  and also in Northern Iran  
and Egypt (Esteban et al., 2003). Sporadic cases has been observed in European 
countries and Australia . Even though anthelmintic treatment is effective against 
disease, drug resistant strains have been reported .  
 
Due to the complexity of the life cycle and the immune suppressive activity of flukes, 
the vaccine development process has been slow. Many studies have concentrated 
on secreting antigens of the adult stage of the parasite. Adult flukes are found at the 
bile duct of the host where they are immunologically safe and not attacked by cell 
mediated defence mechanisms (Dalton et al., 2003a; Hillyer, 2005; McManus & 
Dalton, 2006; Spithill et al., 1997). Van Milligen et al. (1999) has highlighted the 
protective efficacy of NEJ fluke secreted proteins in rats. 
 
Cysteine proteases are produced by all stages of the fluke and may facilitate 
biological functions such as immune evasion, excystment and tissue invasion . 
Among the secreted cysteine proteases, F. hepatica cathepsin L has been 
extensively studied (see for example (Dalton et al., 2003b; Kesik et al., 2007; 
Mulcahy et al., 1999; Smooker et al., 2000; Wedrychowicz et al., 2007; Wijffels et 
al., 1994b)).   
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F. hepatica cathepsin L5 (Irving et al., 2003; Smooker et al., 2000), cathepsin B 
(Beckham et al., 2006; Kennedy et al., 2006; Law et al., 2003; Meemon et al., 2004) 
and F. gigantica cathepsin L1 (Grams et al., 2001; Tantrawatpan et al., 2005; 
Wongkham et al., 2005) appear to be most promising target antigens against 
Fasciola infection. In order to assess cysteine protein vaccine potential, recombinant 
protein expression is highly recommended. The yeast expression system has been 
proven to be fruitful for the functional expression of cathepsin L (Dowd et al., 1994; 
Roche et al., 1997), cathepsin L5  and cathepsin B (Beckham et al., 2006; Law et 
al., 2003). F. hepatica cathepsin L1 and cathepsin L2 have been expressed in S. 
cerevisiae (almost a decade ago) and rapidly purified from yeast culture, however 
no vaccine trials using these proteins have been reported to date (Dowd et al., 1997; 
Roche et al., 1997).  
 
In experiments described in this chapter, the immune potential and vaccine efficacy 
of adult stage F. hepatica cathepsin L5, immature F. gigantica cathepsin L1g and 
juvenile F. hepatica cathepsin B recombinant proteins were analysed in Sprague 
Dawley rats against F. hepatica infection.  
 
 
 
 
 
 
 
  99
4.2. Materials and methods 
 
4.2.1. Recombinant protein vaccine purification 
 
The expression and purification of cathepsin B, cathepsin L5 and cathepsin L1g 
from S. cerevisiae BJ 3505 cells proceeded according to Law et al. (2003) and 
Smooker et al. (2000). The expressed proteins were purified by Ni-NTA affinity 
chromatography and analysed as described in Chapter 3. 
 
4.2.2. Experimental animals 
 
Sprague Dawley male rats were used in the vaccination experiment for testing yeast 
expressed protein vaccines for their protective efficacy against experimental rat 
Fasciola infection. The rats were six weeks old at the time of vaccination and ten 
weeks old at the time of challenge. Seven to nine rats were used per treatment 
group and rats were provided with food and water ad libitum. Animal experiments 
were performed under the supervision of the Monash University animal ethics 
committee, Australia.  
 
4.2.3. Parasite 
 
F. hepatica metacercariae were obtained from laboratory Lymnae tomentosa snail 
cultures at the Macarthur Agricultural Institute, Menangle, NSW, Australia and used 
for challenge infection of rats. Parasites were stored at 4oC prior to infection. 
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4.2.4. Vaccination protocol and time line 
 
Eight vaccine preparations were analysed and are listed in Table 4.1. On the first 
day of the experiment, the recombinant proteins and Quil A adjuvant were mixed 
with 0.9% saline. The rats were bled prior to protein vaccination. One primary dose 
along with two boosting doses of the vaccines was delivered to rats at fortnightly 
intervals (Figure 4.1). Two weeks after the third vaccination, rats were bled from the 
tail vein using a 25 gauge needle. All rats were infected with 25 metacercariae a day 
later.  
 
4.2.5. F. hepatica challenge infection  
 
Rats were challenged with 25 F. hepatica metacercariae/rat orally. Prior to 
challenge, metacercariae were observed under the microscope to ensure viability. 
Viable cysts were selected depending upon their morphology of parasite within the 
cyst. A stock solution was made consisting of 2000 viable metacercariae cysts 
mixed with 70 mL of 0.4% carboxy methyl cellulose (Sigma). The solution (1 mL/ rat) 
was mixed and administered orally to rats using a gavage needle. After each 
delivery, the gavage needle was flushed with Milli Q prior to the next oral dose.  
 
4.2.6. Necropsy 
 
Eight weeks after the oral infection, rats were humanely sacrificed and their livers 
were removed. Pathological lesions of livers were observed by the naked eye. Live 
adult flukes inside the lumen of bile duct were dissected out by using forceps and 
the whole liver was cut into small pieces (Figure 4.2), submerged in saline at 370 C 
for 1 hour and filtered through a 200 µM mesh sieve for detection and counting of 
immature and adult flukes. 
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4.2.7. Pathological and parasitological parameters 
 
4.2.7.1. Anti-fluke effect analysis 
 
The gold standard for anti- fluke vaccine development is the reduction in fluke 
numbers . A reduction in immature flukes in the liver tissue and adult fluke 
establishment in the bile duct determines the vaccine efficacy and protective 
immunity of experimental vaccines in rats (Valero et al., 1998; Valero et al., 1999; 
Valero et al., 2006). The total numbers of adult and immature flukes recovered from 
the each rat was counted. These worm burdens were compared with control groups 
and the reduction in fluke burden per group was calculated as described by Muro et 
al. (1997).  The percentage of protection of vaccinated animals was calculated as 
follows: 
 
Percentage of protection = 1-(Mean number of flukes found in immunised rats/ 
mean number of fluke recovery in challenged control rats) X 100 
 
Percentage of maximal individual protection = 1-(Lowest mean number of fluke 
counts in individual vaccinated rats/ mean number of fluke burden in challenged 
control rats) X 100   
 
The percentage of maximal individual protection in each vaccinated rat group was 
estimated as the least or no fluke recovered from an individual rat liver. The 
percentage of maximal individual protection in each vaccinated rat group will be 100 
% if no flukes are observed in the vaccinated rats .  
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Table 4.1. The experimental design of the Fasciola recombinant protease 
vaccination trial. A total of 20 µg of protein (single or cocktail) in 200µl of 1mg/mL 
Quil A was administered to rats three times at two-weekly intervals.  
 
 
Vaccination 
preparation Rats/group 
Antigen dose for each 
vaccination (µg) 
1.Quil A 
adjuvant as 
control 
8 PBS + 200 µg of Quil A 
2. cathepsin B 8 20µg + 200 µg of Quil A 
3. cathepsin L5 8 20µg + 200 µg of Quil A 
4. cathepsin 
L1g 9 20µg + 200 µg of Quil A 
Cocktail vaccinations 
5. cathepsin 
B/L5 8 
10 µg of cathepsin B 
10 µg of cathepsin L5 
+ 200 µg of Quil A 
6. cathepsin 
B/L1g 7 
10 µg of cathepsin B 
10  µg of cathepsin L1g 
+ 200 µg of Quil A 
7. cathepsin 
L5/L1g 8 
10 µg of cathepsin L5 
10  µg of cathepsin L1g 
+ 200 µg of Quil A 
8. cathepsin 
B/L5/ L1g 7 
6.6 µg of cathepsin B 
6.6 µg of cathepsin L5 
6.6 µg of cathepsin L1g 
+ 200 µg of Quil A 
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Figure 4.1. The experimental time line for vaccination, blood sampling and 
experimental infection in rats 
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4.2.7.2. Evaluation of liver damage 
 
The following macroscopic changes in the liver were observed during the 
dissection of rats: 
 
1. The change of colour in the hepatic parenchyma to greyish white. 
2. Dilatation of the bile ducts and hyperplasia of ductile walls 
3. Fibrosis of hepatic lobes, calcification and granuloma formation, 
mucopurulent discharge and outer surface scar lesions . 
 
The scoring of liver damage was carried out blindly by Dr. David Piedrafita (Monash 
University, Melbourne). The quantitative degree of damage was scored 0 to 5 
depending upon the severity and the intensity of lesions (Raadsma et al., 2007).  
The scoring scheme for liver damage is presented in Table 4.2. 
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A                                                                         B    
 
Figure 4.2. Sectioning of the liver was performed within the 60 minutes of 
culling of the rat.  
 
Photograph A. The liver was cut into small pieces to enable identification of flukes; 
photograph B. A fluke collected from bile duct showing staining with bile pigments 
and blood. This fluke is again presented after washing with Milli Q water in Figure 
4.6, photograph (A).  
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Table 4.2. Liver damage score chart for F. hepatica metacercariae challenged 
animals 
  
 
Liver index 
score 
 
Macroscopic liver lesions 
 
Score 5 
 
 
Heavily damaged with extensive necrosis on more than 50% of 
the liver surface 
 
Score 4 
 
 
Heavy damage of up to 50% of the liver surface 
 
Score 3 
 
 
Moderate damage of up to 30% of the liver surface 
 
 
Score 2 
 
 
Light lesions of up to 15% of the liver surface 
 
 
Score 1 
 
 
Minor damage confined to not less than 5% of liver surface 
 
 
Score 0 
 
 
No signs of damage observed on the liver surface or hepatic 
lobes 
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4.2.8. F. hepatica fluke morphometry analysis 
 
4.2.8.1. Body size and wet weight of recovered flukes 
 
The influence of recombinant vaccines on the fluke body, size and wet weight are 
important factors of protection (Nambi et al., 2005; Ramajo et al., 2001; Valero et al., 
2006). The body size is considered to be a good indicator of fluke development and 
it is estimated that in rats Fasciola measures approximately 6 mm before attaining 
maturity and entering the bile duct lumen (Dalton et al., 1996). The body lengths 
from head to tail and body width of each worm from all vaccinated and control rat 
groups were measured under a dissection microscope with a millimetre scale 
(Valero et al., 2002; Valero et al., 2005).  
 
4.2.9. Haematological parameters 
  
Peripheral blood smears were prepared from vaccinated and control rats and were 
stained using KWIKTm DIFF STAIN KIT (Thermo Electron Corporation). The number 
of neutrophils, eosinophils and lymphocytes were enumerated for pre-and post- 
challenge infection. 
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4.2.10. Immunological parameters   
 
4.2.10.1. ELISA analysis 
 
For ELISA, 96 well plates were coated with cathepsin B, cathepsin L5 or cathepsin 
L1g protein at 5 µg/ mL in carbonate binding buffer pH 9.6 and incubated overnight 
at 40C (see section 2.5.2). Sera from individual rats were serially diluted from a 
starting dilution of 1:1000 and bound antibodies were detected using anti-rat HRP 
conjugate IgG (1:5000 dilutions). The sera from the cocktail or individual vaccine 
groups were analysed against single cathepsins (for example, sera from rats 
vaccinated with cathepsin B, the cocktail of cathepsin B and L5, cathepsin B and 
L1g or cathepsin B, cathepsin L5 and cathepsin L1g were assessed against 
cathepsin B protein in the ELISA (plates coated with cathepsin B).A similar pattern 
of analysis was performed for each other protein, and therefore each group that was 
vaccinated with a particular protein was tested for titre against that protein. The 
reciprocal titre was calculated using an OD450 absorbance with cut-off 0.2 value, and 
each antibody titre was estimated in duplicate.  
 
4.2.10.2. Immunoblotting of vaccinated sera against Fasciola antigens 
 
For assessing immune reactivity of the vaccinated rat sera, cathepsin B, cathepsin 
L5 or cathepsin L1g were separated on 12.5 % SDS-PAGE and transferred to 
nitrocellulose membrane (see section 2.4.4.7.2). The membrane was probed with 
anti-cathepsin B, cathepsin L5 or cathepsin L1g anti-sera (1:3000 dilution) (pooled 
rat sera) from all vaccinated groups overnight at 40 C and then probed with anti-rat 
Ig - alkaline phosphatase (1: 3000) for 1 hour at room temperature and then finally 
developed with BCIP/NCT. 
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4.2.11. Statistical analysis 
 
For each rat from all vaccinated and control groups, the protective efficiency 
determining parameters such as liver damage score, liver fluke count, wet weight, 
size of flukes and blood parameters were statistically analysed. For all the groups 
the mean and standard deviation and correlation was calculated using SPSS 
software. Statistical differences between vaccinated rat groups were analysed using 
one way ANOVA followed by Turkey’s multiple comparison test (GraphPad (3.02 
software), San Diego, USA).  
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4.3. Results 
 
4.3.1. Effect of protease vaccination on worm recovery 
  
The mean number of flukes recovered from from each rat is presented in Table 4.3, 
and the summary is given in Table 4.4. A diagrammatic representation of the 
percentage of protection (calculated as described in 4.2.7.1) is shown in Figure 4.3. 
 
All groups of rats vaccinated with recombinant protein showed a statistically 
significant lowering of the numbers of recovered flukes. An 83% reduction in the 
fluke burden was observed in rats vaccinated with the cocktail vaccine containing 
cathepsin B and cathepsin L5. Fluke numbers in this group were also significantly 
lower than two other vaccinated groups, as shown in Table 4.3. The lowest 
percentage of reduction in fluke burden was observed in rats immunised with 
cathepsin L1g (49%). The cocktail vaccine groups showed a reduction in flukes 
ranging from 60 to 83%.  
 
The percentage of maximal protection with individual rats was 100% in all cocktail 
and cathepsin B vaccinated rats (in other words, these groups each contained rats 
with no flukes). Importantly, vaccines containing cathepsin B and L5 protein showed 
100% maximal individual protection in two rats.  
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 Table 4. 3. The fluke recovery from the individual rats 
  
 
 
Vaccinated rat group Fluke counts in 
individual rats 
Quil A 4,5,5,3,4,5,5,4 
Cat B 1,2,2,3,3,2,0,1 
Cat L5 3,2,2,2,2,2,2,2 
Cat L1g 3,2,1,3,1,1,5,2,2 
Cat B/L5 0,1,1,1,1,1,0,1 
Cat B/L1g 3,0,2,2,2,1,2 
Cat L1g/L5 3,1,3,2,1,0,1,3 
Cat B/L1g/L5 2,3,4,1,1,2,0 
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Table 4. 4. Fluke recovery from the bile ducts and hepatic parenchyma. Mean 
fluke counts from the vaccinated and control rat groups. 
 
 
Vaccine 
groups 
Fluke 
recovery 
from bile 
duct 
Fluke 
recovery 
from hepatic 
parenchyma 
Mean fluke 
count with 
standard 
deviation 
 
Statistical 
significance   
P <0.01 
 
Statistical 
significance 
P <0.05 
Control 18 17 4.37±0.74 - - 
Cat B 2 12 1.75±1.03 - Vs control 
Cat L5 6 11 2.12±0.35 - Vs control 
Cat L1g 10 10 2.22±1.30 - Vs control 
Cat B/L5 1 5 0.75±0.46 
Vs control 
 
Vs control, 
Cat L5, Cat 
L1g 
Cat 
B/L1g 
5 7 1.71±0.95 - Vs control 
Cat 
L1g/L5 
6 8 1.75±1.16 - Vs control 
Cat 
B/L1g/L5 
4 9 1.86±1.34 - Vs control 
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Figure 4.3. Diagrammatic representation of the percentage reduction in fluke 
counts in the vaccinated and control rat groups.  
The reduction in worm burden in vaccinated groups is shown as the percentage 
protection induced by the vaccine. The blue bar indicates the maximal protection 
seen in any rat within a group. 
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4.3.2. Anti-pathology effects of Fasciola protein vaccination 
 
A representative control Quil A and protein vaccinated rat showed hepatic and 
biliary stage pathological signs presented in Figures 4.4 and 4.5. Table 4.5 
represents the liver damage score analysis in control and immunised rats.  Adjuvant 
Quil A only administered rats showed significant hepatic damage, with severe 
lesions on the liver surface after F. hepatica infection. Necrotic tracts with severe 
inflammation of the liver lobules were observed. Calcified granulomas were noticed 
on the entry point of flukes at hepatic tissues (Figure 4.4A). Severe hepatitis with 
loss of normal lobular structure was also observed. Severe hyperplasia and 
dilatation of the bile duct was found (Figure 4.5). 
 
Liver damage scores in the protein vaccinated rats were significantly lower 
compared to control groups (P<0.05). Rats vaccinated with Cathepsin L1g, vaccines 
containing cathepsin B and L1g and the cocktail vaccine of three antigens showed 
approximately the same mean liver damage index (1.9) and this damage was 
confined to five percent of the liver surface. In rats vaccinated with cathepsin B 
alone or cathepsin B and L5, the livers were macroscopically healthy and had a soft 
and pliable structure (Figure 4.4.B) compared to control rat livers.  
 
 
 
 
 
  115
 
 
 
 
 
A                                                               B 
Figure  4.4. Liver pathology in control and vaccinated rat livers at necropsy 
after 8 weeks of challenge infection. Two representative livers are shown.  
 
Photograph (A). Control rat liver. F. hepatica causes calcified granulomas at the 
entry point of flukes (indicated by bold arrows). Hepatic lopes were enlarged with 
necrotic lesions (liver damage score 4). Photograph (B), Cathepsin B vaccinated rat 
liver showed a healthy, pliable and soft glassy appearance (liver damage score 1).  
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A                                  B            
 
C    D 
 
Figure 4.5. Comparison of rat Fasciola infection in control and vaccinated rats. 
Photograph (A), and (B) shows hyperplasia and dilatation of bile ducts. In (B), the 
bold arrow represents a cut section of the bile duct in which the fluke was collected; 
photograph (C) shows extensive hepatic necrosis with bile duct enlargement in the 
control rat liver (liver damage score 4); photograph (D), Macroscopic view of 
cathepsin B and L5 combined vaccine administered rat’s liver where the bold arrow 
indicate the reduction in size of bile duct compared to control rat group. 
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Table 4. 5. Macroscopic liver damage score analysis in control and immunised 
rats  
Vaccinated 
group 
Score 0 Score 1 Score 2 Score 3 Score 4 
Mean liver 
damage score 
± standard 
deviation 
Control - 1 - 2 5 3.3 ± 1.0 
Cat B 2 4 1 1 - 1.2 ± 0.7 
Cat L5 3 3 - 2 - 1.3 ± 1.1 
Cat L1g 0 5 - 3 1 1.9 ± 0.9 
Cat B/ L5 6 - 1 1 - 0.8 ± 0.9 
Cat B/ L1g - 3 2 1 1 1.9 ± 1.0 
Cat L1g / L5 2 3 - 3 - 1.6 ± 1.1 
Cat B/ L1g / L5 1 3 2 1 - 1.9 ± 1.3 
 
 
No livers were found to have the highest score for damage, therefore score 5 has 
not been included in this table. All the mean values of rat liver lesions from the 
immunised groups were significantly lower than in the control rats (P<0.05). 
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4.3.3. Effect of vaccination on the size of recovered flukes  
 
The length and width of flukes represent the extent of maturation and growth. The 
mean length and width of the flukes from each vaccinated group is shown in Table 
4.6 and presented graphically in Figure 4.7. Rats vaccinated with the cocktail 
vaccine containing cathepsin B and L5 yielded flukes that were significantly smaller 
in body length and width than those isolated from control groups and other 
vaccinated rat groups (P<0.01). Flukes recovered from rats vaccinated with this 
cocktail vaccine showed a highly significant percentage reduction in body length 
(83%) and width (79%) of flukes than the control group (P<0.01). As shown in 
Figure 4.6, both cathepsin B and cocktail vaccine cathepsin B/L5 vaccines induced 
a reduction in the length and width of recovered flukes and this leads to a reduction 
in liver pathology.  Cathepsin B, L5 and L1g cocktail vaccine induced a similar 
reduction in size to that induced with the cathepsin L1g/L5 cocktail vaccine.  
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          A                                           B                                       C 
 
Figure 4.6. Morphometric dimension analysis of F. hepatica recovered from 
control and vaccinated rats bile ducts and size comparison with flukes 
recovered from human bile ducts.  
Photographic slide (A); A representative large size fluke from a control rat and a 
smaller fluke from a protein vaccinated rat; photograph (B), The serial reduction in 
the size of flukes from left to right were arranged to show the vaccination effect on 
the length and width of recovered flukes. The larger flukes (first two flukes) were 
extracted from Quil A adjuvant only vaccinated rats, second two recovered from 
cathepsin L1g rats, third two from cocktail vaccine containing cathepsin B/L1g 
administered rats and the last two from cathepsin B as well as cathepsin B/ L5 
vaccinated rats (one fluke from each). Representative flukes are shown.  
Photograph (C) was taken from , and used here for a comparison of flukes 
recovered from the control rat infection with those from a case of human fasciolosis. 
Similar sized flukes were obtained. 
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Table 4.6. The mean length and width of flukes from each vaccinated and 
control group  
 
Vaccine 
group 
Mean body length and 
standard deviation (mm) 
Mean body width  and 
standard deviation (mm) 
Control 23.6 ± 3.41 10.48 ± 3.49 
Cat B 7.86 ± 2.72 4.33 ± 1.58 
Cat L5 10.58± 2.15 4.82 ± 1.50 
Cat L1g 12.15 ± 3.18 5.50 ± 1.19 
Cat B/L5 4.00 ± 2.50 2.25 ± 1.38 
Cat B/L1g 9.53 ± 3.50 5.61 ± 2.02 
Cat L1g/L5 11.00 ± 5.16 5.40 ± 2.24 
Cat B /L1g/ L5 11.07± 4.15 5.53 ± 1.80 
 
All the mean values of fluke length and body width from the immunised groups were 
significantly lower than in the control rats (P<0.05).  
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4.3.4. Reduction in the wet weight of recovered flukes 
 
Cathepsin protein immunised rats showed a significant reduction in the wet weight 
of recovered flukes compared to control rats (Table 4.7 and Figure 4.8). The 
percentage of reduction in the wet weight of flukes in the vaccinated animals ranged 
from 52 to 76.1 %. The wet weight of flukes recovered from groups receiving 
cathepsin L5 and B was also significantly lower compared to those receiving 
cathepsin L5 and cathepsin L1g. They were also significantly lower compared to 
groups receiving the combined vaccine containing cathepsin L1g and L5, as well as 
the cocktail of cathepsin B, L1g and L5.  
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Table 4.7. The mean wet weight with standard deviation of flukes from 
immunised rats. All protein vaccinated groups had significantly reduced wet weight 
compared to the control group (P < 0.05) 
 
Immunised groups Mean wet weight (mg) 
Control 120.57 ± 31.1 
Cat B 44.06 ± 27.8 
Cat L5 50.00 ± 17.2 
Cat L1g 68.65 ± 29.7 
Cat B/L5 28.87 ± 18.7* 
Cat B/L1g 45.06 ± 21.6 
Cat L1g/L5 57.93 ± 24.8 
Cat B/L1g/L5 58.15 ± 32.9 
 
* indicates that the mean wet weights of flukes from cocktail of cathepsin BL5 
vaccinated rats were significantly different to the wet weight of flukes from all other 
immunised and control rats (P<0.05).  
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4.3.5. Immune response 
4.3.5.1. IgG antibody responses 
 
The protein vaccinated and Quil A vaccinated rat sera IgG responses against 
cathepsin B, cathepsin L5 and cathepsin L1g from blood samples taken at the time 
of challenge and culling are presented in Figure 4.9. All the vaccines induced 
significantly antibody titres compared to the control group (P<0.05). The IgG 
antibody responses in vaccinated rat sera attained their peak at the time of 
challenge infection and then dropped at the time of necropsy.  
 
4.3.5.1.1. Cathepsin B specific antibody responses 
 
The cathepsin B specific IgG antibody responses were analysed in rat groups which 
were vaccinated with cathepsin B, including the cocktail vaccine groups. From these 
four vaccine formulations, vaccination with cathepsin B alone induced the highest 
antibody responses. The cocktails of cathepsin B/L1g and the three proteins 
produced the lowest anti-cat B titre. After 8 weeks of challenge infection, cathepsin 
B specific antibody responses decreased in vaccinated rat groups, but increased in 
control rats compared to the time of challenge infection. 
  
4.3.5.1.2. Cathepsin L5 specific antibody responses 
 
Cathepsin L5 specific antibody analysis was performed for the groups that were 
vaccinated with cathepsin L5, including the cocktail vaccine groups. These four 
vaccines induced a significantly higher anti-cathepsin L5 antibody response 
compared to controls. Cathepsin L5 vaccination induced the highest anti-cathepsin 
L5 response, and the cocktail of three proteins evoked the lowest.  After eight weeks 
of infection, antibody responses dropped. At this time, the control rats showed 
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elevated anti-cathepsin L5 antibody responses compared to antibody responses of 
anti-cathepsin B and cathepsin L1g.  
 
4.3.5.1.3. Cathepsin L1g specific antibody responses 
 
Interestingly, the cocktail of cathepsin L1g/L5 vaccine induced higher anti-cathepsin 
L1g responses than control rats.  As shown in Figure 4.9 (C), the cocktail of 
cathepsin B/L1g and cocktail of cathepsin B/L5/L1g elicited low anti-cathepsin L1g 
antibody titres in vaccinated rats. At the time of necropsy, the cathepsin L1g specific 
antibody titre decreased as did anti-cathepsin B and cathepsin L5 antibody 
responses. 
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C. Cathepsin L1g 
 
 
C. Cathepsin L1g 
 
Figure 4.7. The recombinant antigen-specific IgG antibody responses in 
vaccinated rats. (A) cathepsin B; (B) cathepsin L5; (C) cathepsin L1g.  
Point 1 indicates basal immunity (prior to vaccination), 2 refers to the time of 
challenge infection, and 3 refers to time of culling of rats.   
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4.3.5.2. Immunoblot analysis of vaccinated rat sera 
 
The immunoblot analyses of pooled sera from vaccinated and control rats are 
presented in Figure 4.8. The vaccinated rat pooled sera showed reactivity towards 
pro-cathepsins B and L1g. Cathepsin L5 specific rat sera showed positive reactivity 
to pro-cathepsin L5 and mature cathepsin L5. From Figure 4.9, (B), the four reactive 
bands indicate sequentially activated protease. Cathepsin L5 is autoactivated during 
storage and SDS-PAGE (Luke Norbury, personal communication, RMIT University, 
Melbourne). Quil A vaccinated rat sera showed no reactivity to these three antigens. 
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Figure 4.8. Immunoblot analysis of recombinant antigens probed against 
pooled sera from vaccinated rat sera. 
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A. Yeast expressed cathepsin B was separated by 12.5% SDS-PAGE and 
transferred to nitrocellulose strips. The immunoblots of cathepsin B were incubated 
with pooled sera from each group. Strip 1, Quil A adjuvant only; strip 2, cathepsin B; 
strip 3, cocktail of cathepsin B/L5; strip 4, cocktail of cathepsin B/L1g; strip 5, 
cocktail of cathepsin B/L5/L1g; strip 6, pre stained protein marker. 
 
B. Yeast expressed cathepsin L5 was separated by 12.5% SDS-PAGE and 
transferred to nitrocellulose strips. The immunoblots of cathepsin B were incubated 
with pooled sera from each group. Strip 1, Quil A adjuvant only; strip 2, cathepsin 
L5; strip 3, cathepsin B/L5; strip 4, cocktail of cathepsin L5/L1g; strip 5, cocktail of 
cathepsin B/L5/L1g; strip 6, pre stained protein marker. 
 
 C. Yeast expressed cathepsin L1g was separated by 12.5% SDS-PAGE and 
transferred to nitrocellulose strips. The immunoblots of cathepsin B were incubated 
with pooled sera from each group. Strip 1, sera from Quil A adjuvant only; strip 2, 
cathepsin L1g; strip 3, cocktail of cathepsin B/L1g; strip 4, cocktail of cathepsin 
L1g/L5; strip 6, cocktail of cathepsin B /L5/L1g; strip 5, pre stained protein marker. 
. 
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4.3.6. Peripheral leukocyte responses during vaccination and infection 
 
Total leukocyte counts were monitored two weeks after the third vaccination and 
eight weeks after the challenge infection. The lymphocyte, neutrophil and eosinophil 
responses are shown in Figure 4.9. An increase in lymphocyte counts was observed 
in all vaccinated rat groups. A high eosinophil response was observed in rats 
vaccinated with cathepsin B and cocktail vaccine cathepsin B/L5 compared to 
control rats. The highest eosinophil responses were detected in the control rat group 
8 weeks after challenge. High levels of neutrophil responses were observed in all 
cocktail vaccinated rat groups.  
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Figure 4.9. Leukocyte profile of vaccinated and control rats. 
 
A, Mean eosinophil, neutrophil and lymphocyte count of vaccinated and control 
groups at the time of challenge; B, Mean eosinophil, neutrophil and lymphocyte 
count of vaccinated and control groups eight weeks after challenge infection.  
  133
 
4.3.7. The relationship between the parasitic profiles of vaccination outcome 
 
The number of flukes recovered from vaccinated animals is considered to be the 
primary parameter which determines the success of helminth vaccines . All of the 
vaccine preparations used in this rat trial elicit protective immune responses against 
experimental rat infection. To assess the relationship between various protective 
efficacy parameters, correlation and R square values were analysed as described 
by Raadsma et al. (2007). The following statistical analysis of anti-pathological and 
parasitological parameters was performed against fluke burden of each vaccinated 
rat using the SPSS 15.0 for Windows statistical software package. The correlation 
analysis of various protective efficacy parameters with fluke counts is shown in 
Figure 4.10. 
 
4.3.7.1. Fluke burden versus liver damage score 
 
The mean values of fluke recovery and mean value of hepatic lesion score showed 
a positive correlation for the control and each vaccinated group. The correlation 
between these parameters was highly significant at a level of 0.0039 and the R 
square value was 0.775.  
 
4.3.7.2. Fluke burden versus wet weight of flukes 
 
The mean value of fluke burden and wet weight of flukes was positively correlated 
and significant at a level of P = 0.00031 with an R square value of 0.901. 
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4.3.7.3. Fluke burden versus fluke body length and width of flukes 
 
Both fluke body length and width were positively correlated with fluke recovery from 
the vaccinated and control groups. Both showed statistically significant correlation 
with fluke burden (P values of body length and width = 0.0001 and 0.00051, R 
square   value = 0.923 and 0.884 respectively).  
4.3.7.3. Fluke burden versus leukocyte count  
 
Both parameters were positively correlated (R square value =0.292). 
  
 
 
 
 
 
 
 
 
 
 
 
 
  135
 
 
A 
 
B 
  136
 
 
C 
 
D 
  137
 
F 
Figure 4.10. Correlation analysis of protective efficacy parameters of 
vaccination with fluke burden of vaccinated and control rats.   
 
A. The correlation between mean fluke counts and mean liver damage score of 
vaccinated and control rats; B, The correlation between the mean fluke burden and 
mean body length of flukes from vaccinated and control rats; C, The correlation 
between the mean fluke numbers and mean body width of flukes from vaccinated 
and control rats; D, The correlation between the mean fluke numbers and mean wet 
weight of flukes from vaccinated and control rats: F, The correlation between the 
mean fluke burden and  mean leukocyte count per rat.  
 
 
For all graphs: 1 indicates control; 2, cathepsin B vaccinated rats, 3, cathepsin L5 
vaccinated rats; 4, cathepsin L1g vaccinated rats; 5, cocktail of cathepsin B/L5; 6, 
cocktail of cathepsin B/L1g; 7, cocktail of cathepsin L1g/L5; 8, cocktail of cathepsin 
B, L1g and L5. 
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4.4. Discussion 
 
4.4.1. Fluke stage specific antigens 
 
Cathepsin proteases are involved in many essential processes in flukes, such as 
tissue invasion and immune depletion in the host. These proteolytic enzymes have 
been considered as potential vaccine candidates. Although many vaccine studies 
have been performed to develop a vaccine against F. hepatica (McManus & Dalton, 
2006; Spithill et al., 1997), the commercial reality has been hampered for the 
following reasons: 
 
1. The identification of protective immunity-inducing antigens and large scale 
recombinant production from an appropriate expression host (Dalton et al., 2003a; 
Spithill et al., 1997).  
 
2. Immune suppressive activity induced by fluke ES material in the mammalian host 
which leads to non-protective Th2 (immunopathological reaction) immune responses 
(Jefferies et al., 1997; Meeusen et al., 1995; Meeusen & Piedrafita, 2003).  
 
3. Each stage in the Fasciola life cycle contains the same genes, but only those 
genes needed for that stage are expressed (Heussler & Dobbelaere, 1996; Irving et 
al., 2003; Knox & Redmond, 2006; Meemon et al., 2004). Each stage of fluke 
development occurs at a different location in the host and different antigens are 
secreted by the fluke (van Milligen et al., 2000; van Milligen FJ et al., 1998 ). Stage 
specific antigen expression was demonstrated by Tkalcevic et al. (1995). 
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Most vaccine research has concentrated only on target antigens of adult stage 
flukes (McManus & Dalton, 2006; Van Milligen et al., 1999; van Milligen et al., 2000). 
There are very few reports of juvenile fluke secreting proteins, however it is known 
that cathepsin B is a major component of the ES material of juvenile F. hepatica 
(Creaney et al., 1996; Wilson et al., 1998) and stage and tissue specific cathepsin B 
mRNAs were identified in F. gigantica.  
 
The rationale behind the experiment described here was to test each of the three 
cathepsin antigens independently, and as multi-valent vaccines. It is known that at 
least two of these (cat B and cat L1g) are expressed in the juvenile stage and 
cathepsin L5 in the adult stage.  Although vaccination with cathepsin L will induce 
antibodies that should cross-react with most cathepsin L’s, including any that are 
expressed in the juvenile stage, the inclusion of cathepsin B allows these vaccines 
to induce immunity that more strongly targets the juvenile stage of the flukes. 
 
4.4.2. Protective efficacy of yeast expressed proteins 
 
A recombinant form of these vaccine candidates was expressed in yeast which 
produces these eukaryotic antigens in a form more similar to the native enzyme than 
can be produced by standard procedures in E. coli cells (Law et al., 2003; Smooker 
et al., 2000). After vaccination with these proteins, the induced anti-cathepsin L and 
cathepsin B antibodies are believed to reduce the proteolytic activity of F. hepatica 
ES material in the liver and bile duct (Dalton et al., 1996; Mulcahy et al., 1998; 
Mulcahy et al., 1999). The results of this study have demonstrated that a cocktail of 
adult and juvenile fluke secreting antigens resulted in an 83% reduction in fluke 
burden compared with the control group. In addition, a remarkable reduction in the 
fluke body width and length and a significant reduction in liver pathology were 
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observed. Absolute maximal individual protection was observed after cathepsin B 
and all cocktail vaccines administered. There were 6 rats with zero flukes in protein 
vaccinated groups.  
 
The juvenile F. gigantica somatic extract contains cathepsin B which is localised to 
the caecal epithelium in both metacercariae and juvenile stages . As cathepsin B 
and cathepsin L1g are present in the juvenile stage, responses directed to these 
should have their protective effects on the immature stage of flukes before they 
enter into the bile duct.  
 
A recent report revealed that RNA interference of NEJ cathepsin B and cathepsin L 
significantly reduced transcript levels and encoded proteins in the gut. The authors 
of this study have highlighted that the cathepsin B and cathepsin L enzymes are 
essential for NEJ penetration of gut and silencing of either protein showed abnormal 
locomotion and reduction in penetration of rat intestine. Therefore, RNA interference 
with the function of either enzyme reduced the worm virulence. In these protein 
vaccine trials, we have used a total of 60 µg of yeast purified protein (20 µg for each 
injection) and we predict that these protein vaccines may induce immune responses 
that at least partly inhibit the flukes before they reach the hepatic parenchyma.  
 
F. hepatica cathepsin L1 cleaves IgG antibodies which would prevent the antibody 
mediated attachment of eosinophils to juvenile flukes (Smith et al., 1993a; Smith et 
al., 1994). van Milligen et al. (1999) demonstrated that protection against F. hepatica 
infection in rats was highly correlated with IgG1 antibodies in serum and eosinophils 
in gut tissue. Among the vaccinated groups, cathepsin B and the cocktail of 
cathepsin B and L5 induced high eosinophil and neutrophil counts. 
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In addition, these two vaccine preparations induced high IgG responses. However, 
the antibody mediated eosinophil and neutrophil responses may have some 
detrimental effect on fluke growth and maturation in the vaccinated rats.   
4.4.3. Rats are an ideal model for assessing the Fasciola infection  
 
In human liver fluke infection, migratory and adult stage flukes correspond to two 
clinical stages of infection, the hepatic and biliary stages. A few millimetres in length, 
juvenile flukes cause severe necrotic lesions and necrotic cavities resembling 
tunnel-like tracts. Entry of flukes to the liver creates calcification of hepatic lobes, 
whereas adult flukes secreting proteolytic enzyme cause thickening of the bile duct 
wall and dilatation of the bile duct lumen in control rats. 
 
The macroscopic lesions of control rats clearly mimic the human hepatic and biliary 
stage natural infection. In the control group, the mean body lengths were 23 mm and 
mean body width was 10 mm. In a human infection, the adult fluke from bile duct 
measures 20-40 mm in length and 8-13 mm in width. The body length and width of 
the flukes extracted from control rats matches with size of flukes from human bile 
duct. Valero et al. 2006 have confirmed that the rat is a highly suitable model for 
assessing human infection. In addition, adult fluke reside at the distal part of the bile 
duct resulting in dilatation of the bile duct. Therefore, Sprague Dawley rats are an 
ideal model for assessing the pathogenicity of human fasciolosis. 
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4.4.4. Juvenile, immature and adult fluke antigen vaccine efficacy 
 
In an early cocktail vaccine study, cathepsin L2 and Haemoglobin combined vaccine 
showed 72.4 % protection against challenge infection .   The cathepsin L5 has 80% 
sequence identity with cathepsin L2 (Smooker et al, 2000) and vaccination in rats 
elicits high antibody responses, 50% reduction in fluke burden and 59% reduction in 
wet weight of flukes compared to control rats.  
 
F. gigantica cathepsin L1g showed moderate IgG responses compared to cathepsin 
B and cathepsin L5, 49% reduction in fluke counts and 43% reduction in wet weight 
of flukes compared to control rats. Conversely, cathepsin B vaccination in rats 
induced the highest antibody responses, 59% reduction in fluke counts and 63% 
reduction in wet weight of flukes compared to control rats. These results suggest 
that cathepsin B elicits better protection than either cathepsin L5 or cathepsin L1g.  
 
The protective efficacy of cathepsin L1g was low compared to cathepsin B. F. 
gigantica shows lower infectivity than F. hepatica in Wister rats .  Irving et al. (2003) 
demonstrated that F. gigantica and F. hepatica diverged about 19 million years ago, 
however, there is still significant sequence identity between orthologous proteins of 
the two species. 
 
The additive effect of the three antigens (cocktails of cathepsin B, cathepsin L5 and 
cathepsin L1g) might have been expected to give a greater reduction in fluke 
counts, body length and width, but the lesser protective efficacy of this vaccine may 
be due to the lower amount of each protein (6.6 µg of each individual protein out of 
20 µg protein/ dose). Therefore, if as these data suggest cathepsin B has the 
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greatest protective effect, the lower effective dose in the last group may not be 
sufficient for high levels of protection. 
 
4.4.5. The effect of vaccination on pathology and parasitism 
 
Liver damage is always associated with morbidity as well as mortality from infection 
in ruminants . The pathological consequences of NEJ migration lead to high 
mortality in sheep as well as morbidity in cattle (Martinez-Moreno et al., 1997; 
Meeusen et al., 1995). Our results show that vaccination with cathepsin B, cathepsin 
L5 or the multivalent cathepsin B/L5 results in less liver damage than in control rats.  
 
Reduction in the size of flukes in vaccinated animals is a feature of protective 
immunity because it demonstrates a deficiency in their normal physical development 
. Estuningsih et al, (1997) tested native glutathione S-transferase, cathepsin L, 
paramyosin, fatty acid binding protein (FABP), and an E. coli expressed FABP in 
Brahman cattle.  In cattle vaccinated with native FABP, there was a 31% reduction 
in fluke burden and up to 36% reduction in the average wet weight of the flukes. 
 
In this study, the reduction in fluke size and number in vaccinated rats is reflected in 
a reductuion in liver pathology. It may be that a fluke vaccine does not need to 
induce sterile immunity, but reduce the pathology to a level that is tolerated by the 
animal. 
4.4.6. Recombinant proteins induces leukocyte cell changes 
 
Spithill et al, (1997) have hypothesized that fluke ES materials inhibit antibody-
mediated attachment of eosinophils, neutrophils and macrophages to the tegument 
of flukes. Jefferies et al. (1997) reported that inhibition of superoxide release was 
observed in human and sheep activated neutrophils by F. hepatica ES material.  
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The ES material has superoxide dismutase activity (inhibition of release of 
neutrophil superoxide free radicals) and its expression was shown to be higher in F. 
hepatica than F. gigantica (Piedrafita et al., 2000; Piedrafita et al., 2007). Natural 
immunity against infection is thought to be via antibody-mediated cellular cytotoxic 
mechanisms. In this study, the peripheral eosinophil counts tend to increase in all 
protein vaccinated rats at the time of challenge and neutrophil responses tend to 
increase in cocktail vaccinated rats. There was increase in lymphocyte responses at 
time of challenge, but it starts declining at the time of necropsy. The induced 
protective immunity in rats may act via these same immunological events during this 
time period.  
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4.5. Conclusion 
 
The results of this study showed that juvenile antigen cathepsin B induces stronger 
immune protection than the adult fluke antigen cathepsin L5. Cocktails of juvenile 
and adult stage Fasciola recombinant proteins elicited the highest protective 
immunity against experimental infection. This combination of antigens by its ability to 
reduce the parasite load and size in a rat model represents a step forward in the 
development of a vaccine against this disease and now needs to be tested in 
ruminants. 
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Chapter 5 
Immunological characterisation of responses induced by DNA vaccine 
vectors encoding F. hepatica cathepsin B 
 
5.1. Introduction 
 
Juvenile and immature stages of F. hepatica produce ES material and cathepsin B 
is found to be a major part of this material (Tkalcevic et al., 1995; Wilson et al., 
1998). The major action of this cathepsin B is proposed to be assisting in the 
excystment and migration of young flukes into host tissues (Creaney et al., 1996; 
Tkalcevic et al., 1995). Therefore, F. hepatica cathepsin B is considered a potential 
vaccine candidate against Fasciola infection. In the previous chapter recombinant 
cathepsin B was evaluated as a recombinant protein vaccine, and shown to induce 
protective responses in rats. Work described in this chapter evaluates a different 
form of delivery. 
 
DNA immunisation is a novel technology in the field of vaccine development and 
DNA vaccines have been shown to activate both cellular and humoral immunity 
against infectious parasitic diseases (Smooker et al., 2004). DNA vectors encoding 
antigen present major advantages over protein vaccines in terms of protein 
processing, safety and stability . 
 
Many DNA vaccine constructs have been shown to induce Th1 type responses via 
intramuscular delivery, as inferred by IFN-γ cytokine and IgG2a antibody production 
in vaccinated animals. Intradermal DNA vaccination generally generates Th2 
responses  
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with IL-4 and IgG1 production in vaccinated animals (Kennedy et al., 2006; Smooker 
et al., 1999). In order to increase the effectiveness of DNA vaccines, a number of 
vaccine strategies have been employed to increase the immunological potency of 
the antigen. 
 
One strategy has been to use secretory vaccine vectors. For example, plasmid DNA 
encoding secretory and cytoplasmic F. hepatica glutathione S transferase , fatty acid 
binding protein and cathepsin L5 (Smooker et al., 2001) were investigated in mouse 
trials, and the encoded antigens evoked greater immune (humoral) responses when 
in secreted form. 
 
Another strategy involves the use of a chemokines that improves the 
immunogenicity of poorly immunogenic antigens by targeting them to antigen 
presenting cells (APCs) via chemokine receptors. MCP3 has been evaluated by 
cancer biologists and virology researchers as an anti-cancer cytokine and chemo-
attractant of leukocytes (Ben-Baruch et al., 1995; Lanzavecchia & Sallusto, 2007; 
Rosati et al., 2005). 
 
CTLA-4 encoding plasmids are one of the most attractive DNA vaccine vectors 
which attempts to target antigen to APCs in the lymph node by virtue of affinity of 
the protein for CD80/86 (B7-1 and B7-2) on such APCs (Boyle et al., 1998; Boyle et 
al., 1999; Drew et al., 2001). Vaccination with constructs encoding CTLA-4 fusion 
proteins can induce strong antibody responses and provides a novel generic DNA 
vaccine for the development of therapies against a wide range of diseases (Huang 
et al., 2000; Jia et al., 2006; Rainczuk et al., 2003). Targeting of APCs by CTLA-4 
encoding ovalbumin was performed in pigs via gene gun delivery. This DNA 
vaccination induced elevated anti-ovalbumin- IgG, IgA, IgG1 and IgG2 antibody 
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responses. A large-scale DNA vaccination trial was performed with sheep to 
investigate whether an antigen targeted by CTLA-4 enhanced and accelerated the 
humoral immune response (Chaplin et al., 1999). CTLA-4 mediated targeting and 
CpG motifs enhance immunogenicity in DNA prime/protein boost strategy in sheep 
against Fasciola infection was demonstrated by Kennedy et al. (2006).  
 
In work described in this chapter, the humoral and cellular immune responses to 
various DNA vaccines encoding F. hepatica cathepsin B protease were investigated. 
This panel of constructs was analysed for in vitro expression with COS-7 cells and in 
vivo with BALB/c mice via the intramuscular route. 
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5.2. Materials and Methods 
 
5.2.1. F. hepatica DNA vaccines encoding cathepsin B 
 
Cloning of cathepsin B and the construction of DNA vaccines was performed by Dr. 
Peter Smooker and colleagues (Law et al., 2003), and unpublished data. The 
constructs to be tested are as follows: 
 
pVR1012 Cat B. Secretion of cat B using the native signal peptide. 
pVR1020 Cat B. Secretion of cat B using the TPA signal peptide. 
pMCP3 Cat B. Secretion of cat B fused to murine MCP-3. 
pCTLA-4 Cat B. Secretion of cat B fused to murine CTLA4. 
 
The coding region for procathepsin B was inserted into the DNA vaccines. The 
exception was for pVR1012 cat B, where the full coding region, including the native 
cat B signal peptide, was inserted. For fusion protein constructs, the cat B formed 
the C-terminal part of the fusion. 
 
5.2.2. Giga plasmid preparation and purification of DNA vaccines for 
immunisation 
 
The control plasmid VR1012 and the four DNA vectors encoding the pro-mature part 
of cathepsin B were purified from one litre of E. coli culture using an endotoxin free 
plasmid Giga kit (Qiagen) according to the manufacturer’s instructions. Freshly 
transformed DH5α cells containing one of the five plasmids of interest were grown 
on Luria-Bertani (LB) plates supplemented with 100 µg/mL of ampicillin or 50 µg/ml 
of kanamycin. A single colony was inoculated into LB broth and grown at 370 C with 
vigorous shaking at 200 rpm overnight. This culture was diluted (1:1000) into one 
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litre of LB broth and grown for 16 hours prior to plasmid purification (see section 
2.4.2.1). The purified DNA was diluted in endotoxin free 0.9% saline solution at a 
concentration of 1 mg/ml. Plasmid integrity was assessed by restriction enzyme 
digestion and agarose gel electrophoresis.  
 
5.2.3. Analysis of COS-7 cell expression of cathepsin B from DNA vaccine 
vectors 
 
In vitro expression of cathepsin B from DNA vaccines was evaluated by transfecting 
COS-7 cells (a kind gift from Kimberly Dynon, Melbourne University, Parkville) using 
the lipofectamine reagent according to the manufacturer’s instructions. DMEM 
medium supplemented with 10% new born calf serum (NCS) was used for COS-7 
cell growth. The day before transfection, cells were seeded in 6 well sterile tissue 
plates in 2 mL complete medium. Cells were incubated in a 5 % CO2 humidifier at 
370C until the cells attained 80% confluency.  For each transfection, 4 µg of plasmid 
was added to 100 µL of DMEM medium without NCS and 20 µL of lipofectamine 
LTX reagent. The mixture was incubated for 5 minutes at room temperature and this 
was added to COS-7 cells.  After incubation at 370C for 24 hours, one mL of 
complex DMEM medium with NCS (10 %) was added. After incubating for a further 
48 hours at 370C, the cells were washed with PBS and growth media without NCS 
and grown for a further 24 hours. After harvesting of COS-7 cells, the supernatant 
was concentrated using an Amicon ultra filtration unit (cut off value 15 kDa) and 20 
µL of highly concentrated supernatant and/or yeast expressed cathepsin B was 
used for western blotting.  
 
  151
 
 
 
5.2.4. Purification of recombinant cathepsin B from yeast cells 
 
The expression and purification of cathepsin B from S. cerevisiae BJ 3505 cells 
proceeded according to Law et al. (2003), as described in Chapter 3. The purified 
cathepsin B was used for ELISPOT assays, ELISA, IgG avidity assays and western 
blotting. 
 
5.2.5. DNA vaccination protocol  
 
Groups of five 6-8 week old BALB/c female mice were immunised with VR1012 as 
the control, VR1012 cat B, VR1020 cat B, MCP3 cat B and CTLA-4 cat B as 
vaccines. The plasmid DNA was administrated three times at two week intervals via 
an intramuscular injection to the thigh. Mice received 100 µg of DNA in 100 µL of 
0.9% endotoxin free saline solution (50 µL each thigh) on days 0, 14, 28. Mice were 
bled on days 28, 42, 56 and 70. 
 
5.2.6. Indirect ELISA 
 
Indirect ELISA was performed as described previously by Smooker et al. (2001).  
The sterile ELISA plates (96 well) were coated with recombinant cathepsin B at 5 
µg/ mL in carbonate bicarbonate buffer pH 9.6 and incubated overnight at 40C (see 
section 2.5.2). After blocking, sera from individual mice were serially diluted (1:100), 
loaded onto the plates and incubated at 370C for 2 hrs under gentle shaking. The 
bound antibodies were detected using anti-mouse HRP conjugated IgG (1:3000 
dilution), followed by the addition of TMB substrate. The reaction was stopped by 
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adding 2M sulphuric acid. Reciprocal titres were calculated as the dilution that 
yielded an OD450 absorbance of 0.2.  
 
5.2.7. Antibody avidity assay 
 
An antibody avidity assay was performed as described by Kang et al. (1998) and 
Rainczuk et al. (2003b) with the following modifications. Yeast expressed cathepsin 
B (5µg/mL) was used to coat 96 well plates. The sera collected from individual mice 
were added to all wells according to their antibody titre value (OD450 absorbance of 
0.2) and incubated for one hour at 370C, followed by the addition of an increasing 
concentration of urea to 0, 1, 2, 3, 4, 5, 6 and 7 M and further incubation for 30 
minutes at 370C. The humoral responses were assessed using anti-mouse HRP 
conjugate and developed as described for the ELISA above. 
 
The relative avidity was calculated by setting the absorbance reading at OD450 at 
zero molar urea concentration as 100%, with the values at increasing urea 
concentrations expressed as a percentage of this value .  
 
5.2.8. In vitro splenocyte culture 
 
In vitro culturing of spleen cells and ELISPOT assays was performed as described 
previously by Bachtiar et al. (2003). Vaccinated mice were sacrificed at week 10 (4 
weeks after the third vaccination). Spleens were extracted from two animals in each 
group, crushed, cells washed two times using RPMI medium and incubated in ACK 
lysis buffer (see section 2.5.1) for 5 minutes. Cells were washed in 1mL RPMI 
medium and suspended at a concentration of 1x 106 cells/90 µL. 
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5.2.9. IL-4 ELISPOT assay 
 
Methanol treated 96 well multi screen plates (Millipore) were coated with 100 µL of 5 
µg/mL of anti-mouse interleukin-4 overnight, followed by washing with PBS-Tween 
20, blocking with 5% skim milk in PBS for 2 hours and a further washing step with 
PBS-Tween 20. Splenocytes (1X106) were then added to the wells. Splenocytes 
were stimulated with 250 µg/mL of cathepsin B or concanavalin A. Cultures were 
incubated at 370C in a 5% CO2 humidifier for 21 hours. Following washing with PBS, 
biotinylated rabbit polyclonal anti- IL-4 in PBS was added to wells and incubated at 
room temperature for 2 hours. After washing, strepavidin-alkaline phosphatase was 
added and incubated at room temperature for 1 hour.  After washing three washes 
with PBS-Tween 20 and two washes with sterile Milli Q water, the plates were 
developed with ELISA substrate solution (see section 2.5.1) and spots were counted 
using a dissection microscope. Experiments were performed in triplicate and results 
were expressed as the mean number of cytokine secreting cells per 106 
splenocytes. 
 
5.2.10. SDS-PAGE and western blotting  
 
 
COS-7 cell expression of cathepsin B and induction of antibody in mice was 
evaluated by western blotting. For COS-7 cell expression of cathepsin B, the cell 
lysates and supernatants were collected. Cell supernatants were concentrated using 
Amicon ultra filtration membranes. SDS-PAGE was performed (see section 2.4.4.6) 
and proteins were transferred to nitrocellulose membranes (see section 2.4.4.7.2). 
Western blots were probed with rat anti-cathepsin B antibodies (1:100) and followed 
by anti- rat alkaline phosphatase conjugated secondary antibodies (1:100) and 
reactive antibodies were visualised using western blot developing solution (see 
section 2.4.4.1). 
  154
 
For assessing the cathepsin B specific antibodies in pooled sera of vaccinated mice 
groups, cathepsin B was separated (SDS-PAGE) and transferred to nitrocellulose 
membranes. After blocking, the membrane was probed with antisera (1:100 dilution) 
from all vaccinated groups and then probed with anti-mouse Alkaline phosphatase 
conjugated (1:2000 dilution) and then finally developed by western blot developing 
solution (see section 2.4.4.1). 
 
5.2.11. Statistical analysis 
 
For all analyses of antibody titre, antibody avidity and ELISPOT assays, mean± 
standard deviation was calculated and data were analysed using SPSS software.  
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5.3. Results 
 
5.3.1. DNA vaccine vectors, COS-7 cells expression and vaccine purification 
 
A diagrammatic representation of the DNA vaccine vector constructs is shown in 
Figure 5.1. To ensure integrity of the purified plasmid, VR1012 and VR1012 cat B 
were digested with BamH I/Not I, VR1020 cat B and MCP3 cat B with BamH I alone 
and CTLA-4 cat B with Mlu I. The restriction enzyme digestion of the panel of 
vectors yielded the approximately 1 kb fragment encoding cathepsin B (actual size 
depending on the construct) after agarose gel electrophoresis (Figure 5.2). 
 
In order to confirm the functional expression of antigens, the VR1012, VR1012 cat 
B, VR1020 cat B, MCP3 cat B and CTLA-4 cat B constructs were examined for 
protein secretion from COS-7 cells. The five plasmid DNAs were delivered into 
COS-7 cell lines by liposome mediated transfection. Western blotting was used for 
detection of protein in the culture medium from COS-7 cells transfected with DNA 
vectors (Figure 5.3).  
 
Analysis of western blots probed with cathepsin B specific rat sera revealed the 
secretion of proteins from COS-7 cells in each case. The recognition of 36 kDa cat B 
and 50 kDa fusion protein bands was observed. There was no reactivity observed 
when COS-7 cells were transfected with empty vector. 
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VR1012  
 
VR1012 cat B 
 
VR1020 cat B  
 
 
MCP3 cat B 
 
CTLA-4 cat B 
 
 
Figure 5.1. Diagrammatic representation of the DNA vaccine vector constructs 
VR1012, VR1012 cat B, VR1020 cat B, MCP3 cat B and CTLA-4 cat B.  
 
The respective coding regions are detailed as rectangles (cat B) and signal peptide 
as small rectangles. VR1012 cat B has the native cat B signal peptide. VR1020 cat 
B has the TPA signal peptide encoded in the vector.  MCP3 cat B and CTLA4 cat B 
have their own signal peptides.  
 
 
 
 
 
Cat B 
 
 
Cat B 
 
 
 
Cat B 
 
MCP3 
 
Cat B 
 
CTLA-4 
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                                                 1     2    3    4    5           6 
 
 
 
Figure 5.2. Restriction digestion analysis of purified DNA vaccine vectors 
encoding cathepsin B analysed by agrose gel electrophoresis.  
Lane 1, BamH I/Not I digested VR1012; lane 2, BamH I/Not I digested VR1012 cat 
B; lane 3, BamH I digested VR1020 cat B; lane 4, BamH I digested MCP3 cat B; 
lane 5, Mlu I digested CTLA4 cat B; lane 6, Pst I lambda marker. The DNA fragment 
carrying the cathepsin B coding sequence is arrowed  
 
 
 
 
 
 
 5.0 kb 
 
 
1.0 kb 
0.8 kb 
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                                                                       1   2  3  4   5   6       7 
                 
 
 
Figure 5.3. Western blot detection of encoded proteins secreted from COS-7 
cells transfected with DNA vaccine vectors. 
Lane 1, VR1012 transfected cell supernatant; lane 2, pre-stained protein marker; 
lane 3, VR1012 cat B cell supernatant; lane 4, VR1020 cat B cell supernatant; lane 
5, MCP3 cat B cell supernatant; lane 6, CTLA4 cat B cell supernatant; lane 7, yeast 
expressed cathepsin B as a positive control.  
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5.3.2. Analysis of humoral immune responses  
 
5.3.2.1. IgG responses 
 
F. hepatica cathepsin B specific antibody titres induced after vaccination of BALB/c 
mice with DNA vaccines are presented in Figure 5. 4.  Sera were sampled at weeks 
4, 6, 8 and 10. At every time point all groups of animals vaccinated with cat B 
encoding constructs showed enhanced antibody titres when compared with control 
vectors. All four vaccines generated antibody responses by week four after the initial 
dose, but showed varied kinetics of the humoral response.  
 
Mean antibody titres generated in mice immunised with the CTLA-4 targeted 
construct were significantly higher (P<0.05) than all other constructs at week 4. 
There was no significant difference between the mean titres of any of the 4 test 
groups at weeks 6 and 8. However, at week 10 the mean antibody titres in sera of 
mice vaccinated with CTLA-4 tagged cat B was again higher than VR1012 cat B and 
MCP3 cat B, but not VR1020 cat B. Therefore it appears that the CTLA-4 fusion 
construct generally induces titres faster than other constructs, and ultimately 
induced a higher overall titre. The early induction of humoral responses to CTLA-4 
containing DNA vaccine constructs was previously noted in BALB/c mice (Boyle et 
al., 1998). 
 
5.3.2.2. Avidity of IgG responses induced by DNA vaccines encoding 
cathepsin B 
 
An ELISA based IgG avidity assay was performed. The percentage of bound 
antibodies at increasing concentrations of urea was calculated, relative to the bound 
level in zero urea (figure 5.5).  The gradual increase in urea concentration results in 
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the disruption of bound immune complexes. The rapid drop in titre observed for the 
VR1012 group (ie: the negative control) reflects the non-antigen specific nature of 
binding in this group. Although the MCP3 cat B sera showed a higher percentage of 
binding to antigen compared to other groups, the difference between the four 
vaccine groups was not significant.  
 
5.3.2.3. Immunoblotting  
 
Pooled serum (week 10) from all vaccinated mice within a group was used to probe 
yeast expressed cathepsin B by western blotting (shown in Figure 5.6). Sera from all 
groups vaccinated with cathepsin B constructs was able to recognise the protein. No 
signal was detected for control vaccine sera. In these semi-quantitative blots, MCP3 
and CTLA-4 construct showed stronger reactivity than other vaccinated groups.  
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Figure 5. 4. Cathepsin B specific IgG antibody responses in vaccinated mice  
at bi-weekly intervals from weeks 4 to 10 after the first vaccination.  
At every time point, all vaccinated groups with cat B encoding constructs showed 
enhanced antibody titres when compared with control vectors (P<0.05). * indicates 
that the mean antibody titre of CTLA-4 cat B vaccinated mice is statistically higher 
other vaccinate groups at week 4 (P<0.05). ** indicates that the mean antibody titre 
of CTLA-4 cat B vaccinated mice is statistically higher than VR1012 cat B and 
MCP3 cat B, but not VR1020 cat B at week 10 (P< 0.05).  
 
 
 
 
 
 **         
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Figure 5.5. Measurement of the avidity of IgG antibody responses to cathepsin 
B.  
 
(A). The percentage binding relative to 0 M urea is shown plotted against increasing 
urea concentration. 
 
 (B). Relative avidity index of anti-cathepsin B specific IgG antibodies in immunised 
mice.  The mean and standard deviation of avidity index are presented here. The 
relative avidity index was calculated as the urea concentration required to reduce 
the binding percentage to 50%. All the vaccinated groups showed significantly 
higher indeces compared to control (* P < 0.05). 
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                                               1       2        3        4        5 
 
 
Figure 5.6. Western blot of yeast expressed cathepsin B protein probed with 
pooled sera of vaccinated mice. 
Sera from mice vaccinated with: Strip 1, VR1012; strip 2, VR1012 cat B; strip 3, 
VR1020 cat B; strip 4, MCP3 cat B, strip 5, CTLA4 cat B sera. The individual strips 
contain See Blue pre-stained protein markers. Each individual immunoblot shows 
reactivity except the control DNA vaccinated sera.  
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 36 kDa 
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5.3.3. Cellular immune responses 
 
Cellular memory induced after cathepsin B DNA immunisation was estimated using 
the ELISPOT assay to measure the numbers of cathepsin B specific IL-4 cytokine 
secreting cells. Figure 5.8 shows the numbers of IL-4 secreting splenocytes from 
vaccinated mice. 
 
Vaccination with any of the plasmids encoding cathepsin B induced highly significant 
IL-4 cytokine secretion (P<0.005) compared to the control groups. Interestingly, the 
native signal peptide carrying construct (VR1012 cat B) vaccinated mice produced 
the highest level of IL-4 cytokine production. However, there was no significant 
difference between the numbers enumerated from any group vaccinated with a 
cathepsin B encoding construct.  
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Figure 5.7. Quantitative determination of IL-4 secreting spots (ELISPOTs) in 
vaccinated groups (** P < 0.01).  
The mean and standard deviation are presented here. Each vaccine test group 
yielded significantly higher numbers of IL4 secreting cells than the control (SPF -
spot forming T cells).  
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   * *        
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5.4. Discussion 
 
5.4.1. Expression of cathepsin B protein 
 
The DNA vaccines described here encode cathepsin B in a variety of forms, 
however all are designed to be secreted after expression in the host, which should 
facilitate the induction of humoral immunity. As shown in Figure 5.3, each of the 
expressed proteins can be detected in the supernatant after culture of transfected 
COS-7 cells, demonstrating secretion. The detection of protein in the VR1012 catB 
medium indicates that the native cathepsin B signal peptide is able to function in 
these cells. This has also been previously demonstrated for another Fasciola 
protein, cathepsin L (Smooker et al 2001). 
 
5.4.2. Immunogenicity of the DNA vaccines 
 
This study demonstrates that delivery of Fasciola antigen via DNA vaccine vectors 
induces humoral and cellular responses in BALB/c mice. Each of the four DNA 
vaccine vectors tested elicited cathepsin B specific antibody responses as well as 
cell-mediated memory responses. 
 
5.4.3. Humoral responses to cathepsin B 
 
Humoral responses were induced by each of the four test constructs after 
intramuscular vaccination of mice. This was expected, as the COS-7 transfection 
analysis indicated that in vivo expressed protein should be secreted from cells and 
be available for the priming of B cells. The kinetics of antibody induction was 
different between the four constructs, with CTLA-4 cat B inducing a strong response 
at the earliest time point measured (4 weeks) compared to the three other 
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constructs. This confirms what has been seen in several studies- one of the major 
advantages of using CTLA-4 fusion constructs is the early induction of immune 
responses (Boyle et al 1998; Drew et al., 2001). Although the responses at weeks 6 
and 8 were not significantly different between the test groups, at week 10 the 
cathepsin B antibody response in the CTLA4-targeted group had again increased 
relative to VR1012 cat B and MCP-3 cat B.  The CTLA-4 targeting antibody 
efficiency mainly relies on  the size and antigenicity of encoded protein. For 
example, a CTLA-4 construct encoding a Taenia ovis antigen showed 30 fold higher 
immune responses than non-targeted DNA vaccination.  
It has been previously shown that high avidity binding of CTLA4 to its receptor 
requires dimerization (Boyle et al 1998; Drew et al., 2001). The highest Ab 
responses were obtained when CTLA4 and cathepsin B was present via both a 
targeting ligand and a dimerization moiety was required for enhancement.  The 
dimerization is critical for the enhancement effect and this is probably due to the fact 
that dimers bind with much greater avidity than monomers.  
There are a number of reports explaining the speed and magnitude of IgG antibody 
induction in mice vaccinated with secretory vaccine vectors (Boyle et al., 1997; 
Inchauspe et al., 1997; Jia et al., 2006; Rainczuk et al., 2003; Smooker et al., 2001). 
A previous report by Smooker et al. (2001) showed that after DNA vaccination with 
constructs encoding liver fluke antigens, antibody responses peaked (1/2000) at 
week 8 and remained high for 20 weeks. In this study, constructs encoding liver 
fluke FABP only induce antibodies when delivered in a form that will secrete FABP 
from the host cell. Antigen availability for B cell priming is an essential factor in 
designing DNA vaccinations for the induction of humoral responses (Boyle et al., 
1997).   
 
In these experiments, the MCP-3 construct did not induce increased responses over 
those constructs in which unfused cathepsin B was secreted. Other studies (Biragyn 
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et al., 1999; Rainczuk et al., 2003) have shown increased responses. The reason for 
the failure of MCP-3 in these experiments is unknown, and is presumably related to 
the specific combination of antigen and chemokine that is expressed.  
 
 
One way of characterising antibody responses is to estimate the antigen-specific 
affinity and avidity of antibodies. As an indicator of antibody avidity an IgG antibody 
ELISA with urea as a denaturing agent was used. The relative avidity can be 
calculated as the urea concentration required dissociating 50% of the antibody-
antigen complex. The relative avidities are shown in Figure 5.6. This clearly shows 
the sharp drop in binding in the control group, which is obviously reflective of non-
specifically bound antibody. One interesting finding was that the relative avidity of 
MCP3- cat B induced antibodies appeared higher than those induced by other 
vaccines, as inferred by a urea IgG ELISA (Figure 5.6). Rainczuk et al. (2003) tested 
the relative affinity of DNA vaccines (malarial MSP4-5 fused with MCP-3 or CTLA-4) 
and found that the avidity of both these constructs was comparable.  
 
5.4.4. T cell responses 
 
F. hepatica ES material is proposed to induce Th2 polarising activity during the 
chronic stage of natural infection (McManus & Dalton, 2006; Spithill et al., 1997).  
Smooker et al. (2001) observed Th2 dominant responses after vaccination of 
plasmid-encoded (secreted via the native signal peptide) VR1012 cat L5 in BALB/c 
mice.  
 
The induction of IL4 by fluke infection in mice has been well documented by many 
groups (Brady et al., 1999; Cheever et al., 1994; Da'Dara et al., 2006; O'Neill et al., 
2000). As stated above, the migratory juvenile and adult liver fluke ES material 
elicits Th2 responses (Meeusen et al., 1995; Mulcahy et al., 1998). IL-4 acts as a 
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potent stimulus for Th2 differentiation in mice (Abbas et al., 2002). Each of the 
vaccines encoding cathepsin B tested here induced significant numbers of 
splenocytes secreting the IL-4 cytokine, indicating good induction of Th2-like 
memory responses. In L. amazonensis experimental infection, there is observed a 
low level of IFN-γ and high levels of IL-4 and also IgE antibodies. The combined 
effects lead to an immunopathological reaction and the development of inflammatory 
granulomas in the liver (Stanley & Engwerda, 2007). The secreted cathepsin B from 
juvenile flukes may be responsible for the formation of necrotic granulomas 
(immunopathological and inflammatory lesions of the liver) of hepatic lobes, due to 
the induction of cytokines. However, this needs to be confirmed by further studies.  
 
Chen et al. (2005) has investigated the protective effect of a cocktail vaccine 
containing a murine IL-4-encoding cDNA and S. japanicum cathepsin B encoding 
DNA in mice. The percentage of reduction in worm burden was 43.2 % and the egg 
reduction rate was 76.6% over cathepsin B DNA vaccine alone. In future work, 
murine IL-4 DNA as an adjuvant may increase the induction of immune responses to 
F. hepatica cathepsin B in this model system. 
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5.5. Conclusion 
 
Cathepsin B delivered as a DNA vaccine can be secreted from mammalian cells and 
induce humoral and T cell responses in mice. The results of this investigation 
demonstrate that DNA vaccines have potential to activate both humoral and cellular 
immunity against a juvenile fluke target antigen, and that fusion with CTLA-4 is a 
mechanism that may augment the responses somewhat.  
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Chapter 6 
Expression and refolding of recombinant F. gigantica cathepsin L1g 
protease expressed in E. coli 
 
6.1. Introduction  
 
As has been described previously, the cathepsin L-like proteases of Fasciola spp. 
are considered as immunodiagnostic antigens and vaccine candidates (Dalton et al., 
2003b; Spithill et al., 1997; Yamasaki et al., 1992). Cathepsin L1g expression and 
purification is required for exploring further applications of its immunodiagnostic 
potential, enzyme kinetics and vaccine studies. In work described in chapter 3 of this 
thesis, yeast BJ3505 cells expressed F. gigantica cathepsin L1g protease in a 
soluble form, but the yield was low. 
 
E. coli is still the most widely used  expression host because of ease of handling and 
low cost of production, despite limitations such as the lack of ability to perform post-
translational modifications and over-expression into insoluble aggregates . 
Yamasaki et al. (2002) have expressed F. gigantica procathepsin L and pro-peptide 
deleted cathepsin L in E. coli and inferred that the pro-region of the protease is 
essential for refolding of functional protease. Kesik et al. (2007) expressed a 
cysteine protease as inclusion bodies in E. coli and this protein was used for enteral 
vaccination of rats against fasciolosis.  The major problem associated with 
expressing Fasciola cathepsins in bacteria is the inability to correctly form disulphide 
bonds and hence refolding is necessary. For large-scale production of the F. 
gigantica procathepsin L that we have expressed in yeast, bacterial expression is 
desirable.  
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In vitro refolding conditions using fractional factorial screens have been successfully 
used to improve the yield of soluble human pro-cathepsin to support crystallographic 
efforts (D'Alessio et al., 1999; Kramer et al., 2007; Tobbell et al., 2002; Willis et al., 
2005). In this chapter, an efficient procedure to obtain relatively high quantities of 
functionally active F. gigantica cathepsin L1g from E. coli BL21 cells was 
investigated.  
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6.2. Materials and Methods 
 
6.2.1 Cloning and construction of plasmid pRSET-A catL1g 
 
6.2.1.1. Expand PCR  
 
 
The 945 bp fragment containing cDNA of F. gigantica cathepsin L1g cloned into 
pGEMT was a kind gift from Dr. Rudi Grams (Thamasaat University, Thailand) and 
was used as a template for the construction of the expression vector. The cloning 
procedure was presented Figure 4.1. The coding region of cathepsin L1g protease 
was amplified by the expand polymerase chain reaction (Expand-long template 
PCR) according to the procedure given below. The oligonucleotide primer F1-(5’-
ATA GGA TCC AAC GAT GAT TTG CAT GAA TGG AAG CGA-3’) and primer R1–
(5’-ATA GGA TCC TCA CGG AAA TCG TGC CAC CAT-3’) were synthesised by 
Gene Works, Melbourne, Australia. Oligonucleotide F1 was used as the upstream 
primer that introduced a BamH I restriction site (underlined above). Oligonucleotide 
R1 used as the downstream primer that also added a BamH I restriction site to the 
amplified DNA.  
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Figure  6.1. Overview of the cloning procedure 
 
 
     Insert (cathepsin L1g)                                                        Vector pRSET-A 
  
Expand PCR and gel elution                                 Restriction enzyme digestion 
 
TA Cloning and gel elution                                    CIP treatment & Gel elution 
                          
 
                                  Ligation, transformation and plating 
                                           
 
                                     
                                     Colonies grown and analysed 
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The expand PCR programme for amplification of the cathepsin L1g DNA segment 
was as follows: 
(Procedure adopted from Roche diagnostics) 
Number of cycles  Temperature  Duration 
1x  (denaturation)  930C   2 minutes 
10x  (denaturation)  930C   10 seconds 
  (annealing)  500C   30 seconds 
  (elongation)  680C   7 minutes 
15x  (denaturation)  930C   10 seconds 
  (annealing)  530C   30 seconds 
  (elongation)  680C   7 min+ cycle elongation  
for 20s for each cycle                                                                         
1x       (extension) 680C   10 minutes 
 
The 50 µL expand PCR reaction volume has 
 
Template (cathepsin L1g) DNA   x µL (up to 300 ng) 
Forward primer (up to 300 nM)  3 µL 
Reverse primer (up to 300 nm)  3 µL 
dNTPs      0.2 mM 
Expand buffer II     5 µL 
Expand polymerase     0.75 µL 
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6.2.1.2. TA cloning 
 
The PCR product was electrophoresed (0.8% agarose gel) and the band was eluted 
using the QIA quick gel extraction kit. Following quantification, the purified PCR 
product (945 bp) was ligated into the pCR 2.1 (Figure 6.2) vector using T4 DNA 
ligase. The reaction was allowed to proceed overnight at 160 C (see section 2.4.3.2). 
The ligated product was used for transformation of E. coli DH5α competent cells. 
Transformed cells were grown on Luria-bertani (LB) medium plates containing 100 
µg/ml ampicillin, IPTG and X-gal, to allow blue/white colony screening (see section 
2.4.3.3.2). Plasmid DNA was purified from white colonies. Successful ligation was 
confirmed by restriction digestion with BamH I and agarose gel electrophoresis. 
 
6.2.1.3. pRSET- A cloning 
 
To insert the F. gigantica cathepsin L1g fragment into the multiple cloning site 
(MCS) of the pRSET-A vector, the plasmid was digested with BamH I, 
dephosphorylated with calf intestinal phosphatase (refer 2.4.3.1), then ligated to 
BamH I digested, gel eluted cathepsin L1g insert from pCR 2.1. The resulting 
construct encodes pRSET-A catL1g that includes the coding region for the pro-
mature region of the protease. Plasmid DNA was transformed into E. coli strain 
BL21 (DE3) pLysS competent cells. 
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Figure 6.2. Schematic map of vector pRSET and pCR 2.1 (the picture adopted 
from: https://catalog.invitrogen.com/productImages/2100/2042_thumb.GIF and  
http://www.mtsu.edu/~rseipelt/web4460c/12224020.jpg). 
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6.2.1.4. DNA sequence analysis and confirmation of correct orientation of 
pRSET-A cat L1g 
 
Correct orientation of the insert was confirmed by restriction digestion with EcoR I 
and agarose gel electrophoresis.  DNA sequencing was performed to confirm the 
integrity of the construct. The double stranded plasmid DNA was sequenced by the 
Big dye terminator cycle sequencing analysis system (Monash University, Clayton, 
Australia) (see section2.4.3.3.3). Sequencing results were analysed using clone 
manager software (SE Central). 
 
6.2.2. Cathepsin L1g protease expression and refolding  
 
Two pathways were taken to assess the purification and re-folding of the protease 
(Figure 6.3) 
 
6.2.2.1. Expression of Cathepsin L1g and collection of inclusion bodies  
 
Transformed E. coli BL21 (DE3) pLysS was grown in one litre of LB broth 
supplemented with ampicillin (100 µg/mL) at 370C with 200 rpm continuous shaking. 
The bacterial culture was grown until the absorbance at 600 nm reached 0.4 and 
was followed by induction with 1 mM IPTG. Hourly expression was assessed by 
SDS-PAGE. The culture was harvested by centrifugation at 15,000 g for 15 minutes 
at 40C. The supernatant was discarded and the pellet was stored at -800C overnight.  
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Figure 6.3. Schematic outline for purification and refolding of cathepsin L1g 
protease 
           Cell lysis 
        Centrifugation 
            Purification of inclusion bodies 
             Resuspension and centrifugation 
 
 
             Solubilisation of inclusion bodies  
 
 
              6M Gdn HCl and DTT                    8M Urea and 2-Mercaptoethonol 
 
 
            On column refolding                                                         Dilution 
                  
                 
                        Dilution                                                                    Dialysis 
                   
 
                         Dialysis 
                                                        
 
 
 Post refolding analysis 
 
 
    SDS -Gelatin substrate PAGE 
 
 
  Western blotting 
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6.2.2.2. Bacterial cell lysis, washing and harvesting of inclusion bodies  
 
Cell pellets were resuspended in 10 ml of lysis buffer (see section 2.4.4.4) and 
incubated for 30 minutes at room temperature with gentle shaking. The cell lysate 
was disrupted by several sequential freeze/thaw cycles. Before the final cycle, 5 
units/ml of DNase I was added to the lysate, which was then centrifuged at 15,000 g  
for 30 minutes at 40C in a BECKMAN high speed centrifuge to collect the insoluble 
pellet and resultant supernatant was discarded. The remaining aggregated pellet 
was rinsed two times in PBS pH 8.0 containing low concentrations of the non-ionic 
detergent Triton X -100 (1%).  
 
6.2.2.3. Solubilisation of inclusion bodies  
 
 
Once collected, the inclusion bodies were solubilised in one of two buffers. The first 
was the inclusion body solubilisation buffer, containing urea (see section 2.4.4.4) 
(Cabrita & Bottomley, 2004; Middelberg, 2002). One gram of wet pellet was 
dissolved in 10 ml of solubilisation buffer. Urea-solubilised inclusion bodies were 
stirred for 2 hours at room temperature and centrifuged at 15,000g for 30 minutes at 
40C. The supernatant was syringed through a 0.45 µm PVDF sterile filter membrane 
and stored at -200C. The second buffer was guanidine HCl (Section 2.4.4.4). 
Guanidine solubilised inclusion bodies were incubated for 2 hours under shaking at 
40C and then centrifuged, filtered and stored at -200C as above. Further processing 
of the resolubilised inclusion bodies was then undertaken, either by first utilising 
affinity chromatography, followed by dilution/dialysis, or directly to the 
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dilution/dialysis step. The two methods were tested as it was unknown how pure the 
inclusion bodies are, so it was hypothesized that an affinity step may be required. 
 
6.2.2.4. Step-wise urea gradient chromatography of urea solubilised cathepsin 
L1g 
 
Step-wise urea gradient Ni2+- NTA chromatography was performed as described by 
Cabrita and Bottomley (2004) with some modifications. The urea solubilised 
protease was mixed with Ni-NTA resin by gentle shaking for 60 minutes at room 
temperature (Batch chromatography mode). This mixture was then applied to a 
disposable column and the flow-thorough was collected for SDS-PAGE analysis. 
Urea was removed slowly at room temperature using a 10 ml urea gradient buffer 
(see section 2.4.4.4). The final wash containing no urea was supplemented with 50 
mM imidazole. Finally, the bound protease was eluted with 400 mM imidazole. 
Eluted fractions were collected in 1.5 ml eppendorf tubes and stored at -800C. 
 
6.2.2.5 Dilution and dialysis  
 
 
Dilution and dialysis was performed based on published methods for human pro-
cathepsin L (D'Alessio et al., 1999; Kramer et al., 2007) and liver fluke cathepsin L 
(Kesik et al., 2007; Yamasaki et al., 2002). Eluted fractions of affinity purified 
protease or Guanidine hydrochloride solubilised cathepsin L1g protease were slowly 
added drop wise (100 µl/minute) into 100-fold renaturation  buffer (see section 
2.4.4.4) and stirred for 24 h at 40C. The diluted resuspension was concentrated 100-
fold by a VIVAFLOW 50 tangential ultra filter membrane. The concentrated refolded 
proteins were again dialysed against 50 mM Na2HPO4, pH 8.0 containing 0.5 M 
NaCl. The dialysed proteins were desalted by an Amicon ultra centrifugal filter (10 
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kDa), centrifuged at 15,000 g for 30 minutes at 40C and the supernatant was stored 
at -800C.  
 
6.2.2.6. Protease concentration assay 
 
Cathepsin L1g concentration was estimated using the Bradford method, 
Coommassie Blue G 250 was used as the dye reagent to measure the absorbance 
at 600 nm. Bovine serum albumin (BSA) was used to create the standard curve (see 
section 2.4.4.2). 
 
6.2.2.7. SDS-PAGE analysis 
 
The expressed, column purified and refolded proteases were analysed by 12.5% 
SDS-PAGE. The recombinant protease was resuspended in SDS-PAGE sample 
buffer. Gel electrophoresis was performed in Mini-protean Electrophoresis cell (see 
section 2.4.4.6). The gels were stained with Coomassie Brilliant Blue R 250 and 
destained using 10% acetic acid and 10 % ethanol.  
 
6.2.3. Substrate (Gelatin) gel electrophorsis for protease activity analysis  
 
Cathepsin L1g proteolytic activity was determined as described by Kesik et al. 
(2007) and Naggie and Bentley (1998). The refolded proteases were loaded onto 
12.5% SDS-PAGE with a separating gel that contained 0.5% gelatin (see section 
2.4.4.6).  
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6.2.4 Anti-His and anti-cathepsin L western blot analysis 
 
Recombinant cathepsin L1g protease was separated on a 12.5% SDS-PAGE gel 
and transferred to a nitrocellulose membrane (see section 2.4.4.7.2). The 
membrane was incubated with anti-His monoclonal antibody, or anti-cathepsin L 
antisera (1:4000 and 1:2000 dilution respectively) overnight at 40C, washed three 
times in TBS, incubated with anti-mouse alkaline phosphatase (1:4000 and 1:2000 
dilution) and visualised using western blot developing solution containing the 
NBT/BCIP substrate. 
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6.3 Results 
 
6.3.1 Plasmid construction  
 
The expand long template PCR protocol was followed. Primer F1 contained 
sequences for a BamH I site and first eight codons of the cathepsin L1g cDNA 
fragment (starting from the pro-sequence). Primer R1 contained the sequence for a 
BamH I site and the last seven codons of cathpsin L1g, including the stop codon. 
The expand PCR produced a single amplified 945bp DNA fragment as shown in 
Figure 6.3. After ligation sequentially into pCR2.1 and pRSET-A, clones were 
analysed by restriction digestion. The restriction enzyme BamH I digestion of 
miniprep plasmid purification products of pCR 2.1 and pRSET-A cathepsin L1g gave 
an approximately 945 bp fragment (shown in Figure 6.4 and 6.5). 
 
Two miniprep products of pRSET-A cat L1g (pRSET-A cat L1g-8 and pRSET-A cat 
L1g-14) showed the correct orientation after digestion with EcoR I (Figure 6.6). 
During the pilot-scale expression of these two positive constructs in BL 21 cells, 
pRSET-A cat L1g-14 showed high expression and yield, whereas the other clone did 
not. The nucleotide sequence of the first clone was obtained and found to agree with 
that previously obtained from this clone (Luke Norbury, personal communication). All 
further expression work was performed with this clone. 
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                                               1       2     3      4       
 
 
Figure 6.4. Expand PCR products amplified from cDNA encoding cathepsin 
L1g analysed in an agarose gel.  
 
The 945 bp cathepsin L1g amplified fragment is indicated by the bold arrow in lane 
1, 2 and 3; lane 4, Pst I lambda marker. This amplified fragment was eluted and 
utilized further for TA cloning.  
 
 1 kb 
     
  0.8 Kb 
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Figure 6.5. DNA gel electrophoresis of BamH I digested pCR2.1 (3.9 kb) 
miniprep products and CIP treated pRSET-A vector.  
Lane 1 and 2, BamH I digested miniprep products of the pCR2.1 vector (indicated 
by the bold arrow) containing the cathepsin L1g coding sequence (indicated by the 
bold arrow); lane 3 and lane 7, Pst I lambda marker; lane 4, lane 5 and lane 6 BamH 
I digested and CIP treated pRSET-A (2.8 kb size band-referred in bold arrow).  
Kb 
 
 
5.0  
2.8                                                                 
 
 
1  
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Figure 6.6. DNA gel electrophoresis of BamH I and EcoR I digested pRSET-A 
containing F. gigantica cathepsin L1g. 
Lane 1 and lane 2, BamH I digestion of pRSET-A containing F. gigantica cathepsin 
L1g; lane 3 and lane 4, EcoR I digestion of pRSET-A containing F. gigantica 
cathepsin L1g; lane 5, Pst I lambda marker. 
 
5.0 kb 
2.8 kb 
 
1 kb 
 
0.8 kb 
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6.3.2 Expression, inclusion body preparation and solubilisation 
 
The recombinant protease was expressed well in E. coli. The bacterial cells from an 
induced culture were lysed under non-denaturing conditions. After removal of cell 
debris by centrifugation, the protein was analysed by SDS-PAGE (Figure 6.7). The 
best yield was attained when cells were harvested 3 hours after induction with 1 mM 
IPTG. Recombinant protein showed an approximate molecular weight of 40 k Da, 
which corresponds to the size of F. gigantica cathepsin L1g pro-protein with the N-
terminal extension. After purification, cathepsin L1g protease concentration was 8.4 
mg/litre from the urea solubilised inclusion bodies and 5.6 mg/litre from the 
guanidine hydrochloride solubilised inclusion bodies.  
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Figure 6.7. SDS-PAGE analysis of expressed recombinant proteins from E. 
coli BL21 (DE3) cultures.  
After induction, 1 mL aliquots of culture were taken at hourly intervals. Cells were 
collected by centrifugation and resuspended in phosphate buffer (see section 
2.4.4.4). 20 µ L of protein solution was mixed with SDS sample buffer and the 
samples electrophoresed, after which the gel was stained with Coomassie blue. 
Lane 1, marker; lane 2, cell lysate before IPTG induction; lanes 3- 6, lysates from 1 
to 4 hours post-induction.  
 
 
   50 kDa 
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6.3.3 Ni- NTA column purification of urea solubilised cathepsin L1g 
 
Immobilised metal affinity chromatography (IMAC) was applied for the purification of 
cathepsin L1g protease that had been solubilised with urea. Denatured cell lysate 
was incubated with Ni-NTA resin slurry to allow binding of (His)6-cathepsin L1g. In 
order to remove urea from this protease, the column-loaded mixture was washed 
with decreasing concentrations of urea. The final wash (no urea) was supplemented 
with 50 mM imidazole to displace contaminant proteins that are loosely bound to Ni-
NTA agarose and protein was eluted with 400 mM of imidazole (Figure 6.8). The 
proteinase yield was assessed by Bradford assay and was 3.8 mg / litre of culture. 
The eluted fractions had no digestive activity with gelatin gel, indicating that despite 
the removal of urea from the protease, it was not refolded into an active 
conformation (not shown). These results suggested it was necessary to proceed to 
dilution and dialysis. 
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Figure 6.8. SDS-PAGE analysis of fractions of protein samples eluted with 400 
mM from urea gradient Ni-NTA column chromatography.   
20 µL of eluted fractions were mixed with SDS sample buffer and run on 12.5% 
SDS-PAGE (Coomassie stained).  Lane 1-2, 4-8, fractions 1-7. Lane 3, See blue 
pre-stained protein marker. 
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6.3.4 Refolding by Dilution and Dialysis 
 
The column purified protease and/or guanidine hydrochloride denatured proteins 
were slowly diluted into 100-fold refolding buffer with gentle stirring (Drop wise 
dilution method) at 40C. The buffer pH was modified to 10.5 and the redox couple 
millimolar concentration (GSH and GSSG) was increased from 1:0.1 to 4:0.4. 
However, several experiments were performed to optimise the redox couple ratio, to 
determine the ratio that resulted in optimal activity as determined by good gelatin 
digestive activity. 
 
Urea and guanidine hydrochloride are potent aggregation suppressing agents used 
in solubilisation buffers, whereas L-arginine mono hydrochloride has been found to 
be an efficient anti-aggregation agent in refolding buffer. The one litre diluted 
protease was concentrated to 10 ml by VIVA FLOW 50 tangential ultra filters (cut off 
value 10 kDa). The concentrated protein was dialysed against NaCl (one step) by 
using dialysis tubing (cut of value 10 kDa). Proteins were then desalted by an 
Amicon diafilteration (10 kDa). The renatured cathepsin L1g was run on SDS-PAGE 
along with yeast BJ3505 cells expressing cathepsin L1g. Both proteins had an 
approximate molecular weight of 40 kDa in a single band (Figure 6.9). This result 
indicates that the purity of the inclusion bodies is high, as the protein in lane 2 had 
not been subjected to affinity chromatography. 
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Figure 6.9. Commassie SDS-PAGE analysis of refolded and yeast expressed 
cathepsin L1g.  
0.5 µg of protein was mixed with SDS-sample buffer run on 12.5 %SDS- gelatin 
PAGE and stained with Coomassie Blue R250. Lane 1, refolded cathepsin L1 (Urea 
denatured and step-wise urea chromatography purified); lane 2, refolded cathepsin 
L1g (GdnHCl denatured); lane 3, markers; lane 4, yeast-expressed cathepsin L1g.  
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6.3.5 Proteolytic activity assay 
 
The proteolytic activity of refolded cathepsin L1g was assayed under acidic 
conditions (pH 4.5), measured by digestive activity against gelatin substrate SDS-
PAGE and is shown in Figure 6.10. In this gel, yeast expressed cathepsin L1g was 
used as a positive control. The activity was viewed under a light box which revealed 
digestion of gelatin protein by both refolded and yeast expressed cathepsin L1g. 
Two prominent bands are seen corresponding to the pro-mature and mature 
proteins respectively. This indicates that some auto-processing has occurred prior to 
electrophoresis. 
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Figure 6.10. SDS-Gelatin PAGE protease activity assay.  
1 µg of protein was mixed with non- reducing SDS-PAGE sample buffer and run on 
12.5 %SDS-gelatin PAGE. Lane 1, refolded cathepsin L1g (Urea denatured and 
step-wise urea chromatography purified); lane 2, refolded cathepsin L1g (Gdn HCl 
used for denaturation); lane 3, markers; lane 4, yeast–expressed cathepsin L1g. 
Proteolytic activity can be observed in both the E. coli and yeast-expressed 
samples. 
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6.3.6. Western blotting of expressed and refolded cathepsin L1g 
 
The immunoreactivity of pRSET-A cathepsin L1g was assayed against an anti-His 
monoclonal antibody (pRSET-A vector encodes six histidine residues for Ni-NTA 
column purification) as well as an anti-cathepsin L antibody. Reactivity with anti-His 
antibodies at a band size of 40 kDa indicated the pro-cathepsin L1g at this 
molecular weight (Figure 6.11). The E. coli expressed protein from positive clone 
pRSET-A-14 showed anti-His reactivity with the predicted size of cathepsin L1g 
whereas clone pRSET-A-8 expressed a protein with a lower molecular weight than 
expected, indicating a probable C-terminal truncation (sequence analysis of this 
clone was not performed, as the pRSET-A-14 clone was shown to be correct). 
Western blot strips containing renatured cathepsin L1g gave reactive bands identical 
to yeast expressed cathepsin L1g indicating that cathepsin L1g expressed from E. 
coli BL21 was immunologically cross-reactive (Figure 6.12).  
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Figure 6.11. Western blot of pRSET-A cathepsin L1g protease probed with an 
anti-His 6 antibody. 
20 µL of whole cell lysate was mixed with SDS-PAGE sample buffer, run on 12.5 % 
SDS- PAGE and transferred to nitrocellulose membrane. The strip was probed with 
an anti-His antibody. Lane 1, postive clone 14 expressed cathepsin protein; lane 2, 
postive clone 8 expressed protein; lane 3 See blue pre-stained protein marker.  
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Figure 6.12. Western blot analysis using mouse anti-cathepsin L sera.  
1 µg of purified protein was mixed with SDS sample buffer, run on 12.5 % SDS- 
PAGE and transferred to nitrocellulose membrane. The strip was probed with anti-
cathepsin L sera. Lane 1, refolded cathepsin L1g (Urea denatured and step-wise 
urea chromatography purified); lane 2, refolded cathepsin L1g (GdnHCl used for 
denaturation); lane 3, markers; lane 4, yeast-expressed cathepsin L1g. Two reactive 
bands corresponding to the pro-protein and mature protein can be observed.  
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Table 6.1. Purification summary of liver fluke cathepsin L1g 
  
 
Purification step 
 
 
Protein concentration 
mg/litre 
1. Total bacterial lysate 10 
2. Urea denatured extract 8.4 
3. Gunanidine hydrochloride 
denatured extract 
5.6 
4. Column purified protease 
fractions 
3.8 
5. Refolded protease (Both 
methods) 
2.5 
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6.4 Discussion 
 
One of the potential barriers for subunit protein vaccine projects, structural genomics 
studies and production of therapeutic proteins is the successful production of 
soluble, biologically active proteins. To achieve this, researchers often need to 
follow a complex and cumbersome procedure. In addition, soluble expression of 
eukaryotic proteins is generally less successful compared to prokaryotic proteins . 
This is particularly so when bacteria are used as the host. Insoluble pellet formation 
is a common theme in recombinant protein technology. To fully exploit the 
production capacity of cells, efficient strategies for further processing have to be 
developed for each protein.  
 
Cathepsin L1g contains cysteine residues and requires disulfide bond formation for 
correct folding of the protease, but expressed insoluble proteases consist of 
misformed disulfide bridges due to over expression. These misfolded proteases are 
not active. In order to utilize these proteins fully, refolding into an active form was 
pursued. 
 
6.4.1 Protein purification and column chromatography 
 
The recombinant liver fluke protease can be expressed by E. coli BL21 (DE3) at 
high levels in inactive aggregates and can be purified as the pro-mature enzyme. 
Cathepsin L1g was also expressed in yeast strain BJ3505, but the yield was very 
low. The main aim of this study was to develop an expression system to produce 
large quantities of refolded, biologically active parasite protease for vaccine studies. 
Recombinant protease requires denaturants to promote solubilisation and two 
efficient denaturants utilized in this study were urea and guanidine hydrochloride. At 
high concentrations (10 M urea or 6 M guanidine hydrocholoride), protein solubility 
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is greatly improved . However, such solubilised protein is neither active nor suitable 
for vaccination without further processing. 
 
After solubilisation by denaturants, the protease must be refolded before it can 
become active. On column refolding (OCR) has been given much importance in 
recent years for purification of E. coli expressed heterogeneous proteins (Jungbauer 
& Kaar, 2007; Middelberg, 2002). Immobilised metal affinity chromatography has 
opened new prospects for efficient purification of proteins with hexa-histidine tags. 
However, active cathepsin L1g was not achieved by using stepwise urea gradient 
chromatography, perhaps because on the column the purified cathepsin L1g may 
not form the correct pattern of disulphide bridge. To achieve the correct disulphide 
exchanges, further processing need to be performed (dilution and dialysis).  
 
6.4.2 Refolding by dilution and dialysis 
 
Redox pairs are supplemented in the refolding buffer in order to attain the correct 
formation of disulfide bonds. Optimisation of redox pair concentration was performed 
and modified to 4 mM GSH: 0.4 mM GSSG (From 1 mM GSH: 0.1 mM GSSG). 
Renaturation was performed at alkaline pH to promote thiolate anion exchange 
formation and disulfide exchanges .  
 
Suppressing aggregation nuclei without altering protease concentration, yield and 
purity has been achieved by adding an aggregation inhibitor to the refolding buffer. 
L- arginine is considered an important aggregation inhibitor because it destabilizes 
incorrectly folded proteins by reducing improper interactions within parts of 
polypeptide chains. L-arginine (0.7 M) was used in this study to destabilize and 
increase the solubilisation of folding intermediates (Buchner et al., 1992; Gu et al., 
2001). The dialysis buffer was changed to pH 8.0 for enhancing stabilisation of the 
pro-mature form and preventing auto-activation during processing. 
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6.4.3 Protease activity assay 
 
Renaturation attained a yield of 50% and proteins showed activity in gelatin 
substrate SDS-PAGE. This assay is considered to be a selective method because it 
permits the detection of protease activity that is stable in the presence of SDS.  
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6.5. Conclusion 
 
The results of this study suggest that denatured cathepsin L1g was refolded only by 
the dilution and dialysis renaturation method and not by the on column refolding 
procedure. This study has resulted in a simple but highly efficient procedure for the 
optimal refolding and purification of biologically active cathepsin L synthesized from 
E. coli with a high yield.  As there was little dicernable difference between the purity 
of the final protease that had been affinity purified, or simply solubilised in guanidine, 
the later method is preferable. After refolding, the protease is active and 
immunoreactive with anti-cathepsin L sera. 
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Chapter 7 
Concluding remarks 
 
7.1. Expression of stage-specific Fasciola proteases and their evaluation in 
vaccination trials 
 
Liver flukes go through complex developmental and morphological changes from 
metacercariae to the adult stage in mammalian hosts. Different immune responses 
are induced at each stage of fluke infection in the host (Mulcahy et al., 1999; van 
Milligen et al., 1998). The interplay between flukes and the host immune system 
induces specific immunomodulatory mechanisms, partly due to fluke ES material 
which also ensures fluke survivability in the mammalian host . An understanding of 
the host-parasite interactions can assist in vaccine development. 
 
Based on Knox et al. (2001), vaccine development can be classified into three levels 
in the laboratory, such as target antigen selection (for example cathepsin L and 
cathepsin B cysteine proteases), antigen production (such as yeast and E. coli 
expression and purification) and vaccine potential analysis (for example protein and 
DNA vaccination in rats and mice). The advances in genomics as well as proteomics 
lead to the identification of many protective vaccine candidates against Fasciola 
infection (Dalton et al., 2003a; Hillyer, 2005; McManus & Dalton, 2006; Meeusen & 
Piedrafita, 2003; Smith & Zarlenga, 2006; Spithill et al., 1997). 
 
7.2. Recombinant Fasciola protein production 
 
Cysteine proteases are considered to be essential for the life cycle and virulence of 
the liver fluke parasite (Carmona et al., 1992; Carmona et al., 1993; Dalton & 
Heffernan, 1989; Smith et al., 1993a; Wijffels et al., 1994b; Wilson et al., 1998). 
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Vaccine trials with native cathepsin L cysteine proteases and other vaccine 
candidates showed protective immune responses in many reports (Dalton et al., 
1996; Dalton & Mulcahy, 2001; Spithill et al., 1997; van Milligen et al., 2000; Wijffels 
et al., 1994b). The main drawback of this approach is the limited availability of the 
parasite material and that isolated proteins undergo proteolytic degradation (Roche 
et al., 1997). The main challenge at present is to develop recombinant protein 
vaccines with similar efficacy. Recombinant Fasciola cysteine proteins have 
primarily been produced in yeast (Dowd et al., 1997; Law et al., 2003; Roche et al., 
1997; Smooker et al., 2000) or in E. coli (Kesik et al., 2007; Yamasaki et al., 2002). 
These recombinant cathepsin proteins were subjected to vaccine trials against 
challenge infection, although very few reports has been reported in ruminants . 
 
One aim of this project was to confirm the expression and purification of cathepsin 
B, cathepsin L1g and cathepsin L5 proteins from yeast. In this investigation, the 
expressed proteins were purified from yeast supernatant using Ni-NTA affinity 
chromatography and purity was confirmed using SDS-PAGE analysis. The results of 
this study showed that yeast BJ 3505 cells secreted high levels of cathepsin 
proteins compared to the previous reports of Dowd et al. (1997) and Roche et al. 
(1997). Cathepsin B and cathepsin L1g showed the same pattern of migration as a 
single band, whereas cathepsin L5 was found as a doublet in SDS-PAGE. This 
indicates that during processing cathepsin L5, but not L1g or B, can undergo auto-
processing. Immunoblotting results showed that a cathepsin L monoclonal antibody 
recognised cathepsin L5, cathepsin L1g, F. hepatica native cathepsin L and F. 
hepatica and F. gigantica ES material. Recombinant cathepsin B was detected by 
cathepsin B vaccinated rat sera. These proteases were therefore considered 
suitable for vaccine studies. 
7.3. The protective efficacy of expressed Fasciola proteins 
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The crude proteins of adult and juvenile stage F. hepatica have been tested for the 
induction of protective immunity in rats. Results show that juvenile proteins showed 
high protection against challenge infection (van Milligen et al., 2000). Prior to 
analysing the protective efficacy of recombinant proteins in ruminants (which is the 
most appropriate means of testing vaccine efficacy), this investigation has focussed 
on testing three recombinant antigens (two from juvenile parasites) in a rat model.  
 
In addressing this issue, eight vaccines were formulated in Quil A adjuvant, 4 of 
which were cocktail vaccines containg 2 or 3 antigens. Quil A adjuvant was used as 
this is an acceptable adjuvant in the veterinary vaccine industry, unlike Freund’s 
adjuvant which can only be used in experimental settings. The ideal standard for 
anti-fluke vaccine development is reduction in fluke numbers in vaccinated animals 
compared to control animals . This was observed. The influence of recombinant 
vaccines on the fluke body size and wet weight are also considered to be important 
indicators of protection in vaccinated animals (Nambi et al., 2005; Ramajo et al., 
2001; Valero et al., 2006). Most of Fasciola vaccine experiments have correlated 
protection against challenge infection with immunological parameters (Kesik et al., 
2007; Mulcahy et al., 1998; Mulcahy & Dalton, 2001; Wedrychowicz et al., 2003; 
Wedrychowicz et al., 2007). There are few reports of the anti-pathological effects of 
recombinant protein vaccines (Kesik et al., 2007; Nambi et al., 2005). The results of 
this investigation have demonstrated that pathological lesions of the liver (hepatic 
stage and biliary stage) are an important indicator of the protective efficacy of 
administered vaccines in rats (pictorial presentation, chapter 4).  
 
Vaccination with cathepsin B generated rapid and maximal antibody titre (reciprocal 
titre of 105) and a 59% reduction in fluke counts compared to control rats. F. 
gigantica cathepsin L1g which showed moderate IgG responses compared to 
cathepsin B and cathepsin L5 induced a 49% reduction in fluke counts. Cathepsin 
L5 vaccination elicits high antibody responses and 50% reduction in fluke burden 
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compared to control rats. These findings suggest that each of the cathepsin 
proteases can induce a protective effect in rats. Furthermore, stunting of fluke 
growth the resultant reduction in liver damage in vaccinated rats was seen as a 
protective effect of recombinant cathepsin protein vaccination against parasitism 
and pathogenicity caused by the challenge infection.  
 
A biphasic effect on IgG antibody responses in vaccinated rat serum was also 
observed. The protein specific IgG antibody in vaccinated rats peaked at time of 
challenge and then had declined at the time necropsy.  
 
In general, immunisation with cocktail vaccines elicited higher levels of protection as 
compared to vaccination with a single antigen (Dalton et al., 1996; Estuningsih et al., 
1997; Wijffels et al., 1994b). In agreement with previous observation, in these 
studies it was observed that the percentage of protection ranged from 57 to 83% 
depending upon the combination of antigens used. The percentage of maximal 
protection with individual rats was 100% in all cocktail and cathepsin B vaccinated 
rats (in other words, these groups each contained rats with no flukes). The results of 
the study suggested that a cocktail of adult fluke cathepsin L5 and juvenile 
cathepsin B vaccination showed the highest percentage of protection against F. 
hepatica metacercariae challenge, not only reflected by reduced fluke recovery and 
size of flukes, but also reduced intensity of liver lesions in rats vaccinated with these 
combinations. 
 
Results of this study matches with previous observation of Kesik et al. (2007). The 
vaccination of E. coli expressed (CPFhW) cysteine proteins (400 µg) in Sprague 
Dawley rats induced 80% protection against challenge infection . However, our 
results contradict the observation of Reszka et al. (2005) who demonstrated that a 
low percentage of the protection (18%) was induced by yeast expressed cathepsin L 
(125 µg of FhCL3) in Wistar rats. 
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Piedrafita et al. (2007) suggest that in vitro killing of F. hepatica occurs in the first 24 
to 48 hours of infection and is mainly by antibody mediated effector cells 
(eosinophils, and macrophages) releasing nitrous oxide. F. hepatica cathepsin L 
proteinase prevents the adherence of eosinophils to newly excysted juveniles . 
Spithill et al., (1997) have hypothesized that fluke ES materials inhibit antibody 
mediated attachment of eosinophils, neutrophils and macrophages to the tegument 
of flukes. In this investigation, the recombinant protein vaccination induced 
peripheral eosinophilia, and increased neutrophil and lymphocyte responses in 
vaccinated rats at the time of challenge infection. At the time of necropsy, the 
eosinophil counts had tended to decrease and there is an increase in the neutrophil 
counts in the vaccinated rats. The evoked protective immunity in rats may act via 
these same immunological events during this time period. The corollary of previous 
observations suggests that natural killing of juveniles in rats may not confer 
protection to a subsequent infection. However the protective immunity elicited by 
recombinant protein vaccination appears to evoke effector and memory responses 
against infection. 
 
7.4. Novel vaccination strategies for delivery of Fasciola antigen 
 
The application of parasite DNA vaccines in ruminants has been much less 
promising due to the lack of immune responsiveness against administered vaccines 
. The access of antigens to APCs appears to be rate-limiting step in the generation 
of immune responses to DNA vaccines. DNA vaccine targeting either the lymph 
node (CTLA-4) or chemo-attractant (MCP3) represents an attractive immune 
enhancing feature for targeting antigen to APCs and lymph nodes. Juvenile and 
immature fluke cathepsin B has been detected within 5 weeks of infection (Law et 
al., 2003). Considering the immature fluke cause extensive liver damage during this 
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period, a vaccine target against the early period of infection would be helpful to 
reduce the intensity of liver lesions. 
 
The third aim of this thesis was to determine F. hepatica cathepsin B specific 
immune responses in mice vaccinated with a variety of constructs encoding 
cathepsin B. Each construct was designed to secrete cathespin B, as this will 
maximise the humoral response. Previous DNA vaccination studies by Smooker et 
al. (2001) demonstrated in vitro expression from a DNA vaccine encoding cathepsin 
L5 and the subsequent induction of anti-cathepsin L5 specific IgG, IgG1, IgG2a, 
IgG2b and IgE antibodies in BALB/c mice. As a continuation of the above findings, 
firstly the supernatants of DNA vaccine vectors transfected COS-7 cells were 
subjected to the immunoblotting. The supernatants of cells transfected with the four 
vectors encoding protein were recognised by cathepsin B vaccinated rat sera. After 
vaccination of mice, humoral and T cell responses were elicited. 
 
In this investigation the CTLA-4 DNA vaccine shows a more rapid increase in 
antibody titre in BALB/c mice compared to other DNA vaccines in mice. However, 
the increase in titre by either of the targeting molecules (MCP3 or CTLA4) was non-
existent or modest. The ELISPOT results showed significantly higher cathepsin B 
specific IL-4 production in all test groups over the control group. However, there was 
no significant advantage of one construct over another. A recent study by Ingale et 
al. (2008) shows T cell responses during F. gigantica infection was a Th2 type 
responses and no IFN-Y was detected during the early phase of infection of calves. 
High levels of IL-4 production and the resultant Th2 response lead to an 
immunopathological reaction and development of inflammatory lesions in the liver. 
However, the expression of cathepsin B in the early stage of fluke infection (Law et 
al., 2003) and their ability to digest a range of molecules including immunoglobulin, 
gelatin and  albumin  also suggests its possible role in directly causing hepatic 
damage. 
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In the rat vaccine trial, cathepsin B vaccination induced high peripheral eosinophilia. 
High IL-4 production was observed from DNA vaccination. These two observations 
suggested that an allergic type of immune reaction was induced in vaccinated 
animals. The presence of Fasciola specific IgE antibody and eosinophil responses is 
a good indicator of acquired immunity which has been demonstrated elsewhere 
(Hagan et al., 1991; Meeusen et al., 1995; Meeusen & Balic, 2000). 
 
It appears that the addition of a targeting sequence to the DNA vaccine construcst 
has not markedly enhanced immunogenicity. This is possibly a protein- specific 
limitation, whereby the constructs encoding cathepsin B fusion proteins are 
inefficiently expressed or secreted in vivo (although they were efficiently secreted 
from COS-7 cells), or perhaps the fusion proteins are unstable or poorly taken up by 
cells. The results of this study demonstrate that CTLA-4 fusion proteins may be the 
best way for any future delivery of cathepsin B as a DNA vaccine.  
 
7.5. Enhancing the functional activity and refolding of Fasciola target antigen 
from E. coli expressed inclusion bodies 
 
The fourth aim of this work is to produce a functionally active form of F. gigantica 
cathepsin L1g from E. coli BL 21 cells expressed in inclusion bodies. This was 
undertaken due to the very poor expression of this protease in yeast (compared to 
other cathepsin L’s and cathepsin B). The recombinant cathepsin L1g refolding 
process involves denaturation of inclusion bodies, renaturation and functional 
activity analysis. Two efficient solubilising agents used in this study were urea and 
guanidine hydrochloride. It was found that urea denaturation followed by affinity 
chromatography did not result in active protein, and therefore this step could be 
omitted. Indeed, the purity of solubilised proteins with or without the affinity step was 
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similar, hence the easiest procedure to obtain active protein was to collect inclusion 
bodies, solubilise and apply directly to the re-folding buffer. In this was, active 
cathepsin L1g (as determined by gelatin digestion) that was immunoreactive was 
obtained. 
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7.6. Future work 
 
The protective efficacy of E. coli expressed F. gigantica cathepsin L1g and yeast 
expressed cathepsin L1g should be investigated further, as E. coli expressed 
(CPFhW) cysteine proteins showed 80% protection against F. hepatica challenge 
infection. The immune activation of yeast expressed cathepsin L (FhCL3) was 
previously compared with baculovirus expressed proteins against challenge 
infection in Wister rats. Hence, the immune responses induced by proteins 
expressed in various expression systems (yeast, E. coli and baculovirus system) 
should be investigated in ruminants. 
 
The protective immunity of DNA vaccine encoding cathepsin B against challenge 
infection needs to be explored in a challenge model. The results of this current 
investigation (chapter 6) showed IL-4 responses in vaccinated mice. However, mice 
are not a suitable challenge model, and these DNA vaccines could be tested in a 
sheep trial. 
 
The protective efficacy of these yeast expressed stage specific Fasciola antigens 
needs to be investigated in target species, for example sheep and cattle. This is 
considered as the most appropriate means of testing its vaccine efficacy. 
Considering the results obtained of vaccine studies in rats (chapter 4), combinations 
of these recombinant proteins may be effective vaccines when delivered in an 
acceptable veterinary adjuvant in large animals. 
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